
<html lang="en"     class="pb-page"  data-request-id="5d9e2fff-d5c6-4550-8b37-5f39ae4a147f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-11;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.8b00164;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)" /></meta><meta name="dc.Creator" content="Michael&#xA;P.  Smolinski" /></meta><meta name="dc.Creator" content="Yahao  Bu" /></meta><meta name="dc.Creator" content="James  Clements" /></meta><meta name="dc.Creator" content="Irwin H.  Gelman" /></meta><meta name="dc.Creator" content="Taher  Hegab" /></meta><meta name="dc.Creator" content="David L.  Cutler" /></meta><meta name="dc.Creator" content="Jane W. S.  Fang" /></meta><meta name="dc.Creator" content="Gerald  Fetterly" /></meta><meta name="dc.Creator" content="Rudolf  Kwan" /></meta><meta name="dc.Creator" content="Allen  Barnett" /></meta><meta name="dc.Creator" content="Johnson Y. N.  Lau" /></meta><meta name="dc.Creator" content="David G.  Hangauer" /></meta><meta name="dc.Description" content="The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine k..." /></meta><meta name="Description" content="The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine k..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 4, 2018" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00164" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00164" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00164" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00164" /></link>
        
    
    

<title>Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00164" /></meta><meta property="og:title" content="Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0016.jpeg" /></meta><meta property="og:description" content="The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clinical trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing standard therapy. Compound 2 is a phase 1 clinical trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models. The discovery strategy for these compounds iteratively utilized molecular modeling, along with the synthesis and testing of increasingly elaborated proof of concept compounds, until the final clinical candidates were arrived at. This was followed with mechanism of action (MOA) studies that revealed tubulin polymerization inhibition as the second MOA." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00164"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00164">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00164&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00164&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00164&amp;href=/doi/10.1021/acs.jmedchem.8b00164" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4704-4719</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00954" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.7b01601" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Michael P. Smolinski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael P. Smolinski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael%0AP.++Smolinski">Michael P. Smolinski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yahao Bu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yahao Bu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yahao++Bu">Yahao Bu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Clements</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Clements</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Clements">James Clements</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Irwin H. Gelman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Irwin H. Gelman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York 14263, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Irwin+H.++Gelman">Irwin H. Gelman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Taher Hegab</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Taher Hegab</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Taher++Hegab">Taher Hegab</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David L. Cutler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David L. Cutler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+L.++Cutler">David L. Cutler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jane W. S. Fang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jane W. S. Fang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jane+W.+S.++Fang">Jane W. S. Fang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gerald Fetterly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gerald Fetterly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gerald++Fetterly">Gerald Fetterly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rudolf Kwan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rudolf Kwan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rudolf++Kwan">Rudolf Kwan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Allen Barnett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Allen Barnett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Allen++Barnett">Allen Barnett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johnson Y. N. Lau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johnson Y. N. Lau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johnson+Y.+N.++Lau">Johnson Y. N. Lau</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">David G. Hangauer</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David G. Hangauer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Athenex Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 716-573-3654. E-mail: <a href="/cdn-cgi/l/email-protection#640005120d000c505324160b050016110a0a01164a070b09"><span class="__cf_email__" data-cfemail="a9cdc8dfc0cdc19d9ee9dbc6c8cddbdcc7c7ccdb87cac6c4">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+G.++Hangauer">David G. Hangauer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0497-369X" title="Orcid link">http://orcid.org/0000-0002-0497-369X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00164&amp;href=/doi/10.1021%2Facs.jmedchem.8b00164" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4704–4719</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 4, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 January 2018</li><li><span class="item_label"><b>Published</b> online</span>4 April 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 June 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00164" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00164</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editors’ Choice" /></img><span>ACS Editors’ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00164"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6947</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00164" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael\nP.&quot;,&quot;last_name&quot;:&quot;Smolinski&quot;},{&quot;first_name&quot;:&quot;Yahao&quot;,&quot;last_name&quot;:&quot;Bu&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Clements&quot;},{&quot;first_name&quot;:&quot;Irwin&quot;,&quot;last_name&quot;:&quot;H. Gelman&quot;},{&quot;first_name&quot;:&quot;Taher&quot;,&quot;last_name&quot;:&quot;Hegab&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;L. Cutler&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;W. S. Fang&quot;},{&quot;first_name&quot;:&quot;Gerald&quot;,&quot;last_name&quot;:&quot;Fetterly&quot;},{&quot;first_name&quot;:&quot;Rudolf&quot;,&quot;last_name&quot;:&quot;Kwan&quot;},{&quot;first_name&quot;:&quot;Allen&quot;,&quot;last_name&quot;:&quot;Barnett&quot;},{&quot;first_name&quot;:&quot;Johnson&quot;,&quot;last_name&quot;:&quot;Y. N. Lau&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;G. Hangauer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;4704-4719&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00164&quot;},&quot;abstract&quot;:&quot;The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clinical trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing standard therapy. Compound 2 is a phase 1 clinical trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models. The discovery strategy for these compounds iteratively utilized molecular modeling, along with the synthesis and testing of increasingly elaborated proof of concept compounds, until the final clinical candidates were arrived at. This was followed with mechanism of action (MOA) studies that revealed tubulin polymerization inhibition as the second MOA.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00164&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00164" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00164&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00164" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00164&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00164" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00164&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00164&amp;href=/doi/10.1021/acs.jmedchem.8b00164" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00164" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00164" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00164%26sid%3Dliteratum%253Aachs%26pmid%3D29617135%26genre%3Darticle%26aulast%3DSmolinski%26date%3D2018%26atitle%3DDiscovery%2Bof%2BNovel%2BDual%2BMechanism%2Bof%2BAction%2BSrc%2BSignaling%2Band%2BTubulin%2BPolymerization%2BInhibitors%2B%2528KX2-391%2Band%2BKX2-361%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D11%26spage%3D4704%26epage%3D4719%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/jmcmar.2018.61.issue-11/20180614/jmcmar.2018.61.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound <b>1</b> is a phase 3 clinical trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing standard therapy. Compound <b>2</b> is a phase 1 clinical trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models. The discovery strategy for these compounds iteratively utilized molecular modeling, along with the synthesis and testing of increasingly elaborated proof of concept compounds, until the final clinical candidates were arrived at. This was followed with mechanism of action (MOA) studies that revealed tubulin polymerization inhibition as the second MOA.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Src is a nonreceptor protein tyrosine kinase (PTK), identified as the cellular proto-oncogene of the viral transforming gene, v-<i>src</i>, encoded by Rous sarcoma virus.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Elevated levels of Src activity have been shown to play an important role in primary tumor growth and, perhaps even more significantly, in metastasis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The initial promise of Src as an oncology drug target has resulted in a number of ATP-competitive Src inhibitors progressing into clinical trials, however, none has shown strong efficacy as a monotherapy against solid tumors.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> A confounding factor is the homology among tyrosine kinase ATP binding sites, thereby resulting in significant cross activity against a range of additional kinases (aka “multikinase” inhibitors) for ATP site directed inhibitors. The potential advantages of targeting the more unique kinase peptide substrate sites with small molecule inhibitors has been recognized by researchers for decades although this goal has proven generally challenging to achieve.<a onclick="showRef(event, 'ref4 cit5a'); return false;" href="javascript:void(0);" class="ref ref4 cit5a">(4,5a)</a> Potential advantages include much higher kinase inhibition selectivity and greater efficacy within cells because the inhibitor will not need to compete with mM intracellular concentrations of ATP.<a onclick="showRef(event, 'ref4 cit5a'); return false;" href="javascript:void(0);" class="ref ref4 cit5a">(4,5a)</a> Some progress has been reported in discovering nonpeptide small molecule Src inhibitors that are thought to target the peptide substrate binding site, however they generally are weak inhibitors, with IC<sub>50</sub>s > 10 μM against isolated Src and in whole cell assays.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The goal of the drug discovery program described herein was to develop first in class clinically relevant, orally available, Src inhibitors that target the peptide substrate site at nM potencies and that have high selectivity among kinases.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Discovery Pathway for Clinical Src Inhibitors KX2-391 and KX2-361</h3><div class="NLM_p">The discovery pathway for the potent nonpeptide, non-ATP competitive, oral Src inhibitors <b>1</b> (KX2-391, KX-01, KX01)<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and <b>2</b> (KX2-361, KX-02, KX02)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> traces back almost 30 years to the initial conceptual approach described in the 1989 publication from Hangauer and colleagues, then at Merck.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of dual MOA Src and tubulin polymerization inhibitors that are under clinical evaluation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this early proof-of-concept study, the insulin receptor tyrosine kinase (IRTK) was used as a model PTK to determine the feasibility of rationally designing small molecule, nonpeptide, PTK inhibitors that target the peptide substrate binding site. The flow of the conceptual genesis for the IRTK inhibitor <b>3</b> is outlined in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and described in more detail in the 1989 publication.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The basic design concept was to start with the tyrosine residue that is phosphorylated in peptide substrates, taking note of the discovery that a dehydro-Phe can be substituted for Tyr in peptide Src inhibitors, and then utilize a naphthalene scaffold as a conformationally restricted nonpeptide replacement for the dehydro-Phe residue. Finally, the position on the naphthalene scaffold that mimics the peptide substrate Tyr-OH was substituted with an α-hydroxymethyl phosphonate moiety as a hybrid substrate(OH)/product(phosphate) mimetic for interacting with the IRTK catalytic residues. Compound <b>3</b>, albeit a simple compound, inhibited IRTK peptide substrate transphosphorylation with a <i>K</i><sub>i</sub> of 95 μM in a non-ATP competitive manner and was specific for PTKs over protein serine kinases.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Compound <b>3</b> does not cross cell membranes, so a prodrug analogue was prepared and evaluated in whole cells wherein an IC<sub>50</sub> of 10 μM was found, demonstrating that the mM intracellular levels of ATP did not affect potency.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In light of the simplicity of <b>3</b>, and its potency in whole cells, this early compound encouraged us to continue down a similar conceptual path for Src.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Conceptual design process for <b>3</b> as a nonpeptide, non-ATP competitive, insulin receptor tyrosine kinase inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The next step was to identify a small peptide substrate for Src that could be used as a basis for designing initial modified peptide inhibitor analogues. The pentapeptide Ac-Ile-Tyr-Gly-Glu-Phe-NH<sub>2</sub> was identified as the best known small peptide Src substrate with a <i>K</i><sub>m</sub> of 368 μM when tested with isolated Src.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> A general synthetic approach to mimetics of this pentapeptide, containing unnatural amino acid replacements for tyrosine, was developed, including an α-hydroxymethyl phosphonate moiety replacement for a substrate tyrosine OH.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> It was found that small peptides bound weakly to isolated Src, even with unnatural amino acid replacements for the substrate Tyr. An evaluation of the crystal structures of Src available at the time suggested the reason why.</div><div class="NLM_p">One of the early crystal structures of Src was of the inactive form with a nonhydrolyzable ATP analogue bound in the ATP substrate site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This structure showed a well-formed ATP substrate binding site along with an open, poorly formed, peptide substrate binding site. Subsequent Src crystal structures reflecting active forms also did not show a well-formed peptide substrate binding cavity and were not solved with a peptide inhibitor in the active site.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Overall, the Src crystal structures suggested that the ATP substrate site is generally well formed, whereas the peptide substrate site is not, at least when Src is separated from its intracellular protein binding partners. This likely explains why tight binding of ATP site directed inhibitors are much more readily identified than peptide site directed inhibitors when screening with isolated Src.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Domain crystal structure of the inactive form of c-Src kinase (SH1) with nonhydrolyzable ATP analogue, AMP–PNP (red) bound in the ATP site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SRC">2SRC</a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The structure is displayed as a Molcad surface, and the generated image was colored based on hydrophobic potential using Sybyl 6.9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because Src binds to various multiprotein signaling complexes inside cells (e.g., EGFR, PDGFR, FAK, FGFR, etc.) through its SH2 and SH3 domains, we considered the possibility that these Src protein–protein interactions within the various signaling complexes could allosterically cause the Src peptide substrate binding cavity to be fully formed. Furthermore, because each of these dynamic signaling complexes would have its own constellation of proteins for potentially affecting the Src conformation, the shape of the Src peptide substrate binding cavity might differ somewhat from one complex to the next, thereby possibly reducing “cross talk” among the various Src signaling complexes. This would offer the potential for extending the selectivity beyond Src vs other PTKs to Src within certain signaling complexes over others. The Src peptide substrate binding cavity could also potentially be altered as protein members of the signaling complex bind or dissociate as well as when their post translational modification states change. This may result in a large number of Src substrates across multiple signaling complexes, an observation that has been made with anti-poTyr blots of Src-transformed cells.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, these novel concepts presented a practical challenge in that the kinase inhibitor testing methodologies common in the field at the time did not readily apply because various reconstituted multiprotein signaling complexes would need to be utilized. The isolated kinase inhibition assays would not be expected to show potent Src inhibition because the peptide substrate binding site is poorly formed so that the inhibitor would need to capture a rare conformation of the isolated protein, a kinetically and thermodynamically unfavorable process. Whole cell assays would include multiple Src signaling complexes, but this also raised the possibility that the detection of Src inhibition by standard Western blots, interrogated by Src auto- and transphosphorylation-specific antibodies, may be dependent upon the particular cell line used as well as the status of the various Src signaling complexes in response to the cell growth conditions used. Nevertheless, transitioning the peptide site directed Src inhibitor discovery efforts from isolated Src to whole cells wherein the Src multiprotein signaling complexes are formed seemed to be needed. This conclusion was based upon the structural information available showing the poorly formed Src peptide substrate binding site, the μM level binding affinities of peptide substrates and inhibitors with isolated Src, and our finding that binding affinities did not improve significantly upon various peptide/peptide mimetic optimization efforts.</div><div class="NLM_p">While transitioning to whole-cell Src inhibition testing, we still needed qualitative structural guidance as to the families of compounds likely to bind to the Src peptide substrate site. The only PTK crystal structures available at the time that were solved with a peptide bound in the at least a partially formed peptide substrate binding site were for the insulin receptor tyrosine kinase (IRTK).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The activated IRTK structure was solved at 1.9 A resolution with the nonhydrolyzable ATP analogue, adenylyl imido-diphosphate (AMP-PNP), bound in the ATP substrate site, and the 18-residue substrate, KKKLPATGD<u class="uu">Y</u>MNMSPVGD (<i>K</i><sub>m</sub> 24 μM), bound in the peptide substrate site.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> Of these 18 amino acids, only six (GD<u class="uu">Y</u>MNM) were resolved in the active site and the rest were too disordered to resolve (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Color coded MOLCAD substrate site surface of the active form of the insulin receptor tyrosine kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IR3">1IR3</a>)<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> with AMP–PNP bound (left side) and the visible region (GDYMNM, right side) of the peptide substrate KKKLPAT<u class="uu">GDYMNM</u>SPVGD shown as atom color-coded ball and stick structures. Brown and green surfaces are hydrophobic and blue surfaces are hydrophilic as generated using Sybyl 6.9. The substrate tyrosine is clearly seen adjacent to the ATP mimic terminal phosphate. Hydrogen bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The autoinhibited IRTK complex<a onclick="showRef(event, 'cit14b'); return false;" href="javascript:void(0);" class="ref cit14b">(14b)</a> was published earlier and was available at the time of our initial efforts to use it as a qualitative guide for the design of nonpeptide Src inhibitors that can penetrate whole cells (without requiring prodrug derivatization). This structure shows the autoinhibitory IRTK Tyr residue 1,162 bound in the catalytic region of the active site, analogous to a peptide substrate Tyr. The Tyr 1,162 coordinates were used as a 3-dimensional template for a structured-based design (SBD) of conformationally restricted Src inhibitor analogues with the assumption that this IRTK autoinhibitory Tyr may bind in a similar conformation to a Src substrate Tyr. Building up on our earlier results with a naphthalene scaffold-based, non-ATP competitive, IRTK inhibitor described above, we applied this scaffold to the design of conformationally restricted Src inhibitors.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The same approach was used to design analogous indole-based scaffold Src inhibitors,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> both of which are illustrated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Conceptual design for naphthalene and indole conformationally restricted Tyr scaffolds and analogues <b>4</b> and <b>5</b> based upon IRTK autoinhibited crystal structure. The three corresponding pharmacophore H-bonding groups are labeled 1 through 3 within the structures shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Comparative molecular modeling studies indicated that the key hydrogen bonding moieties labeled 1, 2, and 3 in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> can be positioned analogously to the autoinhibitory Tyr in 3-dimensional space with both the naphthalene and indole scaffolds. To gain initial confidence that these families of compounds are Src inhibitors, we tested an array of analogues against isolated Src. Naphthalene scaffold analogue <b>4</b> and indole scaffold analogue <b>5</b> were demonstrated to be non-ATP competitive inhibitors of isolated Src with IC<sub>50</sub>s of 16 and 38 μM, respectively.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Also the structure–activity relationships with these scaffolds<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> confirmed that the H-bond moiety positions shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> are the optimal locations. Indole analogue <b>5</b> was found to have antitumor activity with IC<sub>50</sub>s of 4.2, 59, and 41 μM against KM12 (colon), H460 (lung, NSCL), and A549 (lung, NSCL) tumor cell lines, respectively, all of which have active Src.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Comparing these tumor cell potencies to the isolated Src IC<sub>50</sub> of 38 μM demonstrates that the potency does not decrease when tested against whole cells, suggesting no significant effects due to high intracellular ATP levels or cell penetration limitations.</div><div class="NLM_p">Encouraged by these initial results from qualitative modeling, the IRTK ternary complex (IRTK:AMP–PNP:GD<u class="uu">Y</u>MNM)<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> was then used to construct a homology model of an analogous Src complex with the peptide inhibitor removed (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf" class="ext-link">Supporting Information</a>). Because the IRTK peptide substrate binding site is partially formed, the homology built Src peptide substrate binding site is also partially formed. Indole <b>5</b> was docked in the Src peptide substrate region of the active site as shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Docked indole Src inhibitor <b>5</b> in the Src peptide substrate site built upon a shared homology to that in IRTK. The Src structure is displayed as a Molcad surface, and the generated image was colored based on hydrophobic potential using Sybyl 6.9. H-bonds are indicated by yellow dotted lines, and some of the key interactions are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In our indole scaffold SAR study,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> we noted that the position of the benzyl amide OH in <b>5</b> contributed more significantly to potency than the position of the indole OH. This observation stimulated us to consider a reversed binding mode, i.e., one wherein the benzyl amide OH is positioned analogous to a Tyr substrate OH and the indole scaffold serves as the side chain. This reverse binding mode for <b>5</b>, and the corresponding difluoro analogue <b>6</b>, were successfully modeled in the Src active site built upon homology to the IRTK active site. We also noted that the two hydroxyl groups in <b>5</b> are expected to be potential sites of rapid phase II metabolism in vivo, and consequently replacing them with fluorine atoms as bioisosteric H-bond acceptors was also evaluated (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16,18)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Conceptual genesis of clinical compound <b>1</b> from indole Src inhibitor <b>5</b>. Inhibition data for compounds <b>6</b> through <b>1</b> have been reported previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Difluoro analogue <b>6</b> was more potent than the dihydroxy analogue <b>5</b> against H460 cells, 15 vs 59 μM, respectively.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This result, along with the two key insights that the Src binding mode might be reversed and that the OH’s can be replaced with less metabolically labile F’s, encouraged us to proceed further down this design pathway to the clinical compound <b>1</b> as outlined in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. We then addressed whether the indole side chain could be replaced with a different side chain in order to enhance potency. A number of possibilities were modeled using the Src homology built structure. We settled on a biaryl-based replacements<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> for the indole side chain (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><div class="NLM_p">We moved to testing our new analogues against the HT29 highly active Src colon cancer cell line and a c-Src527F/NIH3T3 engineered cell line (“Src3T3” in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), expressing a constitutively active, oncogenic Src (due to replacement of the autoinhibitory Tyr 527 with Phe). Src3T3 cells were grown with a low initial seeding density, low growth factor serum levels (1.5% FCS), and harvested well short of confluence in order to maximize their dependence on Src signaling for cell growth. Compounds that show potent proliferation inhibition under these conditions would be considered likely Src signaling inhibitors. Under low serum conditions, the GI<sub>50</sub> of <b>7</b> was 349 nM, suggesting that this compound is a Src signaling inhibitor in whole cells. Wider testing of <b>7</b> against KM12 (colon), A549 (NSCLC), and HT29 (colon) cancer cell lines provided GI<sub>50</sub>s of 0.41, 1.03, and 0.88 μM, respectively.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These results showed that the biaryl side chain had broken the micromolar potency barrier when tested in whole cells. The next task was to increase the water solubility so that oral bioavailability could be obtained and to further increase the potency.</div><div class="NLM_p">To increase water solubility, a pyridyl nitrogen was substituted for CH at various positions in the <b>7</b> biaryl moiety.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These analogues indicated that the nitrogen position shown in <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) provided the best potency, with GI<sub>50</sub>s of 269 and 338 nM against the Src3T3 and HT29 tumor cell lines, respectively.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Modeling studies with homology built Src indicated that an aryl nitrogen at that position may function as a H-bond acceptor with Src. Unfortunately, the water solubility increase was not enough to provide good oral bioavailability, which was only 4% for <b>8</b> in mice. To further increase the water solubility, a morpholinoethoxy side chain was appended to <b>8</b> to produce <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Modeling studies of the complex for <b>9</b> with homology built Src indicated that the <i>para</i> position of the terminal phenyl ring would be an acceptable position for this water solubilizing side chain because it would allow the morpholinoethoxy side chain to further extend down the peptide substrate binding channel or extend out into water. Adding this side chain not only increased the oral bioavailability in mice to 64% but also increased the potency against HT29 and Src3T3 cells by about 3-fold (GI<sub>50</sub>s 111 and 118 nM, respectively).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">We finally reconsidered the potential function of the meta-fluorine in <b>9</b>. We initially postulated that this fluorine might enhance binding by functioning as a hydrogen bond acceptor for the Src catalytic Arg-388, similar to a substrate OH, but were also concerned that this interaction may be negated by a repulsive interaction with the nearby catalytic Asp-386 carboxylate. Consequently, the final structural modification that provided the clinical compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) was to remove the meta-fluorine from <b>9</b>. Removing this fluorine improved the potency about 5-fold to 23 and 13 nM against HT29 and Src3T3 cells, respectively.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Our model for <b>1</b> binding in the homology built Src peptide substrate binding site is shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Docked clinical Src inhibitor <b>1</b> in the Src homology-built peptide substrate site. The Src structure is displayed as a Molcad surface, and the generated image was colored based on hydrophobic potential using Sybyl 6.9. H-Bonds are indicated by yellow dotted lines, and some of the key interactions are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> shows the <b>1</b> biaryl pyridyl nitrogen atom engages in a hydrogen bond with Src and the morpholinoethoxy group extending down the peptide substrate binding channel. The amide NH that connects the benzyl moiety to the biaryl moiety is also engaged in a hydrogen bond with Src. This modeled hydrogen bond with Src is in agreement with our finding that <i>N</i>-methylating the amide NH in the earlier analogue <b>7</b> resulted in a large reduction in potency against the Src3T3 transformed cell line (5% inhibition at 1000 nM).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">The GI<sub>50</sub>s for <b>1</b> are 23 and 13 nM against HT29 and Src3T3 cell lines, respectively, when grown in the presence of our standard low growth factor concentration (1.5% FCS). When the growth factor concentration was reduced from 1.5% to 0.5% FCS, thereby further increasing the dependency on Src signaling for growth as described earlier, the potency was improved to 5 and 6.5 nM, respectively, in HT29 and Src3T3 cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Because most cells express multiple members of the nine-member Src-family kinases,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> we addressed how <b>1</b> affects Src-specific proliferative signaling using mouse embryonic fibroblasts deleted of their <i>Src</i>, <i>Fyn</i>, and <i>Yes</i> genes (SYF cells) and transduced with c-Src527F (c-Src527F/SYF). The GI<sub>50</sub>s for <b>1</b> against c-Src527F/SYF cells in the presence of 10% FCS and 2% FCS were 123 and 23 nM, respectively.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The 5-fold improvement in potency when the growth factor concentration is decreased strongly suggests that <b>1</b> is a Src signaling inhibitor because other PTKs would become more involved in controlling growth at the higher growth factor concentrations, leading to decreased potency of a selective Src signaling inhibitor.</div><div class="NLM_p">The inhibition of isolated Src by <b>1</b> was weak (IC<sub>50</sub> 46 μM), as was expected based upon our earlier Src inhibition results described above including the structural observations that the peptide substrate site is not well formed when Src is isolated. Indeed, using <b>1</b> as a control to develop an NMR-based assay with a paramagnetic probe for the identification of non-ATP competitive kinase inhibitors, Moy  et al.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> confirmed that <b>1</b> binds to isolated Src outside of the ATP site, simultaneously with an ATP-site binder, suggesting that it binds in the peptide substrate site. This contrasts with Ple et al., who reported an ATP competitive anilinoquinazoline Src inhibitor (compound <b>28</b> in their publication, labeled AZ28 herein) with high affinity and specificity for Src (isolated Src IC<sub>50</sub> <4 nM, Src3T3 cells IC<sub>50</sub> 110 nM).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We utilized this ATP competitive Src inhibitor for some of our early comparative studies with <b>1</b>.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> shows the correlation between inhibition of Src autophosphorylation and cell proliferation for the Src growth driven cell lines Src3T3 and HT29. There is a good correlation for both compound <b>1</b> and the known ATP-competitive Src inhibitor AZ28, although compound <b>1</b> is more potent than AZ28 in both Src3T3 (20 vs 87 nM, respectively) and HT29 cells (25 vs 647 nM, respectively) in this comparative study. A further comparison in Src3T3 and HT29 cells showed a similar correlation between inhibition of transphosphorylation of the Src substrates Shc (Y239/240), FAK (Y925), and paxillin (Y-31) and growth inhibition.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These results strongly suggest that compound <b>1</b> is a Src signaling inhibitor with ca. 20 nM level potency in whole cells. These results were confirmed by Src kinase inhibition data, in addition to inhibition of downstream signals, in various tumor cell lines and tumor tissues carried out by a number of external laboratories.<a onclick="showRef(event, 'ref23 cit29a cit29b ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref23 cit29a cit29b ref30 ref31">(23,29a,b,30,31)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Comparative inhibition of Src autophosphorylation (Src-poY416) vs growth inhibition for Src3T3 and HT29 cells. Compound <b>1</b> is compared to the ATP competitive Src inhibitor AZ28.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Cells were lysed, subjected to PAGE, and probed with phospho-Src family (poTyr416) antibody (Cell Signaling Technology no. 2101). Densitometry was used to quantify the results from the gels and the <i>Y</i> axis shows the fold change in the Src-Y416 densitometry signal from the control (no inhibitor). The <i>X</i> axis is scored with multiples of the individual compound’s GI<sub>50</sub>. The activity against Src autophosphorylation correlates with the growth inhibition for Src3T3 and HT29 cell lines, driven by active Src.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The selectivity of Src inhibitor <b>1</b> compared to AZ28 across a range of isolated kinases was tested at a set concentration of 10 μM (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf" class="ext-link">Supporting Information</a>). These data showed that <b>1</b> has no activity against the 16 kinases tested, whereas AZ28 showed strong cross inhibitory activity against ABL, EGFR, FYN, LCK, LYN, and YES. The ability of <b>1</b> to inhibit Pdgfr, Egfr, Jak1 and Jak2, LCK, ZAP70, LYN, and BCR-ABL autophosphorylation in Src/Yes/Fyn-null (SYF) mouse embryo fibroblasts, MDA-MB-231 (LCK), Jurkat (ZAP70), DU-145 (LYN), and K562 (BCR-ABL) cell lines was also evaluated. These results demonstrated that <b>1</b> does not inhibit Pdgfr, Egfr, Jak1 and Jak2, LCK, and ZAP70 in whole cells up to a concentration of 10 μM.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> BCR-ABL and LYN were inhibited, but at an IC<sub>50</sub> of about 100–200 nM, i.e., about 10-fold less potently than against Src.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Compound <b>1</b> also induced p53 expression (a tumor suppressor) in Src3T3 cells, PARP cleavage (an apoptosis indicator) in K562 cells and caspase-3 cleavage (an apoptosis indicator) in Src3T3 and HT29 cells, suggesting several mechanisms for its antiproliferative effects.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Compound <b>1</b> was then screened across a broad range of solid and liquid tumor cell lines as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. These data show that <b>1</b> has broad antitumor activity in the low nM range, including against drug resistant tumor cell lines (see also <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>1</b> also showed a broader spectrum of activity, and greater potency, as compared to the ATP competitive Src inhibitor dasatinib, when evaluated against a series of liver cancer cell lines.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Potency of <b>1</b> and Dasatinib against a Range of Solid and Liquid Tumor Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">human solid tumor cell line</th><th class="colsep0 rowsep0" align="center"><b>1</b> GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">human liquid tumor cell line</th><th class="colsep0 rowsep0" align="center"><b>1</b> GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">dasatinib GI<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">K562 (CML)</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT29 (colon)</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="left">K562R (Gleevec resistant CML)</td><td class="colsep0 rowsep0" align="center">0.64</td><td class="colsep0 rowsep0" align="center">0.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SKOV-3 (ovarian)</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="left">MOLT-4 (ALL)</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">644</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC3-MM2 (prostate)</td><td class="colsep0 rowsep0" align="center">9</td><td class="colsep0 rowsep0" align="left">CCRF-HSB-2 (ALL)</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">inactive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">L3.6pl (pancreas)</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="left">Jurkat (adult T cell leukemia)</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231 (breast)</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="left">Ba/F3 + WT BCR-Abl</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549 (lung)</td><td class="colsep0 rowsep0" align="center">9</td><td class="colsep0 rowsep0" align="left">Ba/F3 + E225 K (Gleevec resistant)</td><td class="colsep0 rowsep0" align="center">80</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HuH7 (liver)</td><td class="colsep0 rowsep0" align="center">9</td><td class="colsep0 rowsep0" align="left">Ba/F3 + T315I (Gleevec and dasatinib resistant)</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">769-P (kidney)</td><td class="colsep0 rowsep0" align="center">45</td><td class="colsep0 rowsep0" align="left">KG-1 (AML)</td><td class="colsep0 rowsep0" align="center">16</td><td class="colsep0 rowsep0" align="center">inactive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">RPMI8226 (multiple myeloma)</td><td class="colsep0 rowsep0" align="center">40</td><td class="colsep0 rowsep0" align="center">inactive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">RL (non-Hodgkin’s lymphoma)</td><td class="colsep0 rowsep0" align="center">19</td><td class="colsep0 rowsep0" align="center">NT</td></tr></tbody></table></div></div><div class="NLM_p">The oral bioavailability in mice for <b>1</b> (49%), wherein the fluorine was removed, was similar to that for <b>9</b> (64%) wherein the fluorine is present. The ability of <b>1</b> to penetrate the brain in mice was evaluated after oral administration at 10 mg/kg. The brain-to-plasma AUC ratio was 0.42, indicating the brain tissue exposure to <b>1</b> is 42% of the peripheral exposure. Although this is a respectable level of brain penetration for a small molecule oncology drug, a higher level would be more desirable for treating CNS cancers. The basicity of the morpholino nitrogen in <b>1</b> was expected to be a significant factor in affecting the ability to cross the blood–brain barrier (BBB) because the free base would likely be the form able to cross the lipophilic BBB. The number of rotatable bonds was also expected to be a significant factor. With these two factors in mind, analogue <b>2</b> was designed to reduce the basicity of the morpholino nitrogen, due to conjugation with the aryl ring and attachment to a more electron withdrawing sp<sup>2</sup> hybridized carbon atom, as well as to reduce the number of rotatable bonds. The p<i>K</i><sub>a</sub> of the morpholino nitrogen in <b>1</b> was measured at 6.16 (pyridyl N was 3.50), whereas the p<i>K</i><sub>a</sub> of the morpholino nitrogen in <b>2</b> was 1.71 (pyridyl N was 3.66), showing that the basicity of <b>2</b> was greatly reduced compared with <b>1</b>, hence yielding a much larger proportion of the corresponding free base at a physiological pH near 7. Modeling studies with the homology built Src indicated that the shortened morpholino side chain can be accommodated in the active site. The presence of a fluorine on the benzyl side chain was also postulated to increase the ability of the compound to cross the BBB. The brain-to-plasma AUC ratio for <b>2</b> in mice, after oral administration at 20 mg/kg, was 1.16, indicating that the brain tissue exposure is at least as high as the peripheral tissues.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The oral bioavailability for <b>2</b> in mice was 40% when dosed at 20 mg/kg, indicating that the dual goals of oral bioavailability and very high brain penetration were achieved with these targeted structural changes to <b>1</b>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compound <b>2</b> was demonstrated to be a Src autophosphorylation inhibitor in GL261 mouse glioblastoma cells with an IC<sub>50</sub> of approximately 60 nM.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Analogous to <b>1</b>, <b>2</b> is a weak inhibitor of isolated Src with an IC<sub>50</sub> of 67 μM and likely for the same reasons. Brain penetrating <b>2</b> was tested against a range of CNS tumor cell lines, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, and found to have nM level potency against them all, including the Temodar-resistant cell line T98G.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency of <b>2</b> Compared to Dasatinib against a Range of CNS Tumor Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center"><b>2</b>, GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">dasatinib GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">disease</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Daoy</td><td class="colsep0 rowsep0" align="center">16</td><td class="colsep0 rowsep0" align="center">2927</td><td class="colsep0 rowsep0" align="center">desmoplastic cerebellar medulloblastoma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-N-MC</td><td class="colsep0 rowsep0" align="center">8</td><td class="colsep0 rowsep0" align="center">5114</td><td class="colsep0 rowsep0" align="center">neuroepithelioma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SW1088</td><td class="colsep0 rowsep0" align="center">26</td><td class="colsep0 rowsep0" align="center">898</td><td class="colsep0 rowsep0" align="center">astrocytoma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LN-18</td><td class="colsep0 rowsep0" align="center">2.9</td><td class="colsep0 rowsep0" align="center">565</td><td class="colsep0 rowsep0" align="center">glioma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-N-FI</td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">neuroblastoma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U87</td><td class="colsep0 rowsep0" align="center">76</td><td class="colsep0 rowsep0" align="center">1586</td><td class="colsep0 rowsep0" align="center">glioma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GL261</td><td class="colsep0 rowsep0" align="center">57</td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="center">glioma (mouse)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T98G (<i>Temodar resistant</i>)</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">glioma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U118</td><td class="colsep0 rowsep0" align="center">29</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">glioma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U138</td><td class="colsep0 rowsep0" align="center">51</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">glioma (human)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U373</td><td class="colsep0 rowsep0" align="center">54</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">glioma (human)</td></tr></tbody></table></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Discovery of Tubulin Polymerization Inhibition as the Second MOA for KX2-391 (<b>1</b>) and KX2-361 (<b>2</b>)</h3><div class="NLM_p">The broad range of tumor cell lines in which compounds <b>1</b> and <b>2</b> showed potent growth inhibition suggested that a MOA in addition to Src inhibition may be involved for these compounds. This was reinforced by our comparative tumor cell studies with dasatinib/Sprycel (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), a marketed ATP-competitive Src/multikinase inhibitor.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Because Src will be inhibited by dasatinib, the finding that some cell lines demonstrated sensitivity to <b>1</b> or <b>2</b>, but not to dasatinib, likely indicates that these cell lines are not Src-driven, again suggesting a second MOA for <b>1</b> and <b>2</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Tumor Cell Activity of <b>1</b> in Dasatinib- and Paclitaxel-Resistant Tumor Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="−" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">human tumor cell line</th><th class="colsep0 rowsep0" align="center" char="−"><b>1</b> GI<sub>50</sub>–GI<sub>90</sub> (nM)</th><th class="colsep0 rowsep0" align="center">dasatinib GI<sub>50</sub>–GI<sub>90</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H460 (NSCLC)</td><td class="colsep0 rowsep0" align="char" char="−">51–162</td><td class="colsep0 rowsep0" align="center">90–48880</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H226 (NSCLC)</td><td class="colsep0 rowsep0" align="char" char="−">98–490</td><td class="colsep0 rowsep0" align="center">163–34340</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT116 (colon)</td><td class="colsep0 rowsep0" align="char" char="−">31–195</td><td class="colsep0 rowsep0" align="center">880–not reached</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SW620 (colon)</td><td class="colsep0 rowsep0" align="char" char="−">109–903</td><td class="colsep0 rowsep0" align="center">2418–2940</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>1</b> GI<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">paclitaxel GI<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEX-SA/Dx5 (multidrug resistant uterine sarcoma)</td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="center">1800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI/ADR-RES (multidrug resistant ovarian cancer)</td><td class="colsep0 rowsep0" align="center">56</td><td class="colsep0 rowsep0" align="center">5943</td></tr></tbody></table></div></div><div class="NLM_p">To identify the second MOA, we utilized photoaffinity labeling technology.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We selected a benzophenone as the photoaffinity labeling moiety, and an alkyne to subsequently attach a reporter tag with click chemistry after covalent attachment of the photoaffinity drug analogue to the target proteins within whole cells, as illustrated in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Design of photoaffinity analogue <b>10</b> from <b>1</b> and protein target(s) labeling in whole cells. Details of the labeling experiments are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Importantly, photoaffinity analogue <b>10</b> was equipotent to the parental drug <b>1</b> in both HT29 colon cancer cells (GI<sub>50</sub>s 28 and 25 nM, respectively) and PC3-LN4 prostate cancer cells (GI<sub>50</sub>s 45 and 40 nM, respectively), suggesting that the photoaffinity side chains did not alter drug targeting. HT29 colon cancer cells were treated with photoaffinity analogue <b>10</b> in the presence and absence of a 200-fold excess of the parent drug <b>1</b> in order to identify possible off-target binding by the photoaffinity analogue <b>10</b> (which should be lost in the presence of the parental drug). After photolabeling, lysates were treated with the fluorophore TAMRA azide (tetramethylrhodamine azidetetramethylrhodamine 5-carboxamido-(6-azidohexanyl); Invitrogen B10182), which was appended through click chemistry with the alkyne, and then the labeled target proteins were separated by SDS-PAGE and visualized by in-gel fluorescent scanning (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. SDS-PAGE separation and in-gel fluorescent scanning visualization of protein targets labeled by photoaffinity analogue <b>10</b> in the presence or absence of a 200-fold excess of the parental drug <b>1</b>. Protein labeling that increased with higher concentrations of <b>10</b> and are lost in the presence of excess <b>1</b>, are indicated by the arrows. These proteins appear to be targets for the parent drug <b>1</b>. The left side of the figure indicates molecular weight markers in kD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the limitations of photoaffinity labeling technology is that the most abundant target proteins are the ones that are readily identified (Src abundance is likely too low to be identified by this experiment). As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, a series of target proteins were labeled as potential drug target proteins. The protein at MW 55 kDa was the most obvious drug target protein. A 2-D gel was then utilized to better separate the target proteins. The most strongly labeling proteins shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> were identified through in-gel digestion of excised bands, followed by UPLC Q-ToF MS/MS analysis. The labeled proteins were identified as α and β tubulin.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Analysis of labeled target proteins with <b>10</b> in HT29 cells by 2D gel. One mg of HT29 protein lysates were incubated with 2 μM <b>10</b> in the presence or absence of a 200-fold excess of the parent drug <b>1</b> on ice for 1 h under UV irradiation at 365 nm, followed by click chemistry with a rhodamine-azide tag and 2D-gel electrophoresis. The gel spot indicated by the red circle was excised and subjected to in-gel trypsin digestion followed by LC-MS/MS (MALDI-TOF) analyses for protein identification. The protein IDs with high confidence score are listed in the accompanying table.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With α and β tubulin identified as targets of photoaffinity analogue <b>3</b> whose labeling can be competed with excess <b>1</b>, the drug binding site and functional significance were explored. <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> shows competition experiments of known tubulin binding drugs with photoaffinity analogue <b>10</b> using 100- and 500-fold excesses of the listed drugs. These data clearly showed that only <b>1</b> can compete with photoaffinity analogue <b>10</b>, indicating that it binds to a novel site on tubulin.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Competition of known tubulin-binding drugs with photoaffinity analogue <b>10</b> (200 nM). Purified porcine brain tubulin (2 μg) was incubated with photoaffinity analogue <b>10</b> on ice for 1 h under UV irradiation at 365 nm, followed by click chemistry with a TAMRA-azide tag, SDS-PAGE separation and in-gel fluorescence scanning. The indicated inhibitors were included during the incubation at 100- or 500-fold molar excess relative to <b>10</b>. The lack of competition by other known drugs indicates that <b>1</b> binds to a novel site on tubulin. The left side of the gel shows molecular weight markers in kD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further labeling studies using <b>10</b> and purified tubulin along with mass spectroscopy analyses (Nano-LC/LTQ/OrbitrapETD) indicated that photoaffinity analogue <b>10</b> (and parental drug <b>1</b>) are likely binding at the interface of the α–β tubulin heterodimer.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The functional significance of binding to the novel binding site on α–β tubulin heterodimer was first evaluated by using a standard commercial in vitro tubulin polymerization assay kit (Cytoskeleton Inc., BK011P), which is based on the incorporation of a fluorescent reporter into microtubules as polymerization occurs, and showed that <b>1</b> is an effective tubulin polymerization inhibitor. The ability of <b>1</b> to disrupt the filamentous tubulin structures within tumor cells was then evaluated. As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, compound <b>1</b> disrupts tubulin filaments in human peripheral blood mononuclear cells (PBMCs) in a dose-dependent fashion, with visible disruption evident starting at about 125 nM (about 6-fold higher than the Src inhibition IC<sub>50</sub> in whole cells).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Disruption of microtubule structures in PBMCs by <b>1</b>. Human PBMCs were treated with <b>1</b> at the indicated concentrations for 2 h, followed by indirect immunofluorescence staining with anti-α-tubulin antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When <b>1</b> is washed out of the cell culture, filamentous tubulin structures are restored within 30 min. In close agreement, an external laboratory’s study showed that inhibition of Src by <b>1</b> was evident at 20 nM in cell culture whereas tubulin polymerization inhibition required concentrations of at least 80 nM, i.e., at least 4-fold higher than Src inhibition.<a onclick="showRef(event, 'cit29b'); return false;" href="javascript:void(0);" class="ref cit29b">(29b)</a></div><div class="NLM_p">The same series of experiments were carried out with the brain-penetrating analogue <b>2</b> in order to evaluate a second MOA. Compound <b>2</b> demonstrated competition with photoaffinity analogue <b>10</b> for binding to purified tubulin in the same fashion as <b>1</b>, and similarly <b>2</b> disrupted tubulin filaments in GL261 mouse glioma cells at 250 nM.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This indicated that the Src and tubulin polymerization inhibition mechanisms are engaged for both <b>2</b> and <b>1</b>. Compounds <b>2</b> and <b>1</b> also were found to cause G2/M cell cycle arrest, induction of mitotic catastrophe, increased apoptosis (enhanced cleavage of caspase 3 and PARP), increased aneuploidy, decreased cell migration, increased activation of acute stress-inducing molecules, and reduced p53 expression in tumor cell lines in addition to Src inhibition in a number of external laboratories.<a onclick="showRef(event, 'ref23 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref23 ref29 ref30 ref31">(23,29−31)</a></div><div class="NLM_p">A proteomics analysis of the effect of <b>1</b> and <b>2</b> on about 1500 proteins in the PC3-LN4 prostate cancer cell line, as compared to the tubulin polymerization inhibitor vinblastine, was also carried out.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The results showed that vinblastine, <b>1</b>, and <b>2</b> all downregulated the expression of tubulin isotypes, however, only <b>1</b> and <b>2</b> reduced autophosphorylated Src and affected protein expression levels in the Src signaling pathway. This analysis supported the dual Src and tubulin inhibition MOA for both <b>1</b> and <b>2</b>. The impacts of <b>1</b> and <b>2</b> on these tumor cells, in regard to proteome changes, were found to be more similar to each other than either is to that induced by vinblastine, again supporting another MOA beyond tubulin polymerization inhibition. Additionally, <b>1</b> and <b>2</b> affected proteomes slightly differently, suggesting overlapping yet unique subtilties in their effects on tumor cells.</div><div class="NLM_p last">Importantly, it is also worth noting that <b>1</b> and <b>2</b> are not substrates for the efflux pump P-glycoprotein (P-gp) because <b>1</b> maintains its potency in the high Pgp-expressing paclitaxel-resistant cell lines shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, and <b>2</b> is not excluded from penetrating the CNS due to the Pgp efflux pump active at the BBB.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Preclinical in Vivo Results with KX2-391 (<b>1</b>) and KX2-361 (<b>2</b>)</h3><div class="NLM_p">In vivo antitumor activity of <b>1</b> was assessed using a broad range of orthotopic, transgenic, syngeneic, and xenograft mouse solid and liquid tumor model studies. These include prostate (PC3-MM2-orthotopic and TRAMP C2H CaP-transgenic xenografts), breast (triple-negative MDA-MB-231 and MDA-MB-157, and estrogen receptor-α positive MCF7 orthotopic models), pancreatic (L3.6pl-orthotopic), colon (HT29-xenograft and CT26-syngenic), lung (NSCLC A549-xenograft), ovarian (mucinous xenografts RMUG-S and RMUG-L), and CML (Ba/F3[WT or BCR-Abl-xenograft]) models. Typical dosing in these mouse tumor models was oral either twice daily (5 mg/kg) or once daily (10–15 mg/kg) as a salt (HCl or mesylate), although additional dosing regimens are currently being evaluated. The half-life of <b>1</b> in mice after oral dosing is approximately 1 h, with an oral bioavailability of about 60% in a second study. In rats and dogs, the half-life of <b>1</b> is approximately 2 and 8 h, respectively, and it is also well absorbed orally (50–90%). The twice daily dosing in mouse models was selected when only the Src inhibition MOA was known. Upon the basis of our discovery of tubulin polymerization inhibition as the second MOA, once daily dosing was evaluated in order to achieve a higher <i>C</i><sub>max</sub> and thereby better engage the less potent tubulin MOA as well.</div><div class="NLM_p">All of the mouse model studies demonstrated good efficacy of <b>1</b> against tumor growth. An analysis of the tumor vs plasma AUC in an HT29 xenograft mouse model after oral dosing at 5 mg/kg gave a ratio of 1.52, showing an enhanced tumor tissue exposure relative to the plasma levels. The mouse model studies evaluating <b>1</b> against triple negative breast cancer,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> ERα positive breast cancer,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and mucinous ovarian cancer<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> have been published. In these external lab studies, in vivo inhibition of tubulin and Src was demonstrated in isolated tumor tissues as well as in tumor cell cultures. This resulted in inhibition of tumor growth, reduced tumor cell proliferation, increased apoptosis, antiangiogenesis, and importantly, reduced metastasis. Synergistic in vivo and in vitro efficacy of <b>1</b> with tamoxifen for estrogen receptor-α (ERα) positive breast cancer,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> paclitaxel or doxorubicin for triple negative breast cancer,<a onclick="showRef(event, 'cit29a'); return false;" href="javascript:void(0);" class="ref cit29a">(29a)</a> and oxaliplatin for mucinous ovarian cancer<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> was also demonstrated. Compound <b>1</b> was more efficacious in inhibiting metastasis than was paclitaxel<a onclick="showRef(event, 'cit29a'); return false;" href="javascript:void(0);" class="ref cit29a">(29a)</a> even though both compounds disrupt tubulin dynamics, albeit by inhibition of tubulin polymerization for <b>1</b> vs inhibition of tubulin depolymerization for paclitaxel. This suggests that Src inhibition as the second MOA for <b>1</b> may be increasing its efficacy in blocking metastasis because Src activity has been linked to metastasis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Interestingly, reducing the oral dose of <b>1</b> to 20% of the full dose (i.e., to 1 mg/kg twice daily) in triple negative orthotopic mouse breast cancer models caused re-expression of ERα through changes in histone acetylation, along with increases in the levels of a series of ERα targets and a mesenchymal-to-epithelial transition.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> These changes resulted in a resensitization to tamoxifen treatment in the mouse models. The re-expression of ERα in these models did not occur when <b>1</b> was administered at the full dose (5 mg/kg twice daily) wherein tubulin disruption is also observed. On the other hand, Src inhibition was observed at the lower dose, suggesting that Src inhibition is related to the ERα re-expression. This effect was reversible so that continuous daily dosing with <b>1</b> was needed to maintain ERα re-expression and sensitization to tamoxifen. These results suggested that triple negative breast cancer patients could potentially have less tumor burden and reduced metastasis from daily oral low dose administration of <b>1</b> in addition to co-treatment with tamoxifen and/or other endocrine therapy agents. This drug combination treatment might provide a low toxicity alternative to current cytotoxic chemotherapy cocktails used to treat these breast cancer patients.</div><div class="NLM_p last">Compound <b>2</b> was also evaluated in mouse tumor models. Compound <b>2</b> has an oral bioavailability of about 40%, a half-life of about 2.5 h, and excellent brain penetration (as mentioned earlier) in mice. Most relevant for compound <b>2</b> is a stereotactic intracerebral implantation GL261 glioblastoma multiforme (GBM) tumor model in syngeneic mice. This model is thought to provide a good simulation for GBM in patients because the mouse GL261 tumors tend to grow into the surrounding brain tissues in mice with an intact immune system. Compound <b>2</b>, dosed orally at 30 mg/kg once daily, produced about 30% long-term survivors (i.e., >100 days), whereas vehicle produced 0% survivors within <25 days.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This effect was found to require a fully functional immune system because repeating the experiment in SCID mice lacking T and B cells resulted in longer survival but not >75 days. Additionally, rechallenging syngeneic mice that had survived, due to prior dosing with <b>2</b>, with subcutaneous or intracerebral GL216 reimplantation, resulted in rejection of the tumors in all of the mice without needing to redose <b>2</b>. Immuno-histochemical analysis of the mice from the original experiment that did grow tumors revealed the presence of CD3+ and CD8+ T cell infiltrates into the tumor tissues.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A cohort of mice that survived >75 days were followed to the end of their normal life expectancy (ca. 2 years), and tumor recurrence was not observed in any of the mice. Taken together, these data indicated that compound <b>2</b> combines two avenues of antitumor efficacy, a Src/tubulin targeted effect and an engagement of an adaptive immune response to the glioblastoma tumor cells. This suggests that the potential utility of combining compound <b>2</b> with immunotherapy agents for the treatment of glioblastoma may also be a fruitful future avenue to pursue.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Clinical Evaluation of KX2-391 (<b>1</b>) and KX2-361 (<b>2</b>)</h3><div class="NLM_p">Compound <b>1</b> has completed a phase 1 clinical trial in solid tumor patients, and the results have been published.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This clinical trial was completed before the second MOA (tubulin) for <b>1</b> was discovered and consequently before once daily dosing was considered to be better able to engage the tubulin MOA. Consequently, the trial evaluated continuous twice daily (BID) oral dosing based upon the early mouse BID dosing model studies in order to increase the Src inhibition coverage over a 24 h period. In the initial trial design, the continuous BID dosing was carried out for 3 weeks and the fourth week was a drug holiday in each four week cycle. The maximum tolerated dose (MTD) in this late stage cancer patient population was determined to be 40 mg per dose BID with the 3 weeks on, 1 week off dosing schedule. Subsequently, a continuous dosing schedule without the fourth week off was evaluated and the 40 mg per dose BID was still well tolerated, resulting in this as the final MTD with a continuous dosing schedule. The most common dose-limiting toxicities were liver function test abnormalities (i.e., increased AST and ALT but without increased bilirubin) that were reversible within 1 week, and fatigue.</div><div class="NLM_p">Compound <b>1</b> was well absorbed orally and the drug exposures were dose-proportional in these patients. At the MTD 40 mg dose, the half-life was approximately 4 h, the <i>T</i><sub>max</sub> occurred at about 1 h, and the <i>C</i><sub>max</sub> was about 80 ng/mL (186 nM). The apparent volume of distribution (<i>V</i><sub>z</sub>/<i>F</i>) was about 681 L, indicating good tissue penetration. The highest dose administered in this clinical study was 80 mg/dose BID, resulting in a <i>C</i><sub>max</sub> of 273 ng/mL (633 nM). There was no evidence of drug accumulation over repeated days of dosing.</div><div class="NLM_p">Compound <b>1</b> showed preliminary suggestions of potential efficacy in some of the phase 1 patients. An example is a patient with metastatic ovarian cancer as shown in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>. This patient had been on nine prior therapy regimens, including tubulin targeting drugs. The longest duration of prior therapy was 5 months (carboplatin–paclitaxel combination). This patient’s CA-125 ovarian cancer biomarker clearly responded to compound <b>1</b> treatment, and the patient remained on the treatment for 16 months in spite of the extensive prior drug therapies. This patient achieved a <i>C</i><sub>max</sub> of 231 ng/mL (536 nM) in the first monthly cycle with a 50 mg/dose BID, significantly higher than the <i>C</i><sub>max</sub> mean of 80 ng/mL at the MTD of 40 mg/dose BID.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Phase 1 metastatic ovarian cancer patient sequence of prior therapy before compound <b>1</b> (left side) and response of patient CA-125 ovarian cancer biomarker to compound <b>1</b> (right side).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>1</b> completed a phase 2 clinical study in bone-metastatic castration-resistant prostate cancer patients (CRPC), the results of which have been published.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This clinical study also commenced prior to the tubulin polymerization inhibition second MOA being discovered for compound <b>1</b>. Consequently, the trial was conducted with repeated twice daily oral dosing of compound <b>1</b> at the phase 1 MTD, i.e., 40 mg/dose BID. The median <i>C</i><sub>max</sub> for this dosing regimen was 61 ng/mL (142 nM), lower than the 80 ng/mL <i>C</i><sub>max</sub> for the MTD 40 mg dosing in the phase 1 study with advanced solid tumor patients. This dose of compound <b>1</b> was well tolerated in the phase 2 study, and adverse events were generally mild to moderate. The phase 2 trial did not meet the efficacy end points, however, a modest effect on bone metabolism markers and circulating tumor cell (CTC) counts was observed. The tubulin polymerization inhibition second MOA was discovered after this trial had concluded. A retrospective analysis of the plasma levels of compound <b>1</b> likely needed to begin to engage the tubulin second MOA in solid tumor patients indicated that levels above 142 ng/mL (329 nM) would be needed and can be achieved by dosing at 80 mg/dose or above based upon the phase 1 PK data.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This analysis included the measured effect of plasma binding in cell culture experiments and the 52% enhanced concentration of compound <b>1</b> in preclinical mouse tumor tissues mentioned earlier. It was concluded that the 40 mg/dose BID dosing did not take full advantage of the antitumor activity of compound <b>1</b> and that once daily dosing, at a significantly higher dose, should be evaluated in future clinical studies.</div><div class="NLM_p">In order to evaluate once daily dosing, and to diversify the clinical studies into liquid tumors, a phase 1b study with compound <b>1</b> was carried out in advanced elderly acute myeloid leukemia (AML) patients.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A MTD of about 120 mg/dose, repeated once daily, was established in this patient population. Once daily dosing, even in these frail patients, allowed the administered dose to be increased 3-fold and the total daily dose to be increased by 50%. Compound <b>1</b> partitioned into the bone marrow at concentrations similar to the plasma concentrations. Because there is no enhanced concentration of <b>1</b> in the bone marrow, unlike solid tumor tissue, then the threshold for beginning to engage the tubulin MOA in these liquid tumor patients is about 216 ng/mL (500 nM). At the 120 mg MTD dose, the median <i>C</i><sub>max</sub> was 218 ng/mL (506 nM), with a half-life of about 2.2 h. This drug level is significantly above the 142 ng/mL needed for solid tumor patients, assuming enhanced compound <b>1</b> concentrations in the patient’s tumor tissues as was observed in preclinical studies, but is just reaching the desired 216 ng/mL range for liquid tumor patients. Higher single daily doses for shorter durations, with drug free days in between, are suggested for liquid tumor patients by these PK results. Nevertheless, indications of some efficacy were observed in this phase 1b AML trial. For example, one patient treated with 120 mg repeated daily doses for 165 days had a reduction in splenomegaly from 16 to 4 cm and survived 373 days. An example of a shorter duration, higher dose is a patient that was treated with a 160 mg dose repeated daily for only 12 days and then remained treatment free for about 18 months.</div><div class="NLM_p">The combined phase 1 and 2 PK results for compound <b>1</b> administered orally in solid and liquid tumor patients, along with the concurrent discovery of the tubulin polymerization inhibition second MOA, were very instructive for determining how this compound will likely need to be dosed to maximize its efficacy vs toxicity profile. Peripheral neuropathy, a common side effect of tubulin targeting drugs such as paclitaxel (depolymerization inhibitor) and vincristine (polymerization inhibitor), was not caused by compound <b>1</b> in the clinical trials to date. This reduced clinical neurotoxicity is supported by the observation that <b>1</b> did not alter neurite morphology in a neurite outgrowth assay, whereas vincristine showed a strong effect (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf" class="ext-link">Supporting Information</a>). Other dosing regimens, such as higher single daily doses for a small number of consecutive days, with an appropriate number of drug-free days between the contiguous dosing days, (e.g., “pulse” dosing) are under consideration and preclinical evaluation. Oral dosing provides the flexibility to evaluate such dosing regimens (including “metronomic” dosing) in order to optimize the efficacy vs toxicity profile.</div><div class="NLM_p">A number of literature reports have linked Src activity to the premalignant intraepithelial lesion actinic keratosis (AK) and squamous cell carcinoma (SCC).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> About 65% of SCC’s arise from AK lesions.<a onclick="showRef(event, 'cit37a cit37b'); return false;" href="javascript:void(0);" class="ref cit37a cit37b">(37a,b)</a> Tubulin polymerization inhibition has also been reported to be effective in treating AK lesions.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Because compound <b>1</b> has both MOAs, this opened up another clinical development opportunity. Compound <b>1</b> inhibits the growth of human keratinocytes in vitro with an IC<sub>50</sub> of 32 nM. AK is one of the most common skin conditions that dermatologists see in their patients and is considered a major health concern due to its ability to progress into keratinocyte carcinomas such as SCC.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">A topical formulation for compound <b>1</b> was developed and evaluated in phase 1<a onclick="showRef(event, 'cit40a'); return false;" href="javascript:void(0);" class="ref cit40a">(40a)</a> and phase 2<a onclick="showRef(event, 'cit40b'); return false;" href="javascript:void(0);" class="ref cit40b">(40b)</a> clinical trials and has proceeded into two phase 3<a onclick="showRef(event, 'cit40c cit40d'); return false;" href="javascript:void(0);" class="ref cit40c cit40d">(40c,d)</a> clinical trials for AK. The phase 2 study<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> demonstrated that the compound <b>1</b> ointment, at a 1% strength and administered for only 5 consecutive days to the AK field, was well tolerated. The 100% clearance of AK lesions from the field was 52% on the face and 33% on the scalp.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> This preliminary efficacy, along with the mild local skin reactions that resolved rapidly, formed the basis for proceeding into two phase 3 trials. The combination of good efficacy with low local skin toxicity sets compound <b>1</b> apart from the leading current field treatments for AK wherein good efficacy is coupled with significant local skin toxicity, and promises to provide a new, first in class, treatment for this common precancerous skin disease. The much lower skin toxicity of <b>1</b>, particularly, is expected to result in wider patient and dermatologist acceptance for AK field treatments.</div><div class="NLM_p">Psoriasis is also a hyperproliferative skin disease and compound <b>1</b> is a potent inhibitor of human keratinocyte proliferation. Additionally, Src activity has been shown to be elevated in psoriasis as well as other hyperproliferative skin diseases such as AK and SCC.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Consequently, topical formulations of compound <b>1</b> are also being evaluated in an ongoing phase 1 psoriasis clinical trial.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p last">Compound <b>2</b> has proceeded into phase 1 clinical trials with oral administration in solid tumor patients.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The primary objective is to define the MTD. Secondary objectives are to determine safety and tolerability, PK, and preliminary efficacy. The phase 1 results are not yet available to be released. However, the exceptional brain penetration of <b>2</b>, coupled with the 30% long-term survivors in the mouse GBM model, suggest that <b>2</b> could provide a badly needed first in class efficacious therapy for GBM going forward.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The drug discovery journey described herein was a long one, spanning almost 30 years, albeit with significant blocks of time wherein the project was dormant. It started with the discovery of pentapeptide Src substrate/inhibitors along with some simple naphthalene and indole based small molecule Src (and IRTK) inhibitors that were designed to target the peptide substrate site. The weak binding affinity of peptide substrates/inhibitors, and early nonpeptide analogues, to isolated Src, the poorly formed peptide substrate site in the Src crystal structures, and the knowledge that Src functions in cells while bound within various multiprotein signaling complexes, led to the conclusion that the inhibitors needed to be tested in a whole cell environment. <i>This was a critical insight for the project</i>. Cell growth experiments, wherein the growth is highly dependent upon Src activity, were used to test increasingly elaborated Src inhibitors within a whole cell environment wherein Src is bound to growth controlling signaling complexes. The iterative use of structural/modeling information and proof of concept compounds, followed by potency and in vivo PK optimization, led to two clinical compounds, <b>1</b> and <b>2</b>. Initial mouse xenograft and early clinical trials with <b>1</b> were designed to provide more Src inhibition coverage in a 24 h cycle, and hence twice daily dosing was used. Later MOA studies identified tubulin polymerization inhibition as a second, but somewhat less potent, MOA. An estimation of the plasma levels needed to significantly engage the tubulin second MOA indicated that once daily dosing, at a significantly higher dose, was needed to take advantage of the two MOAs in one drug activity. <i>This was the second important insight in the project</i>. Other dosing regimen variations are also possible to optimize the time at which the plasma levels meet or exceed what is required to engage the tubulin MOA. Dosing in mice verified that the once daily dose can be about 3-fold higher than one of the twice daily doses and that efficacy can be achieved. The MTD dose in oncology patients was also increased from 40 mg/dose twice daily to 120 mg/dose once daily, mirroring the mouse 3-fold increase results.</div><div class="NLM_p">While oral clinical trials with compounds <b>1</b> and <b>2</b> in oncology patients were underway, the idea of evaluating a topical formulation of <b>1</b> for hyperproliferative skin diseases such as actinic keratosis (AK) and psoriasis arose. Phase 1 and 2 clinical trials with <b>1</b> for AK were very promising, and pivotal phase 3 registration clinical trials are currently underway. The unprecedented combination of good efficacy with low local skin toxicity for field AK treatment is providing a breakthrough for treating this common precancerous skin disease. Although the AK clinical application was not envisioned as a potential indication when this program was initiated, it has accelerated quickly. <i>This was the third important insight in the drug discovery and development project</i>. A phase 1 clinical trial of <b>1</b> for psoriasis has also been initiated.</div><div class="NLM_p">Fundamental medicinal chemistry insights were applied to compound <b>1</b> in order to greatly enhance the ability to cross the blood–brain barrier, resulting in compound <b>2</b>. Compound <b>2</b> is a rare example of a potent small molecule oncology compound that fully penetrates the brain. In addition to having a dual Src/tubulin polymerization inhibition MOA, this compound also engages the immune system in a mouse syngeneic model of GBM to further enhance its efficacy and produce long-term survivors. Adding this triple efficacy MOA spectrum to the oral bioavailability, and facile brain penetration, makes compound <b>2</b> a first in class and highly promising compound for treating GBM and other CNS malignancies.</div><div class="NLM_p last">Some of the more general take away concepts from this drug discovery journey are that protein targets that bind within multiprotein complexes in cells may need to be tested in their natural whole cell environment. When doing so, other MOAs may also be unknowingly incorporated into the compound which require subsequent MOA studies to identify. The dosing and clinical applications can be better designed once the full MOA, and potency for each, is known along with the PK.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00164" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53387" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53387" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00164" class="ext-link">10.1021/acs.jmedchem.8b00164</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemical and structural formulas, and the synthesis of compounds <b>1</b>, <b>2</b>, <b>7</b>, <b>8</b>, <b>9</b>, and <b>10</b>, p<i>K</i><sub>a</sub> determinations of compounds <b>1</b> and <b>2</b>, homology modeling, in vitro biological testing, pharmacokinetic studies, and in vivo tumor drug distribution (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">SrcH1 + compound <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">SrcH1 + indole <b>5</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf">jm8b00164_si_001.pdf (613.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_002.csv">jm8b00164_si_002.csv (2.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_003.pdb">jm8b00164_si_003.pdb (442.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_004.pdb">jm8b00164_si_004.pdb (440.35 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00164" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David G. Hangauer</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0497-369X" title="Orcid link">http://orcid.org/0000-0002-0497-369X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a6c2c7d0cfc2ce9291e6d4c9c7c2d4d3c8c8c3d488c5c9cb"><span class="__cf_email__" data-cfemail="91f5f0e7f8f5f9a5a6d1e3fef0f5e3e4fffff4e3bff2fefc">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael
P. Smolinski</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yahao Bu</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Clements</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Irwin H. Gelman</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Genetics & Genomics, Roswell
Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York 14263, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taher Hegab</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David L. Cutler</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane W. S. Fang</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerald Fetterly</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rudolf Kwan</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allen Barnett</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johnson Y. N. Lau</span> - <span class="hlFld-Affiliation affiliation">Athenex
Inc., Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Michael P. Smolinski, Yahao Bu, James Clements, David L. Cutler, Jane W. S. Fang, Gerald Fetterly, Rudolf Kwan, Allen Barnett, Johnson Y. N. Lau, and David G. Hangauer are all either employed by Athenex, Inc. and/or hold equity in Athenex, Inc.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2181-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully thank Dr. Latif Kazim and his co-worker Kyoung-Soo Choi, Roswell Park Comprehensive Cancer Center, for mass spectrum data identifying tubulin as the major protein to which photoaffinity analogue <b>10</b> covalently binds (Figure 12), and Dr. Jun Qu, The University at Buffalo, for mass spectrum data identifying the interface between α–β tubulin heterodimer as the likely binding site for <b>10</b>.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">AK</td><td class="NLM_def"><p class="first last">actinic keratosis</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma multiforme</p></td></tr><tr><td class="NLM_term">PTK</td><td class="NLM_def"><p class="first last">protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">pp60<sup>c-src</sup></p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">IRTK</td><td class="NLM_def"><p class="first last">insulin receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">Src homology 2 domain</p></td></tr><tr><td class="NLM_term">SH3</td><td class="NLM_def"><p class="first last">Src homology 3 domain</p></td></tr><tr><td class="NLM_term">FCS</td><td class="NLM_def"><p class="first last">fetal calf serum</p></td></tr><tr><td class="NLM_term">Src3T3</td><td class="NLM_def"><p class="first last">c-Src527F/NIH3T3 engineered cell line expressing a constitutively active, oncogenic Src</p></td></tr><tr><td class="NLM_term">SYF cells</td><td class="NLM_def"><p class="first last">mouse embryonic fibroblasts deleted of their <i>Src</i>, <i>Fyn</i>, and <i>Yes</i> genes</p></td></tr><tr><td class="NLM_term">c-Src527F/SYF</td><td class="NLM_def"><p class="first last">mouse embryonic fibroblasts deleted of their <i>Src</i>, <i>Fyn</i>, and <i>Yes</i> genes and transduced with c-Src527F</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">PBMCs</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice daily dosing</p></td></tr><tr><td class="NLM_term">AK</td><td class="NLM_def"><p class="first last">actinic keratosis</p></td></tr><tr><td class="NLM_term">SCC</td><td class="NLM_def"><p class="first last">squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">SBD</td><td class="NLM_def"><p class="first last">structure-based design</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">The hunting of the Src</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1038/35073094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2F35073094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=11389470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=467-475&author=G.+S.+Martin&title=The+hunting+of+the+Src&doi=10.1038%2F35073094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The hunting of the Src</span></div><div class="casAuthors">Martin, G. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 120 refs.  The non-receptor tyrosine kinase Src is important for many aspects of cell physiol.  The viral src gene was the 1st retroviral oncogene to be identified, and its cellular counterpart was the 1st protooncogene to be discovered in the vertebrate genome.  Src has been important, not only as an object of study in itself, but also as an entry point into the mol. genetics of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqId3YlI11q77Vg90H21EOLACvtfcHk0li563VwWpVPgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D&md5=36cad805c8b312f84b692efc42b16094</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2F35073094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35073094%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DThe%2520hunting%2520of%2520the%2520Src%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D467%26epage%3D475%26doi%3D10.1038%2F35073094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">The road to Src</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7910</span>– <span class="NLM_lpage">7917</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2Fsj.onc.1208077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=7910-7917&author=G.+S.+Martin&title=The+road+to+Src&doi=10.1038%2Fsj.onc.1208077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208077%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DThe%2520road%2520to%2520Src%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D7910%26epage%3D7917%26doi%3D10.1038%2Fsj.onc.1208077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Src in cancer: Deregulation and consequences for cell behavior</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1602</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/S0304-419X(02)00040-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0304-419X%2802%2900040-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=12020799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=114-130&author=M.+C.+Frame&title=Src+in+cancer%3A+Deregulation+and+consequences+for+cell+behavior&doi=10.1016%2FS0304-419X%2802%2900040-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Src in cancer: deregulation and consequences for cell behavior</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-130</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Considerable evidence now implicates elevated expression and/or activity of Src in cancer development.  In cells, endogenous Src is switched from an inactive to an active state by a variety of mechanisms that simultaneously relieve constraints on the kinase and protein-interacting Src homol. (SH) domains.  As a result, Src is translocated to the cell periphery, often to sites of cell adhesion, where myristylation mediates attachment to the inner surface of the plasma membrane.  From these peripheral sites, Src's catalytic activity initiates intracellular signal transduction pathways that influence cell growth and adhesion strength, the latter contributing to control of cell migration.  De-regulation in cancer cells may therefore enhance tumor growth and/or stimulate migratory or invasive potential in cells that would normally be relatively non-motile.  Evidence now exists to suggest that Src may also influence the life or death decisions that cells make during many biol. processes.  Thus, Src modulation in cancer cells can alter cell responses that are often perturbed in cancer.  Consequently, there is optimism that drugs which inhibit Src's kinase activity, or the activity of its downstream effectors, might have profound effects on cancer cell behavior and be useful therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PUbbCfYCTrVg90H21EOLACvtfcHk0liPDaeSGlCY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D&md5=ac3f4d59c7979798349ea7f0db807d67</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900040-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900040-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DSrc%2520in%2520cancer%253A%2520Deregulation%2520and%2520consequences%2520for%2520cell%2520behavior%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2002%26volume%3D1602%26spage%3D114%26epage%3D130%26doi%3D10.1016%2FS0304-419X%2802%2900040-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Newest findings on the oldest oncogene; how activated src does it</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1242/jcs.01111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1242%2Fjcs.01111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=14996930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVyru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=989-998&author=M.+C.+Frame&title=Newest+findings+on+the+oldest+oncogene%3B+how+activated+src+does+it&doi=10.1242%2Fjcs.01111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Newest findings on the oldest oncogene; how activated src does it</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">989-998</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncogenic forms of the non-receptor tyrosine kinase Src alter cell structure, in particular the actin cytoskeleton and the adhesion networks that control cell migration, and also transmit signals that regulate proliferation and cell survival.  Recent work indicates that they do so by influencing the RhoA-ROCK pathway that controls contractile actin filament assembly, the STAT family of transcription factors needed for transformation, and the Cbl ubiquitin ligase that controls Src protein levels.  These studies also shed light on the role of focal adhesion kinase (FAK) downstream of v-Src and other signaling pathways in controlling migration, invasion and survival of transformed cells.  Src directly phosphorylates integrins and can also modulate R-Ras activity.  Moreover, it stimulates the E-cadherin regulator Hakai, interacts with and phosphorylates the novel podosome-linked adaptor protein Fish, and progressively phosphorylates the gap junction component connexion 43.  A recurring theme is the identification of novel and important Src substrates that mediate key biol. events assocd. with transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6rvTTcPN9XLVg90H21EOLACvtfcHk0liPDaeSGlCY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVyru7g%253D&md5=c50d2426c7d5e3672e9b3d7180b56576</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.01111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.01111%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DNewest%2520findings%2520on%2520the%2520oldest%2520oncogene%253B%2520how%2520activated%2520src%2520does%2520it%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2004%26volume%3D117%26spage%3D989%26epage%3D998%26doi%3D10.1242%2Fjcs.01111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Summy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galllick, G. E.</span></span> <span> </span><span class="NLM_article-title">Src family kinases in tumor progression and metastasis</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1023/A:1023772912750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1023%2FA%3A1023772912750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=12884910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=337-358&author=J.+M.+Summyauthor=G.+E.+Galllick&title=Src+family+kinases+in+tumor+progression+and+metastasis&doi=10.1023%2FA%3A1023772912750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases in tumor progression and metastasis</span></div><div class="casAuthors">Summy, Justin M.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-358</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  The Src family of non-receptor protein tyrosine kinases plays crit. roles in a variety of cellular signal transduction pathways, regulating such diverse processes as cell division, motility, adhesion, angiogenesis, and survival.  Constitutively activated variants of Src family kinases, including the viral oncoproteins v-Src and v-Yes, are capable of inducing malignant transformation of a variety of cell types.  Src family kinases, most notably although not exclusively c-Src, are frequently overexpressed and/or aberrantly activated in a variety of epithelial and non-epithelial cancers.  Activation is very common in colorectal and breast cancers, and somewhat less frequent in melanomas, ovarian cancer, gastric cancer, head and neck cancers, pancreatic cancer, lung cancer, brain cancers, and blood cancers.  Further, the extent of increased Src family activity often correlates with malignant potential and patient survival.  Activation of Src family kinases in human cancers may occur through a variety of mechanisms and is frequently a crit. event in tumor progression.  Exactly how Src family kinases contribute to individual tumors remains to be defined completely, however they appear to be important for multiple aspects of tumor progression, including proliferation, disruption of cell/cell contacts, migration, invasiveness, resistance to apoptosis, and angiogenesis.  This review details the evidence for Src family activation in human tumors, and emphasizes possible consequences to tumor progression.  Given the ability of Src and its family members to participate in so many aspects of tumor progression and metastasis, Src family kinases are attractive targets for future anti-cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkVr5TJ1KYLVg90H21EOLACvtfcHk0liPDaeSGlCY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiu74%253D&md5=9ae3b863e9e79978efbee6e92206cd2b</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023772912750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023772912750%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DGalllick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520family%2520kinases%2520in%2520tumor%2520progression%2520and%2520metastasis%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D337%26epage%3D358%26doi%3D10.1023%2FA%3A1023772912750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Summy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span> <span> </span><span class="NLM_article-title">Treatment for advanced tumors: Src reclaims center stage</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1401</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1078-0432.CCR-05-2692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=16533761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1398-1401&issue=5&author=J.+M.+Summyauthor=G.+E.+Gallick&title=Treatment+for+advanced+tumors%3A+Src+reclaims+center+stage&doi=10.1158%2F1078-0432.CCR-05-2692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment for advanced tumors: Src reclaims center stage</span></div><div class="casAuthors">Summy, Justin M.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1398-1401</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The recent advances in roles of Src in tumor progression and clin./translational advances are discussed.  Src activation in tumor cells indirectly regulates Src activity in endothelial cells.  Increased Src activity in the tumor cells increases VEGF expression, resulting in increased binding to VEGF expression, resulting in increased binding to VEGF receptors on endothelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2D4rtkj8O3LVg90H21EOLACvtfcHk0lgXhhRzR6WAYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D&md5=96eb5f53cf01bd47bc52e250b81e5c71</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2692%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DTreatment%2520for%2520advanced%2520tumors%253A%2520Src%2520reclaims%2520center%2520stage%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26issue%3D5%26spage%3D1398%26epage%3D1401%26doi%3D10.1158%2F1078-0432.CCR-05-2692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yeatman, T. J.</span></span> <span> </span><span class="NLM_article-title">A renaissance for Src</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1038/nrc1366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2Fnrc1366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=15170449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=470-480&author=T.+J.+Yeatman&title=A+renaissance+for+Src&doi=10.1038%2Fnrc1366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">A renaissance for SRC</span></div><div class="casAuthors">Yeatman, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The c-SRC non-receptor tyrosine kinase is overexpressed and activated in a large no. of human malignancies and has been linked to the development of cancer and progression to distant metastases.  These observations have led to the recent targeting of c-SRC for the development of anticancer therapeutics, which show promise as a new avenue for cancer treatment.  Despite this, however, the precise functions of c-SRC in cancer remain unclear.  In addn. to increasing cell proliferation, a key role of c-SRC in cancer seems to be to promote invasion and motility, functions that might contribute to tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCGFL31NDP4LVg90H21EOLACvtfcHk0lgXhhRzR6WAYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D&md5=e14e862826b2881721d0f6bb14356650</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1038%2Fnrc1366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1366%26sid%3Dliteratum%253Aachs%26aulast%3DYeatman%26aufirst%3DT.%2BJ.%26atitle%3DA%2520renaissance%2520for%2520Src%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D470%26epage%3D480%26doi%3D10.1038%2Fnrc1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span> <span> </span><span class="NLM_article-title">Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis</span>. <i>Cell Tissue Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>335</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1007/s00441-008-0682-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs00441-008-0682-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18815812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOru7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2009&pages=249-259&issue=1&author=M.+P.+Kimauthor=S.+I.+Parkauthor=S.+Kopetzauthor=G.+E.+Gallick&title=Src+family+kinases+as+mediators+of+endothelial+permeability%3A+effects+on+inflammation+and+metastasis&doi=10.1007%2Fs00441-008-0682-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis</span></div><div class="casAuthors">Kim, M. P.; Park, S. I.; Kopetz, S.; Gallick, G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell & Tissue Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">CTSRCS</span>;
        ISSN:<span class="NLM_cas:issn">0302-766X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Src family kinases (SFKs) are signaling enzymes that have long been recognized to regulate crit. cellular processes such as proliferation, survival, migration, and metastasis.  Recently, considerable work has elucidated mechanisms by which SFKs regulate normal and pathol. processes in vascular biol., including endothelial cell proliferation and permeability.  Further, when inappropriately activated, SFKs promote pathol. inflammatory processes and tumor metastasis, in part through their effects on the regulation of endothelial monolayer permeability.  In this review, we discuss the roles of aberrantly activated SFKs in mediating endothelial permeability in the context of inflammatory states and tumor cell metastasis.  We further summarize recent efforts to translate Src-specific inhibitors into therapy for systemic inflammatory conditions and numerous solid organ cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqg4M3dV7u7Vg90H21EOLACvtfcHk0lgXhhRzR6WAYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOru7vO&md5=dd515c1f832199b7401753bd8ba082cb</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.1007%2Fs00441-008-0682-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00441-008-0682-9%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BP.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520family%2520kinases%2520as%2520mediators%2520of%2520endothelial%2520permeability%253A%2520effects%2520on%2520inflammation%2520and%2520metastasis%26jtitle%3DCell%2520Tissue%2520Res.%26date%3D2009%26volume%3D335%26issue%3D1%26spage%3D249%26epage%3D259%26doi%3D10.1007%2Fs00441-008-0682-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span> <span> </span><span class="NLM_article-title">Src continues aging: current and future clinical directions</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7232</span>– <span class="NLM_lpage">7236</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1078-0432.CCR-07-1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18094400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCktr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=7232-7236&issue=24&author=S.+Kopetzauthor=A.+N.+Shahauthor=G.+E.+Gallick&title=Src+continues+aging%3A+current+and+future+clinical+directions&doi=10.1158%2F1078-0432.CCR-07-1902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Src Continues Aging: Current and Future Clinical Directions</span></div><div class="casAuthors">Kopetz, Scott; Shah, Ami N.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7232-7236</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of members of the Src family of nonreceptor protein tyrosine kinases is common in solid tumor malignancies and may contribute to the development and/or progression of these tumors.  As a result, four Src inhibitors are now in more than 50 clin. trials for at least 14 different types of solid tumors.  In this review, we briefly discuss the preclin. rationale for Src inhibitors, the development strategies most likely to be successful in the clinic, and the rationale for Src inhibitors in combination with other agents as part of a more comprehensive therapeutic strategy.  As the use of Src family inhibitors in clin. trials on solid tumors is in its infancy, further studies on the roles of Src family kinases in tumor progression, chemoresistance, epidermal-to-mesenchymal transition, and other properties of tumor progression will be important in designing the most effective clin. trials using these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXLm8EfhR0A7Vg90H21EOLACvtfcHk0lgXhhRzR6WAYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCktr%252FO&md5=9035c1e855115b9616c6c9e4f3729222</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1902%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DA.%2BN.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520continues%2520aging%253A%2520current%2520and%2520future%2520clinical%2520directions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D24%26spage%3D7232%26epage%3D7236%26doi%3D10.1158%2F1078-0432.CCR-07-1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span> <span> </span><span class="NLM_article-title">Targeting Src family kinases in anti-cancer therapies: turning promise into triumph</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2011.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.tips.2011.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=22153719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=122-128&author=S.+Zhangauthor=D.+Yu&title=Targeting+Src+family+kinases+in+anti-cancer+therapies%3A+turning+promise+into+triumph&doi=10.1016%2Fj.tips.2011.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src family kinases in anti-cancer therapies: turning promise into triumph</span></div><div class="casAuthors">Zhang, Siyuan; Yu, Dihua</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Src is a non-receptor tyrosine kinase that is deregulated in many types of cancer.  Decades of research have revealed the crucial role of Src in many aspects of tumor development, including proliferation, survival, adhesion, migration, invasion and, most importantly, metastasis, in multiple tumor types.  Despite extensive preclin. evidence that warrants targeting Src as a promising therapeutic approach for cancer, Src inhibitor(s) showed only minimal therapeutic activity in various types of solid tumors when used as a single agent in recent early-phase clin. trials.  In this review, we highlight the most recent advances from preclin. studies and clin. trials that shed light on potential clin. use of Src inhibitor-contg. combinatorial regimens in overcoming resistance to current anticancer therapies and in preventing metastatic recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZvQcvwj_23bVg90H21EOLACvtfcHk0lhO4qqkIoQjGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOqtrk%253D&md5=22c9483e90ec6b390f42b74806d87d21</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DTargeting%2520Src%2520family%2520kinases%2520in%2520anti-cancer%2520therapies%253A%2520turning%2520promise%2520into%2520triumph%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.tips.2011.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bogoyevitch, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketterman, A. J.</span></span> <span> </span><span class="NLM_article-title">Peptide inhibitors of protein kinases—discovery, characterisation and use</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2005.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.bbapap.2005.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=16182621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlagsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=79-99&author=M.+A.+Bogoyevitchauthor=R.+K.+Barrauthor=A.+J.+Ketterman&title=Peptide+inhibitors+of+protein+kinases%E2%80%94discovery%2C+characterisation+and+use&doi=10.1016%2Fj.bbapap.2005.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide inhibitors of protein kinases-discovery, characterisation and use</span></div><div class="casAuthors">Bogoyevitch, Marie A.; Barr, Renae K.; Ketterman, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">79-99</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are now the second largest group of drug targets, and most protein kinase inhibitors in clin. development are directed towards the ATP-binding site.  However, these inhibitors must compete with high intracellular ATP concns. and they must discriminate between the ATP-binding sites of all protein kinases as well the other proteins that also utilize ATP.  It would therefore be beneficial to target sites on protein kinases other than the ATP-binding site.  This review describes the discovery, characterization and use of peptide inhibitors of protein kinases.  In many cases, the development of these peptides has resulted from an understanding of the specific protein-binding partners for a particular protein kinase.  In addn., novel peptide sequences have been discovered in library screening approaches and have provided new leads in the discovery and/or design of peptide inhibitors of protein kinases.  These approaches are therefore providing exciting new opportunities in the development of ATP non-competitive inhibitors of protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4P4RRYVXgzbVg90H21EOLACvtfcHk0lhO4qqkIoQjGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlagsL7P&md5=c148db5b6586ff09ef0c27c239d53971</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DBogoyevitch%26aufirst%3DM.%2BA.%26aulast%3DBarr%26aufirst%3DR.%2BK.%26aulast%3DKetterman%26aufirst%3DA.%2BJ.%26atitle%3DPeptide%2520inhibitors%2520of%2520protein%2520kinases%25E2%2580%2594discovery%252C%2520characterisation%2520and%2520use%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D79%26epage%3D99%26doi%3D10.1016%2Fj.bbapap.2005.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span> <span> </span><span class="NLM_article-title">Progress in the development of non-ATP-competitive protein kinase inhibitors for oncology</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-396492-2.00029-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FB978-0-12-396492-2.00029-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=459-474&author=C.+McInnes&title=Progress+in+the+development+of+non-ATP-competitive+protein+kinase+inhibitors+for+oncology&doi=10.1016%2FB978-0-12-396492-2.00029-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00029-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00029-1%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DC.%26atitle%3DProgress%2520in%2520the%2520development%2520of%2520non-ATP-competitive%2520protein%2520kinase%2520inhibitors%2520for%2520oncology%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D459%26epage%3D474%26doi%3D10.1016%2FB978-0-12-396492-2.00029-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1021/cb5008376</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5008376" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVGmtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=175-189&author=M.+E.+Breenauthor=M.+B.+Soellner&title=Small+molecule+substrate+phosphorylation+site+inhibitors+of+protein+kinases%3A+approaches+and+challenges&doi=10.1021%2Fcb5008376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Substrate Phosphorylation Site Inhibitors of Protein Kinases: Approaches and Challenges</span></div><div class="casAuthors">Breen, Meghan E.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-189</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein kinases are important mediators of cellular communication and attractive drug targets for many diseases.  Although success has been achieved with developing ATP-competitive kinase inhibitors, the disadvantages of ATP-competitive inhibitors have led to increased interest in targeting sites outside of the ATP binding pocket.  Kinase inhibitors with substrate-competitive, ATP-noncompetitive binding modes are promising due to the possibility of increased selectivity and better agreement between biochem. and in vitro potency.  However, the difficulty of identifying these types of inhibitors has resulted in significantly fewer small mol. substrate phosphorylation site inhibitors being reported compared to ATP-competitive inhibitors.  This review surveys reported substrate phosphorylation site inhibitors and methods that can be applied to the discovery of such inhibitors, including a discussion of the challenges inherent to these screening methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIZJGtYNoHhrVg90H21EOLACvtfcHk0li4yptGVBkRDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVGmtr%252FN&md5=6a4eb9aae91c2241d7baa559ef839a0d</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fcb5008376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5008376%26sid%3Dliteratum%253Aachs%26aulast%3DBreen%26aufirst%3DM.%2BE.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DSmall%2520molecule%2520substrate%2520phosphorylation%2520site%2520inhibitors%2520of%2520protein%2520kinases%253A%2520approaches%2520and%2520challenges%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D175%26epage%3D189%26doi%3D10.1021%2Fcb5008376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachacz, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwarcinski, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7010</span>– <span class="NLM_lpage">7013</span>, <span class="refDoi"> DOI: 10.1002/anie.201311096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1002%2Fanie.201311096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=7010-7013&author=M.+B.+Breenauthor=M.+E.+Steffeyauthor=E.+J.+Lachaczauthor=F.+E.+Kwarcinskiauthor=C.+C.+Foxauthor=M.+B.+Soellner&title=Substrate+activity+screening+with+kinases%3A+discovery+of+small-molecule+substrate-competitive+c-Src+inhibitors&doi=10.1002%2Fanie.201311096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201311096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201311096%26sid%3Dliteratum%253Aachs%26aulast%3DBreen%26aufirst%3DM.%2BB.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DLachacz%26aufirst%3DE.%2BJ.%26aulast%3DKwarcinski%26aufirst%3DF.%2BE.%26aulast%3DFox%26aufirst%3DC.%2BC.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DSubstrate%2520activity%2520screening%2520with%2520kinases%253A%2520discovery%2520of%2520small-molecule%2520substrate-competitive%2520c-Src%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D7010%26epage%3D7013%26doi%3D10.1002%2Fanie.201311096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parang, K.</span></span> <span> </span><span class="NLM_article-title">Development of Src tyrosine kinase substrate binding site inhibitors</span>. <i>Curr. Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">613</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=605-613&author=G.+Yeauthor=R.+Tiwariauthor=K.+Parang&title=Development+of+Src+tyrosine+kinase+substrate+binding+site+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DG.%26aulast%3DTiwari%26aufirst%3DR.%26aulast%3DParang%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520Src%2520tyrosine%2520kinase%2520substrate%2520binding%2520site%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D605%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Compositions for Treating Cell Proliferation Disorders</span>. <span class="NLM_patent">US 7,300,931 B2</span>, Nov 27, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+G.+Hangauer&title=Compositions+for+Treating+Cell+Proliferation+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DCompositions%2520for%2520Treating%2520Cell%2520Proliferation%2520Disorders%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods of Treating Cell Proliferation Disorders</span>. U.S. Patent <span class="NLM_patent">US 8,003,641 B2</span>, Aug 23, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+G.+Hangauer&title=Compositions+and+Methods+of+Treating+Cell+Proliferation+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DCompositions%2520and%2520Methods%2520of%2520Treating%2520Cell%2520Proliferation%2520Disorders%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saperstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicario, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strout, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondeyka, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5694</span>– <span class="NLM_lpage">5701</span>, <span class="refDoi"> DOI: 10.1021/bi00439a053</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00439a053" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=5694-5701&author=R.+Sapersteinauthor=P.+P.+Vicarioauthor=V.+S.+Stroutauthor=E.+Bradyauthor=E.+E.+Slaterauthor=W.+J.+Greenleeauthor=D.+L.+Ondeykaauthor=A.+A.+Patchettauthor=D.+G.+Hangauer&title=Design+of+a+selective+insulin+receptor+tyrosine+kinase+inhibitor+and+its+effect+on+glucose+uptake+and+metabolism+in+intact+cells&doi=10.1021%2Fbi00439a053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fbi00439a053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00439a053%26sid%3Dliteratum%253Aachs%26aulast%3DSaperstein%26aufirst%3DR.%26aulast%3DVicario%26aufirst%3DP.%2BP.%26aulast%3DStrout%26aufirst%3DV.%2BS.%26aulast%3DBrady%26aufirst%3DE.%26aulast%3DSlater%26aufirst%3DE.%2BE.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DOndeyka%26aufirst%3DD.%2BL.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DDesign%2520of%2520a%2520selective%2520insulin%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520and%2520its%2520effect%2520on%2520glucose%2520uptake%2520and%2520metabolism%2520in%2520intact%2520cells%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D5694%26epage%3D5701%26doi%3D10.1021%2Fbi00439a053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Identification of efficient pentapeptide substrates for the tyrosine kinase pp60<sup>c-src</sup></span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4276</span>– <span class="NLM_lpage">4283</span>, <span class="refDoi"> DOI: 10.1021/jm00021a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00021a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=4276-4283&author=S.+A.+Nairauthor=M.+H.+Kimauthor=S.+D.+Warrenauthor=S.+Choiauthor=Z.+Songyangauthor=L.+C.+Cantleyauthor=D.+G.+Hangauer&title=Identification+of+efficient+pentapeptide+substrates+for+the+tyrosine+kinase+pp60c-src&doi=10.1021%2Fjm00021a017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm00021a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00021a017%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DWarren%26aufirst%3DS.%2BD.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DSongyang%26aufirst%3DZ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DIdentification%2520of%2520efficient%2520pentapeptide%2520substrates%2520for%2520the%2520tyrosine%2520kinase%2520pp60c-src%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D4276%26epage%3D4283%26doi%3D10.1021%2Fjm00021a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and activity of pentapeptide pp60<sup>c-src</sup> inhibitors containing L-phosphotyrosine mimics</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1998.tb00424.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fj.1399-3011.1998.tb00424.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=9560002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK1cXitFait7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1998&pages=271-281&author=J.+H.+Laiauthor=T.+H.+Marsiljeauthor=S.+Choiauthor=S.+A.+Nairauthor=D.+G.+Hangauer&title=The+design%2C+synthesis+and+activity+of+pentapeptide+pp60c-src+inhibitors+containing+L-phosphotyrosine+mimics&doi=10.1111%2Fj.1399-3011.1998.tb00424.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and activity of pentapeptide pp60c-src inhibitors containing L-phosphotyrosine mimics</span></div><div class="casAuthors">Lai, Jack H.; Marsilje, Thomas H.; Choi, Sun; Nair, Shrikumar A.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-281</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Efficient syntheses of 4-(R,S-hydroxyphosphonomethyl)-L-phenylalanine and 4-carboxy-L-phenylalanine within the context of the pentapeptide Ac-Ile-X-Gly-Glu-Phe-NH2 (wherein X = the unnatural amino acid) illustrate the use of a divergent synthetic strategy from an advanced common peptide intermediate to more readily access peptide-based tyrosine kinase inhibitors.  The key intermediate, Ac-Ile-Phe(4-formyl)-Gly-Glu(O-tBu)-Phe-NH2, was synthesized by a facile palladium-catalyzed carbonylation of Ac-Ile-Phe(4-iodo)-Gly-Glu(O-tBu)-Phe-NH2.  Oxidn. of Ac-Ile-Phe(4-formyl)-Gly-Glu(O-tBu)-Phe-NH2 with tetrabutylammonium permanganate or addn. of di-t-butylphosphite, both followed by trifluoroacetic acid deprotection, gave the target pentapeptide inhibitors wherein X = 4-carboxy-L-phenylalanine or 4-(R,S-hydroxyphosphonomethyl)-L-phenylalanine, resp.  These two peptides gave somewhat more potent inhibition of the tyrosine kinase pp60c-src than the corresponding pentapeptide wherein X = L-phenylalanine, demonstrating that appended functionalities at the 4-position are accepted and can enhance binding through added interactions within the catalytic region of the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPdRuBRDFzKbVg90H21EOLACvtfcHk0ljjvbo7ftg1DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitFait7k%253D&md5=78e2d98f3df2c5c07282ecdfe3b8511f</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1998.tb00424.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1998.tb00424.x%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DS.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520activity%2520of%2520pentapeptide%2520pp60c-src%2520inhibitors%2520containing%2520L-phosphotyrosine%2520mimics%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D1998%26volume%3D51%26spage%3D271%26epage%3D281%26doi%3D10.1111%2Fj.1399-3011.1998.tb00424.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Tetrapeptide tyrosine kinase inhibitors: enantioselective synthesis of p-hydroxymethyl-L-phenylalanine, incorporation into a tetrapeptide, and subsequent elaboration into p-(hydroxy-phosphonomethyl) L-phenylalanine</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1994.tb00182.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fj.1399-3011.1994.tb00182.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=7896504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK2MXisFykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1994&pages=457-465&author=M.+H.+Kimauthor=J.+H.+Laiauthor=D.+G.+Hangauer&title=Tetrapeptide+tyrosine+kinase+inhibitors%3A+enantioselective+synthesis+of+p-hydroxymethyl-L-phenylalanine%2C+incorporation+into+a+tetrapeptide%2C+and+subsequent+elaboration+into+p-%28hydroxy-phosphonomethyl%29+L-phenylalanine&doi=10.1111%2Fj.1399-3011.1994.tb00182.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrapeptide tyrosine kinase inhibitors. Enantioselective synthesis of p-hydroxymethyl-L-phenylalanine, incorporation into a tetrapeptide, and subsequent elaboration into p-(R,S-hydroxyphosphonomethyl)-L-phenylalanine</span></div><div class="casAuthors">Kim, Moon H.; Lai, Jack H.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-65</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A convenient enantioselective synthesis of p-hydroxymethyl-L-phenylalanine (I) was developed which produces a 4/1 ratio of L/D enantiomers resulting from a chiral phase transfer-catalyzed alkylation.  I was coupled into the p561ck tyrosine kinase substrate Ac-Leu-Pro-Tyr-Ala-NHMe as a replacement for Tyr and can subsequently be elaborated into a variety of potential tyrosine kinase inhibitor designs of general structure Ac-Leu-Pro-AA-Ala-NHCH3, wherein AA is an unnatural amino acid.  The contaminating D enantiomer was readily removed after coupling to L-Ala-NHMe of this sequence.  The utility of the p-hydroxymethyl functionality in an efficient divergent synthetic strategy leading to various inhibitor designs is illustrated with the synthesis of Ac-Leu-Pro-AA-Ala-NHMe, wherein AA is p-(R,S-hydroxyphosphonomethyl)-L-phenylalanine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwmU9yR_dkurVg90H21EOLACvtfcHk0ljjvbo7ftg1DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisFykt70%253D&md5=0e660e546c32b6602b7203d571b173d7</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1994.tb00182.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1994.tb00182.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DTetrapeptide%2520tyrosine%2520kinase%2520inhibitors%253A%2520enantioselective%2520synthesis%2520of%2520p-hydroxymethyl-L-phenylalanine%252C%2520incorporation%2520into%2520a%2520tetrapeptide%252C%2520and%2520subsequent%2520elaboration%2520into%2520p-%2528hydroxy-phosphonomethyl%2529%2520L-phenylalanine%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1994%26volume%3D44%26spage%3D457%26epage%3D465%26doi%3D10.1111%2Fj.1399-3011.1994.tb00182.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">638</span>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SRC">2SRC</a> <span class="refDoi"> DOI: 10.1016/S1097-2765(00)80356-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS1097-2765%2800%2980356-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10360179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=629-638&author=W.+Xuauthor=A.+Doshiauthor=M.+Leiauthor=M.+J.+Eckauthor=S.+C.+Harrison&title=Crystal+structures+of+c-Src+reveal+features+of+its+autoinhibitory+mechanism&doi=10.1016%2FS1097-2765%2800%2980356-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span></div><div class="casAuthors">Xu, Wenqing; Doshi, Amish; Lei, Ming; Eck, Michael J.; Harrison, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-638</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Src family kinases are maintained in an assembled, inactive conformation by intramol. interactions of their SH2 and SH3 domains.  Full catalytic activity requires release of these restraints as well as phosphorylation of Tyr-416 in the activation loop.  In previous structures of inactive Src kinases, Tyr-416 and flanking residues are disordered.  We report here four addnl. c-Src structures in which this segment adopts an ordered but inhibitory conformation.  The ordered activation loop forms an α helix that stabilizes the inactive conformation of the kinase domain, blocks the peptide substrate-binding site, and prevents Tyr-416 phosphorylation.  Disassembly of the regulatory domains, induced by SH2 or SH3 ligands, or by dephosphorylation of Tyr-527, could lead to exposure and phosphorylation of Tyr-416.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsIh6d9RHa7Vg90H21EOLACvtfcHk0ljjvbo7ftg1DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D&md5=926f6a6a4097ce667168b5b81d9a1092</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980356-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980356-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%26aulast%3DDoshi%26aufirst%3DA.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DHarrison%26aufirst%3DS.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520c-Src%2520reveal%2520features%2520of%2520its%2520autoinhibitory%2520mechanism%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D629%26epage%3D638%26doi%3D10.1016%2FS1097-2765%2800%2980356-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebetanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1016/j.str.2005.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.str.2005.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=15939018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=861-871&author=S.+W.+Cowan-Jacobauthor=G.+Fendrichauthor=P.+W.+Manleyauthor=W.+Jahnkeauthor=D.+Fabbroauthor=J.+Liebetanzauthor=T.+Meyer&title=The+crystal+structure+of+a+c-Src+complex+in+an+active+conformation+suggests+possible+steps+in+c-Src+activation&doi=10.1016%2Fj.str.2005.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Fendrich, Gabriele; Manley, Paul W.; Jahnke, Wolfgang; Fabbro, Doriano; Liebetanz, Janis; Meyer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramol. interactions between the SH3, SH2, and kinase (SH1) domains.  We have detd. the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail.  This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe.  NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as obsd. for Abl, suggesting that c-Src may also be regulated by myristate binding.  In addn., the structure contains a des-Me analog of the antileukemia drug imatinib (STI571; Gleevec).  This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipzhBFIZrQ7Vg90H21EOLACvtfcHk0lg46NOeHv1_2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D&md5=f0de83e5bca45fe96795e5327e6d1369</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DThe%2520crystal%2520structure%2520of%2520a%2520c-Src%2520complex%2520in%2520an%2520active%2520conformation%2520suggests%2520possible%2520steps%2520in%2520c-Src%2520activation%26jtitle%3DStructure%26date%3D2005%26volume%3D13%26spage%3D861%26epage%3D871%26doi%3D10.1016%2Fj.str.2005.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenlechner, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kairies, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koll, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of active Src kinase domain complexes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2005.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.jmb.2005.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=16168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=222-231&author=C.+B.+Breitenlechnerauthor=N.+A.+Kairiesauthor=K.+Honoldauthor=S.+Scheiblichauthor=H.+Kollauthor=E.+Greiterauthor=S.+Kochauthor=W.+Schaferauthor=R.+Huberauthor=R.+A.+Engh&title=Crystal+structures+of+active+Src+kinase+domain+complexes&doi=10.1016%2Fj.jmb.2005.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Active Src Kinase Domain Complexes</span></div><div class="casAuthors">Breitenlechner, Christine B.; Kairies, Norman A.; Honold, Konrad; Scheiblich, Stefan; Koll, Hans; Greiter, Eva; Koch, Stefan; Schaefer, Wolfgang; Huber, Robert; Engh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">C-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs.  Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form.  Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms.  Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolns. ranging from 2.9 Å to 1.95 Å.  The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation.  The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340.  In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3P258chhrbVg90H21EOLACvtfcHk0lg46NOeHv1_2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF&md5=9bc8e1670457d34ac88e6b5b20efea21</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenlechner%26aufirst%3DC.%2BB.%26aulast%3DKairies%26aufirst%3DN.%2BA.%26aulast%3DHonold%26aufirst%3DK.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKoll%26aufirst%3DH.%26aulast%3DGreiter%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520active%2520Src%2520kinase%2520domain%2520complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D222%26epage%3D231%26doi%3D10.1016%2Fj.jmb.2005.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanafusa, H.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of cellular proteins in rous sarcoma virus-infected cells: analysis by use of anti-phosphotyrosine antibodies</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3035</span>– <span class="NLM_lpage">3042</span>, <span class="refDoi"> DOI: 10.1128/MCB.8.8.3035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1128%2FMCB.8.8.3035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=2463469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaL1cXltVygsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1988&pages=3035-3042&issue=8&author=M.+Hamaguchiauthor=C.+Grandoriauthor=H.+Hanafusa&title=Phosphorylation+of+cellular+proteins+in+rous+sarcoma+virus-infected+cells%3A+analysis+by+use+of+anti-phosphotyrosine+antibodies&doi=10.1128%2FMCB.8.8.3035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of cellular proteins in Rous sarcoma virus-infected cells:  analysis by use of anti-phosphotyrosine antibodies</span></div><div class="casAuthors">Hamaguchi, Michinari; Grandori, Carla; Hanafusa, Hidesaburo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3035-42</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The protein substrates for the tyrosine protein kinases in cells transformed by avian sarcoma viruses were analyzed by gel electrophoresis in combination with immunoblotting or immunopptn. by antibodies against phosphotyrosine.  More than 90% of phosphotyrosine-contg. cellular proteins can be immunopptd. by these antibodies.  The level of phosphotyrosine-contg. cellular proteins detectable by this method markedly increased upon transformation with Rous sarcoma virus-transformed cells.  Most of these phosphotyrosine-contg. proteins had not been identified by other methods, and their presence appeared to correlate with morphol. transformation in cells infected with various Rous sarcoma virus mutants and Y73, PRCII, and Fujinami sarcoma viruses.  However, considerably different patterns were obtained with cells infected with nontransforming Rous sarcoma virus mutants that encode nonmyristylated src kinases, indicating that most substrates that correlate with transformation can only be recognized by p60v-src assocd. with the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqMmr66XuaBLVg90H21EOLACvtfcHk0lg46NOeHv1_2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVygsbc%253D&md5=765c83949af11e5b5bb7de21525d0c9a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FMCB.8.8.3035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.8.8.3035%26sid%3Dliteratum%253Aachs%26aulast%3DHamaguchi%26aufirst%3DM.%26aulast%3DGrandori%26aufirst%3DC.%26aulast%3DHanafusa%26aufirst%3DH.%26atitle%3DPhosphorylation%2520of%2520cellular%2520proteins%2520in%2520rous%2520sarcoma%2520virus-infected%2520cells%253A%2520analysis%2520by%2520use%2520of%2520anti-phosphotyrosine%2520antibodies%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1988%26volume%3D8%26issue%3D8%26spage%3D3035%26epage%3D3042%26doi%3D10.1128%2FMCB.8.8.3035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S.
R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5572</span>– <span class="NLM_lpage">5581</span>, <span class="refDoi"> DOI: 10.1093/emboj/16.18.5572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1093%2Femboj%2F16.18.5572" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5572-5581&issue=18&author=S.%0AR.+Hubbard&title=Crystal+structure+of+the+activated+insulin+receptor+tyrosine+kinase+in+complex+with+peptide+substrate+and+ATP+analog&doi=10.1093%2Femboj%2F16.18.5572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.18.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.18.5572%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520activated%2520insulin%2520receptor%2520tyrosine%2520kinase%2520in%2520complex%2520with%2520peptide%2520substrate%2520and%2520ATP%2520analog%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26issue%3D18%26spage%3D5572%26epage%3D5581%26doi%3D10.1093%2Femboj%2F16.18.5572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/372746a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2F372746a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=7997262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=746-754&author=S.+R.+Hubbardauthor=L.+Weiauthor=W.+A.+Hendrickson&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+human+insulin+receptor&doi=10.1038%2F372746a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span></div><div class="casAuthors">Hubbard, Stevan R.; Wei, Lei; Ellis, Leland; Hendrickson, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">746-54</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The x-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been detd. by multiwavelength anomalous diffraction phasing and refined to 2.1 Å resoln.  The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1162, is bound in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp222kk0byoTrVg90H21EOLACvtfcHk0lgW00vkLddX8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D&md5=ad60bacc76a642b2957c55ff82274cab</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1038%2F372746a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372746a0%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520human%2520insulin%2520receptor%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D746%26epage%3D754%26doi%3D10.1038%2F372746a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 1: hydroxynaphthalene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00039-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0960-894X%2800%2900039-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=477-481&author=T.+H.+Marsiljeauthor=K.+L.+Milkiewiczauthor=D.+G.+Hangauer&title=The+design%2C+synthesis+and+activity+of+non-ATP+competitive+inhibitors+of+pp60c-src+tyrosine+kinase.+Part+1%3A+hydroxynaphthalene+derivatives&doi=10.1016%2FS0960-894X%2800%2900039-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900039-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900039-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520activity%2520of%2520non-ATP%2520competitive%2520inhibitors%2520of%2520pp60c-src%2520tyrosine%2520kinase.%2520Part%25201%253A%2520hydroxynaphthalene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D477%26epage%3D481%26doi%3D10.1016%2FS0960-894X%2800%2900039-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, R. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 2: hydroxyindole derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00040-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0960-894X%2800%2900040-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=483-486&author=K.+L.+Milkiewiczauthor=T.+H.+Marsiljeauthor=R.+P.+Woodworthauthor=N.+Bifulcoauthor=M.+J.+Hangauerauthor=D.+G.+Hangauer&title=The+design%2C+synthesis+and+activity+of+non-ATP+competitive+inhibitors+of+pp60c-src+tyrosine+kinase.+Part+2%3A+hydroxyindole+derivatives&doi=10.1016%2FS0960-894X%2800%2900040-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900040-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900040-8%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DWoodworth%26aufirst%3DR.%2BP.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DHangauer%26aufirst%3DM.%2BJ.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520activity%2520of%2520non-ATP%2520competitive%2520inhibitors%2520of%2520pp60c-src%2520tyrosine%2520kinase.%2520Part%25202%253A%2520hydroxyindole%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D483%26epage%3D486%26doi%3D10.1016%2FS0960-894X%2800%2900040-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span>Southern Research Institute, Birmingham, AL. Unpublished
results..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Southern+Research+Institute%2C+Birmingham%2C+AL.+Unpublished%0Aresults.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span>; <span class="NLM_string-name">El-Araby, M. E.</span>; <span class="NLM_string-name">Milkiewicz, K. L.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase and Phosphatase Inhibitors and Methods for Designing Them</span>. U.S. Patents <span class="NLM_patent">US 7,772,216 B2</span>, Aug 10, <span class="NLM_year">2010</span>, and <span class="NLM_patent">US 7,005,445, B2</span>, Feb 28, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+G.+Hangauer&author=M.+E.+El-Araby&author=K.+L.+Milkiewicz&title=Protein+Kinase+and+Phosphatase+Inhibitors+and+Methods+for+Designing+Them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DProtein%2520Kinase%2520and%2520Phosphatase%2520Inhibitors%2520and%2520Methods%2520for%2520Designing%2520Them%26date%3D2010%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods of Treating Cell Proliferation Disorders</span>. <span class="NLM_patent">US 8,980,890 B2</span>, Mar 17, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+G.+Hangauer&title=Compositions+and+Methods+of+Treating+Cell+Proliferation+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DCompositions%2520and%2520Methods%2520of%2520Treating%2520Cell%2520Proliferation%2520Disorders%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span>; <span class="NLM_string-name">Bu, Y.</span>; <span class="NLM_string-name">Smithgall, T.</span>; <span class="NLM_string-name">Hangauer, D. G.</span>; <span class="NLM_string-name">Gelman, I. H.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gao%2C+L.%3B+Bu%2C+Y.%3B+Smithgall%2C+T.%3B+Hangauer%2C+D.+G.%3B+Gelman%2C+I.+H.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moy, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stochaj, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosyak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, D. H. H.</span></span> <span> </span><span class="NLM_article-title">Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1021/jm901525b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901525b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1238-1249&author=F.+J.+Moyauthor=A.+Leeauthor=L.+K.+Gavrinauthor=Z.+B.+Xuauthor=A.+Sieversauthor=E.+Kierasauthor=W.+Stochajauthor=L.+Mosyakauthor=J.+McKewauthor=D.+H.+H.+Tsao&title=Novel+synthesis+and+structural+characterization+of+a+high-affinity+paramagnetic+kinase+probe+for+the+identification+of+non-ATP+site+binders+by+nuclear+magnetic+resonance&doi=10.1021%2Fjm901525b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901525b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901525b%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DXu%26aufirst%3DZ.%2BB.%26aulast%3DSievers%26aufirst%3DA.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DStochaj%26aufirst%3DW.%26aulast%3DMosyak%26aufirst%3DL.%26aulast%3DMcKew%26aufirst%3DJ.%26aulast%3DTsao%26aufirst%3DD.%2BH.%2BH.%26atitle%3DNovel%2520synthesis%2520and%2520structural%2520characterization%2520of%2520a%2520high-affinity%2520paramagnetic%2520kinase%2520probe%2520for%2520the%2520identification%2520of%2520non-ATP%2520site%2520binders%2520by%2520nuclear%2520magnetic%2520resonance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1238%26epage%3D1249%26doi%3D10.1021%2Fjm901525b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van
der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1021/jm030317k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030317k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=871-887&author=P.+A.+Pl%C3%A9author=T.+P.+Greenauthor=L.+F.+Hennequinauthor=J.+Curwenauthor=M.+Fennellauthor=J.+Allenauthor=C.+Lambert-van%0Ader+Bremptauthor=G.+Costello&title=Discovery+of+a+new+class+of+anilinoquinazoline+inhibitors+with+high+affinity+and+specificity+for+the+tyrosine+kinase+domain+of+c-Src&doi=10.1021%2Fjm030317k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm030317k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030317k%26sid%3Dliteratum%253Aachs%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520new%2520class%2520of%2520anilinoquinazoline%2520inhibitors%2520with%2520high%2520affinity%2520and%2520specificity%2520for%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520c-Src%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D871%26epage%3D887%26doi%3D10.1021%2Fjm030317k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span>; <span class="NLM_string-name">Bu, Y.</span>; <span class="NLM_string-name">Munich, S. A.</span>; <span class="NLM_string-name">Smolinski, M. P.</span>; <span class="NLM_string-name">Clements, J. L.</span>; <span class="NLM_string-name">Lau, J. Y. N.</span>; <span class="NLM_string-name">Hangauer, D. G.</span>; <span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">KX2-361: A novel small molecule inhibitor of Src signaling and tubulin polymerization that prolongs survival in mice with GL261 cerebral gliomas</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ciesielski%2C+M.+J.%3B+Bu%2C+Y.%3B+Munich%2C+S.+A.%3B+Smolinski%2C+M.+P.%3B+Clements%2C+J.+L.%3B+Lau%2C+J.+Y.+N.%3B+Hangauer%2C+D.+G.%3B+Fenstermaker%2C+R.+A.+KX2-361%3A+A+novel+small+molecule+inhibitor+of+Src+signaling+and+tubulin+polymerization+that+prolongs+survival+in+mice+with+GL261+cerebral+gliomas.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26atitle%3DKX2-361%253A%2520A%2520novel%2520small%2520molecule%2520inhibitor%2520of%2520Src%2520signaling%2520and%2520tubulin%2520polymerization%2520that%2520prolongs%2520survival%2520in%2520mice%2520with%2520GL261%2520cerebral%2520gliomas" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span>; <span class="NLM_string-name">Munich, S. A.</span>; <span class="NLM_string-name">Hangauer, D. G.</span>; <span class="NLM_string-name">Dyster, L. M.</span>; <span class="NLM_string-name">Clements, J. L.</span>; <span class="NLM_string-name">Barnett, A.</span>; <span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">KX02 a novel therapeutic for glioma</span>. In  <i>AACR 101st Annual Meeting, Washington, DC, April 17–21</i>, <span class="NLM_year">2010</span>; poster abstract no.  <span class="NLM_fpage">5598</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=5598&author=M.+J.+Ciesielski&author=S.+A.+Munich&author=D.+G.+Hangauer&author=L.+M.+Dyster&author=J.+L.+Clements&author=A.+Barnett&author=R.+A.+Fenstermaker&title=KX02+a+novel+therapeutic+for+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26atitle%3DKX02%2520a%2520novel%2520therapeutic%2520for%2520glioma%26jtitle%3DAACR%2520101st%2520Annual%2520Meeting%252C%2520Washington%252C%2520DC%252C%2520April%252017%25E2%2580%259321%26date%3D2010%26spage%3D5598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fex, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span> <span> </span><span class="NLM_article-title">2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of <i>N</i>-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent <i>pan</i>-Src kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6819</span>– <span class="NLM_lpage">6832</span>, <span class="refDoi"> DOI: 10.1021/jm060727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=F.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-Aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure-activity+relationship+studies+toward+the+discovery+of+N-%282-Chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor&doi=10.1021%2Fjm060727j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure-Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor</span></div><div class="casAuthors">Das, Jagabandhu; Chen, Ping; Norris, Derek; Padmanabha, Ramesh; Lin, James; Moquin, Robert V.; Shen, Zhongqi; Cook, Lynda S.; Doweyko, Arthur M.; Pitt, Sidney; Pang, Suhong; Shen, Ding Ren; Fang, Qiong; de Fex, Henry F.; McIntyre, Kim W.; Shuster, David J.; Gillooly, Kathleen M.; Behnia, Kamelia; Schieven, Gary L.; Wityak, John; Barrish, Joel C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6819-6832</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Aminothiazole was discovered as a novel Src family kinase inhibitor template through screening of our internal compd. collection.  Optimization through successive structure-activity relationship iterations identified analogs I [R = 4-(2-hydroxyethyl)piperazino, Q] (Dasatinib, BMS-354825) and I [R = Me]as pan-Src inhibitors with nanomolar to subnanomolar potencies in biochem. and cellular assays.  Mol. modeling was used to construct a putative binding model for Lck inhibition by this class of compds.  The framework of key hydrogen-bond interactions proposed by this model was in agreement with the subsequent, published crystal structure of I [R = Q] bound to structurally similar Abl kinase.  The oral efficacy of this class of inhibitors was demonstrated with I [R = Me] in inhibiting the proinflammatory cytokine IL-2 ex vivo in mice (ED50 ∼ 5 mg/kg) and in reducing TNF levels in an acute murine model of inflammation (90% inhibition in LPS-induced TNFα prodn. when dosed orally at 60 mg/kg, 2 h prior to LPS administration).  The oral efficacy of I [R = Me] was further demonstrated in a chronic model of adjuvant arthritis in rats with established disease when administered orally at 0.3 and 3 mg/kg twice daily.  I [R = Q] is currently in clin. trials for the treatment of chronic myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrbDd3Qks9cLVg90H21EOLACvtfcHk0lhC8ikEpbd2Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI&md5=9eed66048de7ab90b8a8015385d6f581</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DF.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-Aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure-activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-Chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832%26doi%3D10.1021%2Fjm060727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity labeling in target- and binding-site identification</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.4155%2Ffmc.14.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=25686004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=159-183&issue=2&author=E.+Smithauthor=I.+Collins&title=Photoaffinity+labeling+in+target-+and+binding-site+identification&doi=10.4155%2Ffmc.14.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labeling in target- and binding-site identification</span></div><div class="casAuthors">Smith, Ewan; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-183</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Photoaffinity labeling (PAL) using a chem. probe to covalently bind its target in response to activation by light has become a frequently used tool in drug discovery for identifying new drug targets and mol. interactions, and for probing the location and structure of binding sites.  Methods to identify the specific target proteins of hit mols. from phenotypic screens are highly valuable in early drug discovery.  In this review, we summarize the principles of PAL including probe design and exptl. techniques for in vitro and live cell investigations.  We emphasize the need to optimize and validate probes and highlight examples of the successful application of PAL across multiple disease areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpIXjEh35goLVg90H21EOLACvtfcHk0lh5ffhXJTGR1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D&md5=ca00880405324587a542f19f8bd10d6c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.152%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DPhotoaffinity%2520labeling%2520in%2520target-%2520and%2520binding-site%2520identification%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26issue%3D2%26spage%3D159%26epage%3D183%26doi%3D10.4155%2Ffmc.14.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazim, L.</span>; <span class="NLM_string-name">Choi, K.-S.</span></span> <span class="NLM_publisher-name">Roswell Park Cancer Institute</span>: <span class="NLM_publisher-loc">Buffalo, NY</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kazim%2C+L.%3B+Choi%2C+K.-S.+Roswell+Park+Cancer+Institute%3A+Buffalo%2C+NY.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DKazim%26aufirst%3DL.%26pub%3DRoswell%2520Park%2520Cancer%2520Institute" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span> <span class="NLM_publisher-name">University at Buffalo</span>: <span class="NLM_publisher-loc">Buffalo, NY</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Qu%2C+J.+University+at+Buffalo%3A+Buffalo%2C+NY.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DJ.%26pub%3DUniversity%2520at%2520Buffalo" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span> <span> </span><span class="NLM_article-title">An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2012.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.jprot.2012.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=22982362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Klsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=187-201&author=C.+Tuauthor=J.+Liauthor=Y.+Buauthor=D.+Hangauerauthor=J.+Qu&title=An+ion-current-based%2C+comprehensive+and+reproducible+proteomic+strategy+for+comparative+characterization+of+the+cellular+responses+to+novel+anti-cancer+agents+in+a+prostate+cell+model&doi=10.1016%2Fj.jprot.2012.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model</span></div><div class="casAuthors">Tu, Chengjian; Li, Jun; Bu, Yahao; Hangauer, David; Qu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187-201</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Proteome-level investigation of the mol. targets in anticancer action of promising pharmaceutical candidates is highly desirable but remains challenging due to the insufficient proteome coverage, limited capacity for biol. replicates, and largely unregulated false pos. biomarker discovery of current methods.  This study described a practical platform strategy to address these challenges, using comparison of drug response proteomic signatures by two promising anti-cancer agents (KX01/KX02) as the model system for method development/optimization.  Drug-treated samples were efficiently extd. followed by pptn./on-pellet-digestion procedure that provides high, reproducible peptide recovery.  High-resoln. sepns. were performed on a 75-cm-long, heated nano-LC column with a 7-h gradient, with a highly reproducible nano-LC/nanospray configuration.  An LTQ Orbitrap hybrid mass spectrometer with a charge overfilling approach to enhance sensitivity was used for detection.  Anal. procedures were optimized and well-controlled to achieve high run-to-run reproducibility that permits numerous replicates in one set, and an ion-current-based approach was utilized for quantification.  The false positives of biomarker discovery arising from tech. variability was controlled based on FBDR measurement by comparing biomarker nos. in each drug-treated group vs. "sham samples", which were analyzed in an order randomly interleaved with the anal. drug-treated samples.  More than 1500 unique protein groups were quantified under stringent criteria, and of which about 30% displayed differential expression with FBDR of 0.3-2.1% across groups.  Comparison of drug-response proteomic signatures and the subsequent immunoassay revealed that the action mechanisms of KX01/KX02 are similar but significantly different from vinblastine, which correlates well with clin. and pre-clin. observations.  Furthermore, the results strongly supported the hypothesis that KX01/KX02 are dual-action agents (through inhibition of tubulin and Src).  Moreover, informative insights into the drug-actions on cell cycle, growth/proliferation, and apoptosis were obtained.  This platform technol. provides extensive evaluation of drug candidates and facilitates in-depth mechanism studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF7cSS9rdVKbVg90H21EOLACvtfcHk0lh5ffhXJTGR1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Klsr3O&md5=cd3761a487119886c37ed72387e9927a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2012.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2012.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DQu%26aufirst%3DJ.%26atitle%3DAn%2520ion-current-based%252C%2520comprehensive%2520and%2520reproducible%2520proteomic%2520strategy%2520for%2520comparative%2520characterization%2520of%2520the%2520cellular%2520responses%2520to%2520novel%2520anti-cancer%2520agents%2520in%2520a%2520prostate%2520cell%2520model%26jtitle%3DJ.%2520Proteomics%26date%3D2012%26volume%3D77%26spage%3D187%26epage%3D201%26doi%3D10.1016%2Fj.jprot.2012.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1535-7163.MCT-12-0146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=22784709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1936-1947&issue=9&author=M.+Anbalaganauthor=A.+Aliauthor=R.+K.+Jonesauthor=C.+G.+Marsdenauthor=M.+Shengauthor=L.+Carrierauthor=Y.+Buauthor=D.+Hangauerauthor=B.+G.+Rowan&title=Peptidomimetic+Src%2Fpretubulin+inhibitor+KX-01+alone+and+in+combination+with+paclitaxel+suppresses+growth%2C+metastasis+in+human+ER%2FPR%2FHER2-negative+tumor+xenografts&doi=10.1158%2F1535-7163.MCT-12-0146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts</span></div><div class="casAuthors">Anbalagan, Muralidharan; Ali, Alaa; Jones, Ryan K.; Marsden, Carolyn G.; Sheng, Mei; Carrier, Latonya; Bu, Yahao; Hangauer, David; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1936-1947</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Src kinase is elevated in breast tumors that are ER/PR neg. and do not overexpress HER2, but clin. trials with Src inhibitors have shown little activity.  The present study evaluated preclin. efficacy of a novel peptidomimetic compd., KX-01 (KX2-391), that exhibits dual action as an Src and pretubulin inhibitor.  KX-01 was evaluated as a single-agent and in combination with paclitaxel in MDA-MB-231, MDA-MB-157, and MDA-MB-468 human ER/PR/HER2-neg. breast cancer cells.  Treatments were evaluated by growth/apoptosis, isobologram anal., migration/invasion assays, tumor xenograft vol., metastasis, and measurement of Src, focal adhesion kinase (FAK), microtubules, Ki67, and microvessel d.  KX-01 inhibited cell growth in vitro and in combination with paclitaxel resulted in synergistic growth inhibition.  KX-01 resulted in a dose-dependent inhibition of MDA-MB-231 and MDA-MB-157 tumor xenografts (1 and 5 mg/kg, twice daily).  KX-01 inhibited activity of Src and downstream mediator FAK in tumors that was coincident with reduced proliferation and angiogenesis and increased apoptosis.  KX01 also resulted in microtubule disruption in tumors.  Combination of KX-01 with paclitaxel resulted in significant regression of MDA-MB-231 tumors and reduced metastasis to mouse lung and liver.  KX-01 is a potently active Src/pretubulin inhibitor that inhibits breast tumor growth and metastasis.  As ER/PR/HER2-neg. patients are candidates for paclitaxel therapy, combination with KX-01 may potentiate antitumor efficacy in management of this aggressive breast cancer subtype.  Mol Cancer Ther; 11(9); 1936-47. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPQgufjmNZ7Vg90H21EOLACvtfcHk0lirBafvYJvIJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI&md5=dd688323209801ec45284d3dc86ead48</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0146%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DR.%2BK.%26aulast%3DMarsden%26aufirst%3DC.%2BG.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DPeptidomimetic%2520Src%252Fpretubulin%2520inhibitor%2520KX-01%2520alone%2520and%2520in%2520combination%2520with%2520paclitaxel%2520suppresses%2520growth%252C%2520metastasis%2520in%2520human%2520ER%252FPR%252FHER2-negative%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D9%26spage%3D1936%26epage%3D1947%26doi%3D10.1158%2F1535-7163.MCT-12-0146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor effect of KX-01 through inhibiting Src family kinases and mitosis</span>. <i>Cancer Research and Treatment</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.4143/crt.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.4143%2Fcrt.2016.168" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=643-655&issue=3&author=S.+Kimauthor=A.+Minauthor=K.-H.+Leeauthor=Y.+Yangauthor=T.-Y.+Kimauthor=J.+M.+Limauthor=S.+J.+Parkauthor=H.-J.+Namauthor=J.+E.+Kimauthor=S.-H.+Songauthor=S.-W.+Hanauthor=D.-O.+Ohauthor=J.+H.+Kimauthor=T.-Y.+Kimauthor=D.+Hangauerauthor=J.+Y-N.+Lauauthor=K.+Imauthor=D.+S.+Leeauthor=Y.-J.+Bangauthor=S.-A.+Im&title=Anti-tumor+effect+of+KX-01+through+inhibiting+Src+family+kinases+and+mitosis&doi=10.4143%2Fcrt.2016.168"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DLim%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DNam%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DJ.%2BE.%26aulast%3DSong%26aufirst%3DS.-H.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DOh%26aufirst%3DD.-O.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DJ.%2BY-N.%26aulast%3DIm%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BS.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DIm%26aufirst%3DS.-A.%26atitle%3DAnti-tumor%2520effect%2520of%2520KX-01%2520through%2520inhibiting%2520Src%2520family%2520kinases%2520and%2520mitosis%26jtitle%3DCancer%2520Research%2520and%2520Treatment%26date%3D2017%26volume%3D49%26issue%3D3%26spage%3D643%26epage%3D655%26doi%3D10.4143%2Fcrt.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glodowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1007/s10549-011-1513-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs10549-011-1513-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=21509526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=391-409&issue=2&author=M.+Anbalaganauthor=L.+Carrierauthor=S.+Glodowskiauthor=D.+Hangauerauthor=B.+Shanauthor=B.+G.+Rowan&title=KX-01%2C+a+novel+Src+kinase+inhibitor+directed+toward+the+peptide+substrate+site%2C+synergizes+with+tamoxifen+in+estrogen+receptor+%CE%B1+positive+breast+cancer&doi=10.1007%2Fs10549-011-1513-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span></div><div class="casAuthors">Anbalagan, Muralidharan; Carrier, Latonya; Glodowski, Seth; Hangauer, David; Shan, Bin; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-409</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX-01 is the first clin. Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase.  The present study was designed to evaluate the effects of KX-01 as a single agent and in combination with tamoxifen (TAM) on cell growth and apoptosis of ERα pos. breast cancer in vitro and in vivo.  Flow cytometry demonstrated that KX-01 induced cell cycle arrest in G2/M phase.  Immunofluorescent staining for mitotic phase markers and TUNEL staining indicated that cells had arrested in the mitotic phase and mitotic arrested cells were undergoing apoptosis.  KX-01 induced nuclear accumulation of cyclin B1, and activation of CDK1, MPM2, and Cdc25C that is required for progression past the G2/M checkpoint.  Apoptosis resulted from activation of caspases 6, 7, 8, and 9.  Combinational index anal. revealed that combinations of KX-01 with TAM resulted in synergistic growth inhibition of breast cancer cell lines.  KX-01 combined with TAM resulted in decreased ERα phosphorylation at Src-regulated phosphorylation sites serines 118 and 167 that were assocd. with reduced ERα transcriptional activity.  Orally administered KX-01 resulted in a dose dependent growth inhibition of MCF-7 tumor xenografts, and in combination with TAM exhibited synergistic growth inhibition.  Immunohistochem. anal. revealed that combinational treatment reduced angiogenesis, and ERα signaling in tumors compared to either drug alone that may underlie the synergistic tumor growth inhibition.  Combinations of KX-01 with endocrine therapy present a promising new strategy for clin. management of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjBSgfh5qJbVg90H21EOLACvtfcHk0lirBafvYJvIJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D&md5=e55cc94c076cfd5f38a715c4b55b15dd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1513-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1513-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DGlodowski%26aufirst%3DS.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DKX-01%252C%2520a%2520novel%2520Src%2520kinase%2520inhibitor%2520directed%2520toward%2520the%2520peptide%2520substrate%2520site%252C%2520synergizes%2520with%2520tamoxifen%2520in%2520estrogen%2520receptor%2520%25CE%25B1%2520positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26issue%3D2%26spage%3D391%26epage%3D409%26doi%3D10.1007%2Fs10549-011-1513-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecot, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottsford-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumovitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeting Src and tubulin in mucinous ovarian carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6532</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1078-0432.CCR-13-1305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=24100628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6532-6543&issue=23&author=T.+Liuauthor=H.+Huauthor=H.+J.+Daltonauthor=H.+J.+Choiauthor=J.+Huangauthor=Y.+Kangauthor=S.+Pradeepauthor=T.+Miyakeauthor=J.+H.+Songauthor=Y.+Wenauthor=C.+Luauthor=C.+V.+Pecotauthor=J.+Bottsford-Millerauthor=B.+Zandauthor=N.+B.+Jenningsauthor=C.+Ivanauthor=G.+E.+Gallickauthor=K.+A.+Baggerlyauthor=D.+G.+Hangauerauthor=R.+L.+Colemanauthor=M.+Frumovitzauthor=A.+K.+Sood&title=Targeting+Src+and+tubulin+in+mucinous+ovarian+carcinoma&doi=10.1158%2F1078-0432.CCR-13-1305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src and Tubulin in Mucinous Ovarian Carcinoma</span></div><div class="casAuthors">Liu, Tao; Hu, Wei; Dalton, Heather J.; Choi, Hyun Jin; Huang, Jie; Kang, Yu; Pradeep, Sunila; Miyake, Takahito; Song, Jian H.; Wen, Yunfei; Lu, Chunhua; Pecot, Chad V.; Bottsford-Miller, Justin; Zand, Behrouz; Jennings, Nicholas B.; Ivan, Cristina; Gallick, Gary E.; Baggerly, Keith A.; Hangauer, David G.; Coleman, Robert L.; Frumovitz, Michael; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6532-6543</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian carcinoma.  Exptl. Design: The in vitro and in vivo effects and mol. mechanisms of KX-01, which inhibits Src pathway and tubulin polymn., were examd. in mucinous ovarian cancer models.  Results: In vitro studies using RMUG-S and RMUG-L cell lines showed that KX-01 inhibited cell proliferation, induced apoptosis, arrested the cell cycle at the G2-M phase, and enhanced the cytotoxicity of oxaliplatin in the KX-01-sensitive cell line, RMUG-S.  In vivo studies showed that KX-01 significantly decreased tumor burden in RMUG-S and RMUG-L mouse models relative to untreated controls, and the effects were greater when KX-01 was combined with oxaliplatin.  KX-01 alone and in combination with oxaliplatin significantly inhibited tumor growth by reducing cell proliferation and inducing apoptosis in vivo.  PTEN knock-in expts. in RMUG-L cells showed improved response to KX-01.  Reverse phase protein array anal. showed that in addn. to blocking downstream mols. of Src family kinases, KX-01 also activated acute stress-inducing mols.  Conclusion: Our results showed that targeting both the Src pathway and tubulin with KX-01 significantly inhibited tumor growth in preclin. mucinous ovarian cancer models, suggesting that this may be a promising therapeutic approach for patients with mucinous ovarian carcinoma.  Clin Cancer Res; 19(23); 6532-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-wBwf5SGhLVg90H21EOLACvtfcHk0lhF8hapCK_dfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM&md5=cea052b1774b6850f996f05a5d02d10b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1305%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DPradeep%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DJ.%2BH.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPecot%26aufirst%3DC.%2BV.%26aulast%3DBottsford-Miller%26aufirst%3DJ.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DFrumovitz%26aufirst%3DM.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DTargeting%2520Src%2520and%2520tubulin%2520in%2520mucinous%2520ovarian%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D23%26spage%3D6532%26epage%3D6543%26doi%3D10.1158%2F1078-0432.CCR-13-1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matossian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins-Burow, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">Dual Src kinase/pretubulin inhibitor KX-01, sensitizes ERα-negative breast cancers to tamoxifen through ERα reexpression</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-16-0297-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1541-7786.MCR-16-0297-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=28751463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGisrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1491-502&issue=11&author=M.+Anbalaganauthor=M.+Shengauthor=B.+Fleischerauthor=Y.+Zhangauthor=Y.+Gaoauthor=V.+Hoangauthor=M.+Matossianauthor=H.+E.+Burksauthor=M.+E.+Burowauthor=B.+M.+Collins-Burowauthor=D.+Hangauerauthor=B.+G.+Rowan&title=Dual+Src+kinase%2Fpretubulin+inhibitor+KX-01%2C+sensitizes+ER%CE%B1-negative+breast+cancers+to+tamoxifen+through+ER%CE%B1+reexpression&doi=10.1158%2F1541-7786.MCR-16-0297-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression</span></div><div class="casAuthors">Anbalagan, Muralidharan; Sheng, Mei; Fleischer, Brian; Zhang, Yifang; Gao, Yuanjun; Hoang, Van; Matossian, Margarite; Burks, Hope E.; Burow, Matthew E.; Collins-Burow, Bridgette M.; Hangauer, David; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1491-1502</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Unlike breast cancer that is pos. for estrogen receptor-α (ERα), there are no targeted therapies for triple-neg. breast cancer (TNBC).  ERα is silenced in TNBC through epigenetic changes including DNA methylation and histone acetylation.  Restoring ERα expression in TNBC may sensitize patients to endocrine therapy.  Expression of c-Src and ERα are inversely correlated in breast cancer suggesting that c-Src inhibition may lead to reexpression of ERα in TNBC.  KX-01 is a peptide substrate-targeted Src/pretubulin inhibitor in clin. trials for solid tumors.  KX-01 (1 mg/kg body wt.-twice daily) inhibited growth of tamoxifen-resistant MDA-MB-231 and MDA-MB-157 TNBC xenografts in nude mice that was correlated with Src kinase inhibition.  KX-01 also increased ERα mRNA and protein, as well as increased the ERα targets progesterone receptor (PR), pS2 (TFF1), cyclin D1 (CCND1), and c-myc (MYC) in MDA-MB-231 and MDA-MB-468, but not MDA-MB-157 xenografts.  MDA-MB-231 and MDA-MB-468 tumors exhibited redn. in mesenchymal markers (vimentin, β-catenin) and increase in epithelial marker (E-cadherin) suggesting mesenchymal-to-epithelial transition (MET).  KX-01 sensitized MDA-MB-231 and MDA-MB-468 tumors to tamoxifen growth inhibition and tamoxifen repression of the ERα targets pS2, cyclin D1, and c-myc.  Chromatin immunopptn. (ChIP) of the ERα promoter in KX-01-treated tumors demonstrated enrichment of active transcription marks (acetyl-H3, acetyl-H3Lys9), dissocn. of HDAC1, and recruitment of RNA polymerase II.  Methylation-specific PCR and bisulfite sequencing demonstrated no alteration in ERα promoter methylation by KX-01.  These data demonstrate that in addn. to Src kinase inhibition, peptidomimetic KX-01 restores ERα expression in TNBC through changes in histone acetylation that sensitize tumors to tamoxifen.  Implications: Src kinase/pretubulin inhibitor KX-01 restores functional ERα expression in ERα- breast tumors, a novel treatment strategy to treat triple-neg. breast cancer.  Mol Cancer Res; 15(11); 1491-502. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTO0z5LBghubVg90H21EOLACvtfcHk0lhF8hapCK_dfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGisrfO&md5=d7704aa0b28922ff3067dd3c00021504</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-16-0297-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-16-0297-T%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DFleischer%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DHoang%26aufirst%3DV.%26aulast%3DMatossian%26aufirst%3DM.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DBurow%26aufirst%3DM.%2BE.%26aulast%3DCollins-Burow%26aufirst%3DB.%2BM.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DDual%2520Src%2520kinase%252Fpretubulin%2520inhibitor%2520KX-01%252C%2520sensitizes%2520ER%25CE%25B1-negative%2520breast%2520cancers%2520to%2520tamoxifen%2520through%2520ER%25CE%25B1%2520reexpression%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2017%26volume%3D15%26issue%3D11%26spage%3D1491%26epage%3D502%26doi%3D10.1158%2F1541-7786.MCR-16-0297-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. S.</span></span> <span> </span><span class="NLM_article-title">Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1474</span>, <span class="refDoi"> DOI: 10.1007/s10620-008-0519-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs10620-008-0519-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18979199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslOktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=1465-1474&issue=7&author=G.+M.+Lauauthor=G.+M.+Lauauthor=G.-L.+Yuauthor=I.+H.+Gelmanauthor=A.+Gutowskiauthor=D.+Hangauerauthor=W.+S.+Fang&title=Expression+of+Src+and+FAK+in+hepatocellular+carcinoma+and+the+effect+of+Src+inhibitors+on+hepatocellular+carcinoma+in+vitro&doi=10.1007%2Fs10620-008-0519-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro</span></div><div class="casAuthors">Lau, Grace M.; Lau, Gillian M.; Yu, Guo-Liang; Gelman, Irwin H.; Gutowski, Alan; Hangauer, David; Fang, Jane W. S.</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1465-1474</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The expressions of c-Src and focal adhesion kinase (FAK) were studied in 65 Chinese patients with hepatocellular carcinoma (HCC) by immunohistochem. using rabbit monoclonal antibodies.  Expressions of total Src, an active form of Src, and FAK were found in 44/65 (67.7%), 36/45 (55.4%), and 33/56 (58.9%) HCC cases, resp.  There was a good correlation between the expression of total Src, active form of Src, and FAK in these HCC cases (P < 0.001).  Expression of Src was not correlated to any clin. parameters, cancer cell phenotypic markers, and pathol. features apart from a pos. correlation with alpha-fetoprotein (P < 0.01).  The expression of FAK was correlated with earlier onset and the expression of Ki-67 but not proliferating cell nuclear antigen (PCNA) in these HCC cases.  Four liver-cancer-derived cell lines (three derived from HCC and one from hepatoblastoma) were then tested with inhibitors against Src.  A small mol., KX2-391, designed to target the substrate binding pocket of Src, was found to have more broad-spectrum activity and better potency than Dasatinib, an ATP-competitive inhibitor in vitro.  The authors' data indicates that Src and FAK expression are both elevated and active in Chinese patients with HCC and that Src may play a key role in supporting HCC progression.  Src antagonism with specific inhibitors may be an attractive treatment paradigm for patients with HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTP7JpKNhgbVg90H21EOLACvtfcHk0lhF8hapCK_dfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslOktrw%253D&md5=124da89ed8688b1e4124da5fd6cb7c3c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs10620-008-0519-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-008-0519-0%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DG.%2BM.%26aulast%3DLau%26aufirst%3DG.%2BM.%26aulast%3DYu%26aufirst%3DG.-L.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DGutowski%26aufirst%3DA.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DW.%2BS.%26atitle%3DExpression%2520of%2520Src%2520and%2520FAK%2520in%2520hepatocellular%2520carcinoma%2520and%2520the%2520effect%2520of%2520Src%2520inhibitors%2520on%2520hepatocellular%2520carcinoma%2520in%2520vitro%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2009%26volume%3D54%26issue%3D7%26spage%3D1465%26epage%3D1474%26doi%3D10.1007%2Fs10620-008-0519-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dy, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of KX2–391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">973</span>, <span class="refDoi"> DOI: 10.1007/s10637-013-9929-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs10637-013-9929-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=967-973&issue=4&author=A.+Naingauthor=R.+Cohenauthor=G.+K.+Dyauthor=D.+S.+Hongauthor=L.+Dysterauthor=D.+G.+Hangauerauthor=R.+Kwanauthor=G.+Fetterlyauthor=R.+Kurzrockauthor=A.+A.+Adjei&title=A+phase+I+trial+of+KX2%E2%80%93391%2C+a+novel+non-ATP+competitive+substrate-pocket-+directed+SRC+inhibitor%2C+in+patients+with+advanced+malignancies&doi=10.1007%2Fs10637-013-9929-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-9929-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-9929-8%26sid%3Dliteratum%253Aachs%26aulast%3DNaing%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DDyster%26aufirst%3DL.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DFetterly%26aufirst%3DG.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520KX2%25E2%2580%2593391%252C%2520a%2520novel%2520non-ATP%2520competitive%2520substrate-pocket-%2520directed%2520SRC%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26issue%3D4%26spage%3D967%26epage%3D973%26doi%3D10.1007%2Fs10637-013-9929-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, M-F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyster, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M. A.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of KX2–391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2079-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs00280-013-2079-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=23314737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=883-892&issue=4&author=E.+S.+Antonarakisauthor=E.+I.+Heathauthor=E.+M.+Posadasauthor=E.+Y.+Yuauthor=M.+R.+Harrisonauthor=J.+Y.+Bruceauthor=S.+Y.+Choauthor=G.+E.+Wildingauthor=G.+J.+Fetterlyauthor=D.+G.+Hangauerauthor=M-F.+R.+Kwanauthor=L.+M.+Dysterauthor=M.+A.+Carducci&title=A+phase+2+study+of+KX2%E2%80%93391%2C+an+oral+inhibitor+of+Src+kinase+and+tubulin+polymerization%2C+in+men+with+bone-metastatic+castration-resistant+prostate+cancer&doi=10.1007%2Fs00280-013-2079-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Antonarakis, Emmanuel S.; Heath, Elisabeth I.; Posadas, Edwin M.; Yu, Evan Y.; Harrison, Michael R.; Bruce, Justine Y.; Cho, Steve Y.; Wilding, Gregory E.; Fetterly, Gerald J.; Hangauer, David G.; Kwan, Min-Fun R.; Dyster, Lyn M.; Carducci, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymn.  In phase 1 trials, prostate-specific antigen (PSA) declines were seen in patients with advanced prostate cancer.  We conducted a single-arm phase 2 study evaluating KX2-391 in men with chemotherapy-naive bone-metastatic castration-resistant prostate cancer (CRPC).  We treated 31 patients with oral KX2-391 (40 mg twice-daily) until disease progression or unacceptable toxicity.  The primary endpoint was 24-wk progression-free survival (PFS); a 50 % success rate was pre-defined as clin. significant.  Secondary endpoints included PSA progression-free survival (PPFS) and PSA response rates.  Exploratory outcomes included pharmacokinetic studies, circulating tumor cell (CTC) enumeration, and anal. of markers of bone resorption [urinary N-telopeptide (uNTx); C-telopeptide (CTx)] and formation [bone alk. phosphatase (BAP); osteocalcin].  The trial closed early after accrual of 31 patients, due to a pre-specified futility rule.  PFS at 24 wk was 8 %, and median PFS was 18.6 wk.  The PSA response rate (≥30 % decline) was 10 %, and median PPFS was 5.0 wk.  Addnl., 18 % of men with unfavorable (≥5) CTCs at baseline converted to favorable (<5) CTCs with treatment.  The proportion of men with declines in bone turnover markers was 32 % for uNTx, 21 % for CTx, 10 % for BAP, and 25 % for osteocalcin.  In pharmacokinetic studies, median C max was 61 (range 16-129) ng/mL, and median AUC was 156 (35-348) ng h/mL.  Common toxicities included hepatic derangements, myelosuppression, fatigue, nausea, and constipation.  KX2-391 dosed at 40 mg twice-daily lacks antitumor activity in men with CRPC, but has modest effects on bone turnover markers.  Because a C max of ≥142 ng/mL is required for tubulin polymn. inhibition (defined from preclin. studies), higher once-daily dosing will be used in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok7d6u2qkQ_7Vg90H21EOLACvtfcHk0lhE-LoQ8b_LEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D&md5=117681a5f5cb6d09865c707673ec3e27</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2079-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2079-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DYu%26aufirst%3DE.%2BY.%26aulast%3DHarrison%26aufirst%3DM.%2BR.%26aulast%3DBruce%26aufirst%3DJ.%2BY.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DWilding%26aufirst%3DG.%2BE.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DKwan%26aufirst%3DM-F.%2BR.%26aulast%3DDyster%26aufirst%3DL.%2BM.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26atitle%3DA%2520phase%25202%2520study%2520of%2520KX2%25E2%2580%2593391%252C%2520an%2520oral%2520inhibitor%2520of%2520Src%2520kinase%2520and%2520tubulin%2520polymerization%252C%2520in%2520men%2520with%2520bone-metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26issue%3D4%26spage%3D883%26epage%3D892%26doi%3D10.1007%2Fs00280-013-2079-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasner, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. E.</span></span> <span> </span><span class="NLM_article-title">A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2–391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">7043</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.7043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1200%2FJCO.2017.35.15_suppl.7043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=7043&author=M.+T.+Kasnerauthor=E.+K.+Ritchieauthor=D.+Cutlerauthor=G.+J.+Fetterlyauthor=D.+Kramerauthor=D.+Hangauerauthor=J.+E.+Thompson&title=A+phase+1b+dose+escalation+study+to+evaluate+safety%2C+tolerability+and+pharmacokinetics+of+oral+monotherapy+with+KX2%E2%80%93391+in+elderly+subjects+with+acute+myeloid+leukemia+who+are+refractory+to+or+have+declined+standard+induction+therapy&doi=10.1200%2FJCO.2017.35.15_suppl.7043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.7043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.7043%26sid%3Dliteratum%253Aachs%26aulast%3DKasner%26aufirst%3DM.%2BT.%26aulast%3DRitchie%26aufirst%3DE.%2BK.%26aulast%3DCutler%26aufirst%3DD.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DKramer%26aufirst%3DD.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DJ.%2BE.%26atitle%3DA%2520phase%25201b%2520dose%2520escalation%2520study%2520to%2520evaluate%2520safety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520oral%2520monotherapy%2520with%2520KX2%25E2%2580%2593391%2520in%2520elderly%2520subjects%2520with%2520acute%2520myeloid%2520leukemia%2520who%2520are%2520refractory%2520to%2520or%2520have%2520declined%2520standard%2520induction%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D7043%26doi%3D10.1200%2FJCO.2017.35.15_suppl.7043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ainger, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, R. A.</span></span> <span> </span><span class="NLM_article-title">Src and SCC: getting to the FAKs</span>. <i>Experimental dermatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1111/exd.12725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fexd.12725" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=487-488&issue=7&author=S.+A.+Aingerauthor=R.+A.+Sturm&title=Src+and+SCC%3A+getting+to+the+FAKs&doi=10.1111%2Fexd.12725"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1111%2Fexd.12725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.12725%26sid%3Dliteratum%253Aachs%26aulast%3DAinger%26aufirst%3DS.%2BA.%26aulast%3DSturm%26aufirst%3DR.%2BA.%26atitle%3DSrc%2520and%2520SCC%253A%2520getting%2520to%2520the%2520FAKs%26jtitle%3DExperimental%2520dermatology%26date%3D2015%26volume%3D24%26issue%3D7%26spage%3D487%26epage%3D488%26doi%3D10.1111%2Fexd.12725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.-S.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and Src expression in premalignant and malignant skin lesions</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1111/exd.12676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fexd.12676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=25711159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=361-364&author=C.+W.+Choiauthor=Y.+H.+Kimauthor=J.+H.+Sohnauthor=H.+Leeauthor=W.-S.+Kim&title=Focal+adhesion+kinase+and+Src+expression+in+premalignant+and+malignant+skin+lesions&doi=10.1111%2Fexd.12676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and Src expression in premalignant and malignant skin lesions</span></div><div class="casAuthors">Choi, Chong Won; Kim, Yoon Hwan; Sohn, Jin Hee; Lee, Hyunjoo; Kim, Won-Serk</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-364</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">1600-0625</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) and Src are non-receptor tyrosine kinases.  FAK and Src play a crit. role in inducing malignant transformation in tumor cells.  We performed immunohistochem. staining for total and phosphorylated forms of FAK and Src, to evaluate the role of FAK and Src in the development of premalignant and malignant skin lesions.  A total of 59 facial skin samples (30 actinic keratoses, 10 Bowen's diseases, 13 squamous cell carcinomas and six perilesional skins) were immunohistochem. stained for Ki-67, total (t) and phosphorylated (p) form of FAK and Src.  Cells pos. for t-Src, p-Src-y530, t-FAK and pFAK-s722 were detected in premalignant intra-epithelial lesions (PELs) and squamous cell carcinomas (SCCs), but not in the perilesional skin.  There was a tendency towards high correlation between Ki-67 and t-FAK or pFAK-s722, suggestive of the active role of FAK in cell proliferation.  However, our findings of higher t-Src and p-Src-y530 pos. cells in PELs, as compared to SCCs (with higher Ki-67 level), are suggestive of the other role of Src in tumor formation and progression, which requires further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxSZeLjvao8bVg90H21EOLACvtfcHk0lgwpx-Uy2dWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGksr0%253D&md5=8c81b87591dbdf4495851f76ed9b66d3</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1111%2Fexd.12676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.12676%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSohn%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.-S.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520Src%2520expression%2520in%2520premalignant%2520and%2520malignant%2520skin%2520lesions%26jtitle%3DExp.%2520Dermatol.%26date%3D2015%26volume%3D24%26spage%3D361%26epage%3D364%26doi%3D10.1111%2Fexd.12676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Montagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallichet-Blanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sng, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottaz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degueurce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruchet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antsiferova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Saati, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">tan, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahli, W.</span></span> <span> </span><span class="NLM_article-title">Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1002/emmm.201302666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1002%2Femmm.201302666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=24203162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=80-98&author=A.+Montagnerauthor=M.+B.+Delgadoauthor=C.+Tallichet-Blancauthor=J.+S.+K.+Chanauthor=M.+K.+Sngauthor=H.+Mottazauthor=G.+Degueurceauthor=Y.+Lippiauthor=C.+Moretauthor=M.+Baruchetauthor=M.+Antsiferovaauthor=S.+Wernerauthor=D.+Hohlauthor=T.+Al+Saatiauthor=P.+J.+Farmerauthor=N.+S.+tanauthor=L.+Michalikauthor=W.+Wahli&title=Src+is+activated+by+the+nuclear+receptor+peroxisome+proliferator-activated+receptor+%CE%B2%2F%CE%B4+in+ultraviolet+radiation-induced+skin+cancer&doi=10.1002%2Femmm.201302666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37cR"><div class="casContent"><span class="casTitleNuber">37c</span><div class="casTitle"><span class="NLM_cas:atitle">Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer</span></div><div class="casAuthors">Montagner, Alexandra; Delgado, Maria B.; Tallichet-Blanc, Corinne; Chan, Jeremy S. K.; Sng, Ming K.; Mottaz, Helene; Degueurce, Gwendoline; Lippi, Yannick; Moret, Catherine; Baruchet, Michael; Antsiferova, Maria; Werner, Sabine; Hohl, Daniel; Al Saati, Talal; Farmer, Pierre J.; Tan, Nguan S.; Michalik, Liliane; Wahli, Walter</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-98</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Although non-melanoma skin cancer (NMSC) is the most common human cancer and its incidence continues to rise worldwide, the mechanisms underlying its development remain incompletely understood.  Here, we unveil a cascade of events involving peroxisome proliferator-activated receptor (PPAR) β/δ and the oncogene Src, which promotes the development of UV-induced skin cancer in mice.  UV-induced PPARβ/δ activity, which directly stimulated Src expression, increased Src kinase activity and enhanced the EGFR/Erk1/2 signalling pathway, resulting in increased epithelial-to-mesenchymal transition (EMT) marker expression.  Consistent with these observations, PPARβ/δ-null mice developed fewer and smaller skin tumors, and a PPARβ/δ antagonist prevented UV-dependent Src stimulation.  Furthermore, the expression of PPARβ/δ pos. correlated with the expression of SRC and EMT markers in human skin squamous cell carcinoma (SCC), and critically, linear models applied to several human epithelial cancers revealed an interaction between PPARβ/δ and SRC and TGFβ1 transcriptional levels.  Taken together, these observations motivate the future evaluation of PPARβ/δ modulators to attenuate the development of several epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKDhlgcaReIrVg90H21EOLACvtfcHk0lgwpx-Uy2dWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKhuw%253D%253D&md5=daebc7b735f53c0dad38e00b09139d9f</span></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=10.1002%2Femmm.201302666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201302666%26sid%3Dliteratum%253Aachs%26aulast%3DMontagner%26aufirst%3DA.%26aulast%3DDelgado%26aufirst%3DM.%2BB.%26aulast%3DTallichet-Blanc%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%2BS.%2BK.%26aulast%3DSng%26aufirst%3DM.%2BK.%26aulast%3DMottaz%26aufirst%3DH.%26aulast%3DDegueurce%26aufirst%3DG.%26aulast%3DLippi%26aufirst%3DY.%26aulast%3DMoret%26aufirst%3DC.%26aulast%3DBaruchet%26aufirst%3DM.%26aulast%3DAntsiferova%26aufirst%3DM.%26aulast%3DWerner%26aufirst%3DS.%26aulast%3DHohl%26aufirst%3DD.%26aulast%3DAl%2BSaati%26aufirst%3DT.%26aulast%3DFarmer%26aufirst%3DP.%2BJ.%26aulast%3Dtan%26aufirst%3DN.%2BS.%26aulast%3DMichalik%26aufirst%3DL.%26aulast%3DWahli%26aufirst%3DW.%26atitle%3DSrc%2520is%2520activated%2520by%2520the%2520nuclear%2520receptor%2520peroxisome%2520proliferator-activated%2520receptor%2520%25CE%25B2%252F%25CE%25B4%2520in%2520ultraviolet%2520radiation-induced%2520skin%2520cancer%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D80%26epage%3D98%26doi%3D10.1002%2Femmm.201302666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Serrels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldeschi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackintosh, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansom, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span> <span> </span><span class="NLM_article-title">A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgn278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1093%2Fcarcin%2Fbgn278" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=249-257&issue=2&author=B.+Serrelsauthor=A.+Serrelsauthor=S.+M.+Masonauthor=C.+Baldeschiauthor=G.+H.+Ashtonauthor=M.+Canelauthor=L.+J.+Mackintoshauthor=B.+Doyleauthor=T.+P.+Greenauthor=M.+C.+Frameauthor=O.+J.+Sansomauthor=V.+G.+Brunton&title=A+novel+Src+kinase+inhibitor+reduces+tumour+formation+in+a+skin+carcinogenesis+model&doi=10.1093%2Fcarcin%2Fbgn278"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37d&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgn278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgn278%26sid%3Dliteratum%253Aachs%26aulast%3DSerrels%26aufirst%3DB.%26aulast%3DSerrels%26aufirst%3DA.%26aulast%3DMason%26aufirst%3DS.%2BM.%26aulast%3DBaldeschi%26aufirst%3DC.%26aulast%3DAshton%26aufirst%3DG.%2BH.%26aulast%3DCanel%26aufirst%3DM.%26aulast%3DMackintosh%26aufirst%3DL.%2BJ.%26aulast%3DDoyle%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DSansom%26aufirst%3DO.%2BJ.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26atitle%3DA%2520novel%2520Src%2520kinase%2520inhibitor%2520reduces%2520tumour%2520formation%2520in%2520a%2520skin%2520carcinogenesis%2520model%26jtitle%3DCarcinogenesis%26date%3D2009%26volume%3D30%26issue%3D2%26spage%3D249%26epage%3D257%26doi%3D10.1093%2Fcarcin%2Fbgn278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picarles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsaesser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolopp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winiski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meingassner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Brugerolle de Fraissinette, A.</span></span> <span> </span><span class="NLM_article-title">LAV694, a new antiproliferative agent showing improved skin tolerability vs. clinical standards for the treatment of actinic keratosis</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1895</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(03)00369-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0006-2952%2803%2900369-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2003&pages=1885-1895&author=J.+Medinaauthor=V.+Picarlesauthor=B.+Greinerauthor=C.+Elsaesserauthor=M.+Koloppauthor=A.+Mahlauthor=D.+Romanauthor=B.+Vogelauthor=P.+Nussbaumerauthor=A.+Winiskiauthor=J.+Meingassnerauthor=A.+de+Brugerolle+de+Fraissinette&title=LAV694%2C+a+new+antiproliferative+agent+showing+improved+skin+tolerability+vs.+clinical+standards+for+the+treatment+of+actinic+keratosis&doi=10.1016%2FS0006-2952%2803%2900369-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2803%2900369-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252803%252900369-1%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DPicarles%26aufirst%3DV.%26aulast%3DGreiner%26aufirst%3DB.%26aulast%3DElsaesser%26aufirst%3DC.%26aulast%3DKolopp%26aufirst%3DM.%26aulast%3DMahl%26aufirst%3DA.%26aulast%3DRoman%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DB.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DWiniski%26aufirst%3DA.%26aulast%3DMeingassner%26aufirst%3DJ.%26aulast%3Dde%2BBrugerolle%2Bde%2BFraissinette%26aufirst%3DA.%26atitle%3DLAV694%252C%2520a%2520new%2520antiproliferative%2520agent%2520showing%2520improved%2520skin%2520tolerability%2520vs.%2520clinical%2520standards%2520for%2520the%2520treatment%2520of%2520actinic%2520keratosis%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2003%26volume%3D66%26spage%3D1885%26epage%3D1895%26doi%3D10.1016%2FS0006-2952%2803%2900369-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulent Tastan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbil, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumlu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gur, A. R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratosis</span>. <i>J. Dermatol. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1080/09546630152696314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1080%2F09546630152696314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=12241628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtV2ksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=199-203&author=A.+Akarauthor=H.+Bulent+Tastanauthor=H.+Erbilauthor=E.+Arcaauthor=Z.+Kurumluauthor=A.+R.+Gur&title=Efficacy+and+safety+assessment+of+0.5%25+and+1%25+colchicine+cream+in+the+treatment+of+actinic+keratosis&doi=10.1080%2F09546630152696314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses</span></div><div class="casAuthors">Akar, Ahmet; Tastan, H. Bulent; Erbil, Hakan; Arca, Ercan; Kurumlu, Zafer; Gur, Ali Riza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Treatment</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">199-203</span>CODEN:
                <span class="NLM_cas:coden">JDTREY</span>;
        ISSN:<span class="NLM_cas:issn">0954-6634</span>.
    
            (<span class="NLM_cas:orgname">Martin Dunitz Ltd.</span>)
        </div><div class="casAbstract">Background: Topical colchicine has been reported to be an effective treatment for actinic keratoses, but the optimal concn. has not been fully defined.  Objective: The aim of this study was to further support the beneficial effect of topical colchicine therapy for actinic keratoses, and to compare the efficacy and safety of two different concns. of colchicine cream, 0.5% and 1%.  Methods: Sixteen patients with actinic keratoses were enrolled in this comparative randomized study.  Eight patients applied 1% colchicine cream, twice daily on their lesions while the other eight were treated with a 0.5% colchicine cream for 10 days.  Some patients were applied a second course of 10 days' therapy.  Patients were examd. before treatment and at 10 days, and followed up at 1, 2 and 6 mo of treatment.  Visible and palpable actinic keratoses lesions in each group were counted.  Safety and efficacy were also assessed by clin. examn. at each study visit.  Routine lab. tests were performed before and after treatment.  Results: Actinic keratoses lesions showed significant clin. improvement following treatment with 0.5% and 1% colchicine cream.  Complete healing of actinic keratoses were obsd. in six of the eight patients in the 1% colchicine group, and in seven of the eight patients in the 0.5% colchicine group.  The redn. rate in no. of actinic keratoses at the end of treatment in the 1% colchicine group was 73.9% (48/65) (p < 0.001), and the redn. rate in the 0.5% colchicine group was 77.7% (52/67) in total (p < 0.001).  The redn. in no. of actinic keratoses (mean ± SD) at the end of treatment was similar in the 1% colchicine group (0.7 ± 1.3), and the 0.5% colchicine group (mean 0.6 ± 1.7) (p > 0.05).  Systemic side effects were not seen in either concn.  Conclusions: Topical colchicine is an effective and safe alternative agent.  Cream contg. 0.5% of colchicine is equally effective as 1% colchicine cream in the treatment of actinic keratoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFXR59Mt0s47Vg90H21EOLACvtfcHk0li1mcgTVCC5vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtV2ksrw%253D&md5=45d73e565ae1bbc4b5a6e607828416f5</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1080%2F09546630152696314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09546630152696314%26sid%3Dliteratum%253Aachs%26aulast%3DAkar%26aufirst%3DA.%26aulast%3DBulent%2BTastan%26aufirst%3DH.%26aulast%3DErbil%26aufirst%3DH.%26aulast%3DArca%26aufirst%3DE.%26aulast%3DKurumlu%26aufirst%3DZ.%26aulast%3DGur%26aufirst%3DA.%2BR.%26atitle%3DEfficacy%2520and%2520safety%2520assessment%2520of%25200.5%2525%2520and%25201%2525%2520colchicine%2520cream%2520in%2520the%2520treatment%2520of%2520actinic%2520keratosis%26jtitle%3DJ.%2520Dermatol.%2520Treat.%26date%3D2001%26volume%3D12%26spage%3D199%26epage%3D203%26doi%3D10.1080%2F09546630152696314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korgavkar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M. A.</span></span> <span> </span><span class="NLM_article-title">Current perspective on actinic keratosis: a review</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1111/bjd.14852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fbjd.14852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=27500794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A280%3ADC%252BC2s3osVentA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=350-358&author=J.+A.+Siegelauthor=K.+Korgavkarauthor=M.+A.+Weinstock&title=Current+perspective+on+actinic+keratosis%3A+a+review&doi=10.1111%2Fbjd.14852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspective on actinic keratosis: a review</span></div><div class="casAuthors">Siegel J A; Korgavkar K; Weinstock M A; Siegel J A; Korgavkar K; Weinstock M A</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-358</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Actinic keratoses (AKs) are common, with prevalence in the U.S.A. estimated at almost 40 million in 2004 and annual costs of > $1 billion (U.S.D.).  However, there is no universally accepted definition of AK and thus it is difficult to identify reliably.  AKs are lesions of epidermal keratinocytic dysplasia that result from chronic sun exposure and have the ability to progress to invasive squamous cell carcinoma (SCC), but clinicians disagree about whether AKs are premalignant lesions, superficial SCCin situ or epiphenomena of chronically sun-damaged skin.  Yearly AK to SCC progression rates of 0·6% were reported in an elderly population with multiple prior keratinocyte carcinomas (KCs); and rates of spontaneous AK regression have been reported to be > 50%, but regressed lesions often reappear.  As AKs have both cosmetic consequences and potential for malignant transformation, there are multiple reasons for treatment.  There is no current agreement on the most efficacious treatment, but 5-fluorouracil has been shown to both prevent and treat AKs, and imiquimod and photodynamic therapy may have the best cosmetic outcomes.  AKs may be treated to improve appearance and relieve symptoms, but the keratinocytic dysplasia that gives rise to malignancy, and sometimes appears as an AK, may be what actually threatens patient health.  Thus, treatments should aim to decrease the risk of KC or facilitate KC diagnosis by reducing the potential for misidentification created when a KC appears in a field of AKs.  Improved agreement among clinicians on AK definition may improve management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSwkYWOJcD75NiNltV31zlfW6udTcc2ea9ZFhSp2RQvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3osVentA%253D%253D&md5=e0016ac6105073f8ccb59c8bb9e53d58</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14852%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DJ.%2BA.%26aulast%3DKorgavkar%26aufirst%3DK.%26aulast%3DWeinstock%26aufirst%3DM.%2BA.%26atitle%3DCurrent%2520perspective%2520on%2520actinic%2520keratosis%253A%2520a%2520review%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2017%26volume%3D177%26spage%3D350%26epage%3D358%26doi%3D10.1111%2Fbjd.14852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="note"><p class="first last">Compound <b>1</b> clinical trials for actinic keratosis listed on ClinicalTrials.gov:</p></div><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span>Phase 1: NCT02337205. A phase
1, single-center, safety, tolerability, and pharmacokinetic study
of KX2-391 ointment in subjects with actinic keratosis..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+1%3A+NCT02337205.+A+phase%0A1%2C+single-center%2C+safety%2C+tolerability%2C+and+pharmacokinetic+study%0Aof+KX2-391+ointment+in+subjects+with+actinic+keratosis.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span>Phase
2: NCT02838628. A phase 2a, open-label, multicenter, activity, and
safety study of KX2-391 ointment in subjects with actinic keratosis
on the face or scalp..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase%0A2%3A+NCT02838628.+A+phase+2a%2C+open-label%2C+multicenter%2C+activity%2C+and%0Asafety+study+of+KX2-391+ointment+in+subjects+with+actinic+keratosis%0Aon+the+face+or+scalp.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40c"><span><span class="NLM_label">(c) </span>Phase 3: NCT03285477. A phase 3, double-blind,
vehicle-controlled, randomized, parallel group, multicenter, efficacy,
and safety study of KX2–391 ointment 1% in adult subjects with
actinic keratosis on the face or scalp..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+3%3A+NCT03285477.+A+phase+3%2C+double-blind%2C%0Avehicle-controlled%2C+randomized%2C+parallel+group%2C+multicenter%2C+efficacy%2C%0Aand+safety+study+of+KX2%E2%80%93391+ointment+1%25+in+adult+subjects+with%0Aactinic+keratosis+on+the+face+or+scalp.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40d"><span><span class="NLM_label">(d) </span>Phase 3: NCT03285490. A phase
3, double-blind, vehicle-controlled, randomized, parallel group, multicenter,
efficacy and safety study of KX2-391 ointment 1% in adult subjects
with actinic keratosis on the face or scalp..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+3%3A+NCT03285490.+A+phase%0A3%2C+double-blind%2C+vehicle-controlled%2C+randomized%2C+parallel+group%2C+multicenter%2C%0Aefficacy+and+safety+study+of+KX2-391+ointment+1%25+in+adult+subjects%0Awith+actinic+keratosis+on+the+face+or+scalp.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span>; <span class="NLM_string-name">Jarratt, M.</span>; <span class="NLM_string-name">Kempers, S.</span>; <span class="NLM_string-name">Forman, S.</span>; <span class="NLM_string-name">Cutler, D.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Kwan, R.</span></span> <span> </span><span class="NLM_article-title">Phase II study of KX2-391 ointment 1%, a novel field treatment based on Src/tubulin polymerization inhibition, for actinic keratosis</span>. In  <i>American Academy of Dermatology Meeting in Feb. 17</i>, <span class="NLM_year">2018</span>. Oral presentation and online ePoster ID  <span class="NLM_fpage">6134</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=6134&author=J.+Fang&author=M.+Jarratt&author=S.+Kempers&author=S.+Forman&author=D.+Cutler&author=H.+Wang&author=R.+Kwan&title=Phase+II+study+of+KX2-391+ointment+1%25%2C+a+novel+field+treatment+based+on+Src%2Ftubulin+polymerization+inhibition%2C+for+actinic+keratosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520study%2520of%2520KX2-391%2520ointment%25201%2525%252C%2520a%2520novel%2520field%2520treatment%2520based%2520on%2520Src%252Ftubulin%2520polymerization%2520inhibition%252C%2520for%2520actinic%2520keratosis%26jtitle%3DAmerican%2520Academy%2520of%2520Dermatology%2520Meeting%2520in%2520Feb.%252017%26date%3D2018%26spage%3D6134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayli, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenitsas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seykora, J. T.</span></span> <span> </span><span class="NLM_article-title">Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders</span>. <i>J. Cutaneous Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0560.2007.00807.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fj.1600-0560.2007.00807.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18251740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FpsVektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=273-277&issue=3&author=E.+E.+Ayliauthor=W.+Liauthor=T.+T.+Brownauthor=A.+Witkiewiczauthor=R.+Elenitsasauthor=J.+T.+Seykora&title=Activation+of+Src-family+tyrosine+kinases+in+hyperproliferative+epidermal+disorders&doi=10.1111%2Fj.1600-0560.2007.00807.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders</span></div><div class="casAuthors">Ayli Elias E; Li Weijie; Brown Tamu T; Witkiewicz Agnieszka; Elenitsas Rosalie; Seykora John T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cutaneous pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Src-family tyrosine kinases (SFKs) are important regulators of keratinocyte growth and differentiation.  In a broad range of cell types, persistent activation of SFKs correlates with increased cell proliferation.  In this study, we determined if SFK activity is increased in cutaneous neoplasia and psoriasis, common hyperproliferative epidermal disorders.  METHODS:  Formalin-fixed tissue sections of unremarkable epidermis, psoriasis, actinic keratoses (AKs), squamous cell carcinoma in situ (SCIS) and squamous cell carcinoma (SCC) were subjected to immunohistochemical staining for activated SFKs.  RESULTS:  All psoriasis specimens displayed significantly greater staining for activated SFKs than sections of unremarkable skin.  In the psoriasis biopsies, the degree of epidermal hyperplasia was proportional to the level of activated SFK staining.  All AKs, SCISs and SCCs exhibited more prominent staining than sections of unremarkable epidermis.  No discernable difference in activated SFK staining was seen between AKs, SCIS and SCC specimens.  CONCLUSIONS:  This study shows increased staining of activated SFKs in human biopsy specimens of psoriasis and cutaneous neoplasia.  These data provide direct evidence for increased activation of SFKs in the pathogenesis of hyperproliferative epidermal disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1SM7m24OtqLqxQ2mb9Pu8fW6udTcc2ebDt_x7eAGATrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FpsVektw%253D%253D&md5=4410af9243e307f3f3f3dd8833a92855</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0560.2007.00807.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0560.2007.00807.x%26sid%3Dliteratum%253Aachs%26aulast%3DAyli%26aufirst%3DE.%2BE.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DBrown%26aufirst%3DT.%2BT.%26aulast%3DWitkiewicz%26aufirst%3DA.%26aulast%3DElenitsas%26aufirst%3DR.%26aulast%3DSeykora%26aufirst%3DJ.%2BT.%26atitle%3DActivation%2520of%2520Src-family%2520tyrosine%2520kinases%2520in%2520hyperproliferative%2520epidermal%2520disorders%26jtitle%3DJ.%2520Cutaneous%2520Pathol.%26date%3D2008%26volume%3D35%26issue%3D3%26spage%3D273%26epage%3D277%26doi%3D10.1111%2Fj.1600-0560.2007.00807.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="note"><p class="first last">Taiwan clinical trial KX01-PS-01-TW in collaboration with Athenex Inc. partner PharmaEssentia Corp.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="note"><p class="first last">ClinicalTrials.gov, NCT02326441, A phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of KX2-361 in subjects with advanced malignancies that are refractory to conventional therapies.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e','cit2f','cit2g'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37a','cit37b','cit37c','cit37d'],'ref38':['cit38a','cit38b'],'ref39':['cit39'],'ref40':['cit40a','cit40b','cit40c','cit40d'],'ref41':['cit41'],'ref42':['cit42'],'ref43':[],'ref44':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wen Shuai, Guan Wang, Yiwen Zhang, Faqian Bu, Sicheng Zhang, Duane D. Miller, Wei Li, Liang Ouyang, <span class="NLM_string-name hlFld-ContribAuthor">Yuxi Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7963-7990. <a href="https://doi.org/10.1021/acs.jmedchem.1c00100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00100%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bon%252BTubulin%252BInhibitors%252Bwith%252BDual%252BTargeting%252BCapabilities%252Bfor%252BCancer%252BTherapy%26aulast%3DShuai%26aufirst%3DWen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19012021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D7963%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lun Wang, Yunhua Zheng, Dan Li, Jianhong Yang, Lei Lei, Wei Yan, Wei Zheng, Minghai Tang, Mingsong Shi, Ruijia Zhang, Xiaoying Cai, Hengfan Ni, Xu Ma, Na Li, Feng Hong, Haoyu Ye, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8127-8141. <a href="https://doi.org/10.1021/acs.jmedchem.0c01961" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01961%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBioactivity%252BEvaluation%252Bof%252BDual-Target%252BInhibitors%252Bof%252BTubulin%252Band%252BSrc%252BKinase%252BGuided%252Bby%252BCrystal%252BStructure%26aulast%3DWang%26aufirst%3DLun%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12112020%26date%3D03062021%26volume%3D64%26issue%3D12%26spage%3D8127%26epage%3D8141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angela Yen  Moore</span>, <span class="hlFld-ContribAuthor ">Stephen  Moore</span>. </span><span class="cited-content_cbyCitation_article-title">Topical tirbanibulin eradication of periungual squamous cell carcinoma. </span><span class="cited-content_cbyCitation_journal-name">JAAD Case Reports</span><span> <strong>2021,</strong> <em>14 </em>, 101-103. <a href="https://doi.org/10.1016/j.jdcr.2021.06.013" title="DOI URL">https://doi.org/10.1016/j.jdcr.2021.06.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jdcr.2021.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jdcr.2021.06.013%26sid%3Dliteratum%253Aachs%26jtitle%3DJAAD%2520Case%2520Reports%26atitle%3DTopical%252Btirbanibulin%252Beradication%252Bof%252Bperiungual%252Bsquamous%252Bcell%252Bcarcinoma%26aulast%3DMoore%26aufirst%3DAngela%2BYen%26date%3D2021%26volume%3D14%26spage%3D101%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Megan  Conlon</span>, <span class="hlFld-ContribAuthor ">Carson D.  Poltorack</span>, <span class="hlFld-ContribAuthor ">Giovanni C.  Forcina</span>, <span class="hlFld-ContribAuthor ">David A.  Armenta</span>, <span class="hlFld-ContribAuthor ">Melodie  Mallais</span>, <span class="hlFld-ContribAuthor ">Marcos A.  Perez</span>, <span class="hlFld-ContribAuthor ">Alex  Wells</span>, <span class="hlFld-ContribAuthor ">Alexis  Kahanu</span>, <span class="hlFld-ContribAuthor ">Leslie  Magtanong</span>, <span class="hlFld-ContribAuthor ">Jennifer L.  Watts</span>, <span class="hlFld-ContribAuthor ">Derek A.  Pratt</span>, <span class="hlFld-ContribAuthor ">Scott J.  Dixon</span>. </span><span class="cited-content_cbyCitation_article-title">A compendium of kinetic modulatory profiles identifies ferroptosis regulators. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (6)
                                     , 665-674. <a href="https://doi.org/10.1038/s41589-021-00751-4" title="DOI URL">https://doi.org/10.1038/s41589-021-00751-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41589-021-00751-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41589-021-00751-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DA%252Bcompendium%252Bof%252Bkinetic%252Bmodulatory%252Bprofiles%252Bidentifies%252Bferroptosis%252Bregulators%26aulast%3DConlon%26aufirst%3DMegan%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D6%26spage%3D665%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew M.  Waters</span>, <span class="hlFld-ContribAuthor ">Tala O.  Khatib</span>, <span class="hlFld-ContribAuthor ">Bjoern  Papke</span>, <span class="hlFld-ContribAuthor ">Craig M.  Goodwin</span>, <span class="hlFld-ContribAuthor ">G. Aaron  Hobbs</span>, <span class="hlFld-ContribAuthor ">J. Nathaniel  Diehl</span>, <span class="hlFld-ContribAuthor ">Runying  Yang</span>, <span class="hlFld-ContribAuthor ">A. Cole  Edwards</span>, <span class="hlFld-ContribAuthor ">Katherine H.  Walsh</span>, <span class="hlFld-ContribAuthor ">Rita  Sulahian</span>, <span class="hlFld-ContribAuthor ">James M.  McFarland</span>, <span class="hlFld-ContribAuthor ">Kevin S.  Kapner</span>, <span class="hlFld-ContribAuthor ">Thomas S.K.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Clint A.  Stalnecker</span>, <span class="hlFld-ContribAuthor ">Sehrish  Javaid</span>, <span class="hlFld-ContribAuthor ">Anna  Barkovskaya</span>, <span class="hlFld-ContribAuthor ">Kajal R.  Grover</span>, <span class="hlFld-ContribAuthor ">Priya S.  Hibshman</span>, <span class="hlFld-ContribAuthor ">Devon R.  Blake</span>, <span class="hlFld-ContribAuthor ">Antje  Schaefer</span>, <span class="hlFld-ContribAuthor ">Katherine M.  Nowak</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Klomp</span>, <span class="hlFld-ContribAuthor ">Tikvah K.  Hayes</span>, <span class="hlFld-ContribAuthor ">Michelle  Kassner</span>, <span class="hlFld-ContribAuthor ">Nanyun  Tang</span>, <span class="hlFld-ContribAuthor ">Olga  Tanaseichuk</span>, <span class="hlFld-ContribAuthor ">Kaisheng  Chen</span>, <span class="hlFld-ContribAuthor ">Yingyao  Zhou</span>, <span class="hlFld-ContribAuthor ">Manpreet  Kalkat</span>, <span class="hlFld-ContribAuthor ">Laura E.  Herring</span>, <span class="hlFld-ContribAuthor ">Lee M.  Graves</span>, <span class="hlFld-ContribAuthor ">Linda Z.  Penn</span>, <span class="hlFld-ContribAuthor ">Hongwei H.  Yin</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Aguirre</span>, <span class="hlFld-ContribAuthor ">William C.  Hahn</span>, <span class="hlFld-ContribAuthor ">Adrienne D.  Cox</span>, <span class="hlFld-ContribAuthor ">Channing J.  Der</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports</span><span> <strong>2021,</strong> <em>35 </em>
                                    (13)
                                     , 109291. <a href="https://doi.org/10.1016/j.celrep.2021.109291" title="DOI URL">https://doi.org/10.1016/j.celrep.2021.109291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.celrep.2021.109291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.celrep.2021.109291%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%26atitle%3DTargeting%252Bp130Cas-%252Band%252Bmicrotubule-dependent%252BMYC%252Bregulation%252Bsensitizes%252Bpancreatic%252Bcancer%252Bto%252BERK%252BMAPK%252Binhibition%26aulast%3DWaters%26aufirst%3DAndrew%2BM.%26date%3D2021%26volume%3D35%26issue%3D13%26spage%3D109291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kewei  Sun</span>, <span class="hlFld-ContribAuthor ">Zhonghao  Sun</span>, <span class="hlFld-ContribAuthor ">Fenglan  Zhao</span>, <span class="hlFld-ContribAuthor ">Guangzhi  Shan</span>, <span class="hlFld-ContribAuthor ">Qingguo  Meng</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (9)
                                     , 839-858. <a href="https://doi.org/10.4155/fmc-2020-0376" title="DOI URL">https://doi.org/10.4155/fmc-2020-0376</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0376%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bresearch%252Bof%252Bcolchicine%252Bbinding%252Bsite%252Binhibitors%252Band%252Btheir%252Binteraction%252Bmodes%252Bwith%252Btubulin%26aulast%3DSun%26aufirst%3DKewei%26date%3D2021%26volume%3D13%26issue%3D9%26spage%3D839%26epage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Markham</span>, <span class="hlFld-ContribAuthor ">Sean  Duggan</span>. </span><span class="cited-content_cbyCitation_article-title">Tirbanibulin: First Approval. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2021,</strong> <em>81 </em>
                                    (4)
                                     , 509-513. <a href="https://doi.org/10.1007/s40265-021-01479-0" title="DOI URL">https://doi.org/10.1007/s40265-021-01479-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-021-01479-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-021-01479-0%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DTirbanibulin%25253A%252BFirst%252BApproval%26aulast%3DMarkham%26aufirst%3DAnthony%26date%3D2021%26date%3D2021%26volume%3D81%26issue%3D4%26spage%3D509%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Blauvelt</span>, <span class="hlFld-ContribAuthor ">Steven  Kempers</span>, <span class="hlFld-ContribAuthor ">Edward  Lain</span>, <span class="hlFld-ContribAuthor ">Todd  Schlesinger</span>, <span class="hlFld-ContribAuthor ">Stephen  Tyring</span>, <span class="hlFld-ContribAuthor ">Seth  Forman</span>, <span class="hlFld-ContribAuthor ">Glynis  Ablon</span>, <span class="hlFld-ContribAuthor ">George  Martin</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">David L.  Cutler</span>, <span class="hlFld-ContribAuthor ">Jane  Fang</span>, <span class="hlFld-ContribAuthor ">Min-Fun R.  Kwan</span>. </span><span class="cited-content_cbyCitation_article-title">Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. </span><span class="cited-content_cbyCitation_journal-name">New England Journal of Medicine</span><span> <strong>2021,</strong> <em>384 </em>
                                    (6)
                                     , 512-520. <a href="https://doi.org/10.1056/NEJMoa2024040" title="DOI URL">https://doi.org/10.1056/NEJMoa2024040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1056/NEJMoa2024040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1056%2FNEJMoa2024040%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520England%2520Journal%2520of%2520Medicine%26atitle%3DPhase%252B3%252BTrials%252Bof%252BTirbanibulin%252BOintment%252Bfor%252BActinic%252BKeratosis%26aulast%3DBlauvelt%26aufirst%3DAndrew%26date%3D2021%26volume%3D384%26issue%3D6%26spage%3D512%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua T.  Kowalczyk</span>, <span class="hlFld-ContribAuthor ">Xiaolin  Wan</span>, <span class="hlFld-ContribAuthor ">Edjay R.  Hernandez</span>, <span class="hlFld-ContribAuthor ">Ruibai  Luo</span>, <span class="hlFld-ContribAuthor ">Gaelyn C.  Lyons</span>, <span class="hlFld-ContribAuthor ">Kelli M.  Wilson</span>, <span class="hlFld-ContribAuthor ">Devorah C.  Gallardo</span>, <span class="hlFld-ContribAuthor ">Kristine A.  Isanogle</span>, <span class="hlFld-ContribAuthor ">Christina M.  Robinson</span>, <span class="hlFld-ContribAuthor ">Arnulfo  Mendoza</span>, <span class="hlFld-ContribAuthor ">Christine M.  Heske</span>, <span class="hlFld-ContribAuthor ">Jinqui-Qiu  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoling  Luo</span>, <span class="hlFld-ContribAuthor ">Alexander E.  Kelly</span>, <span class="hlFld-ContribAuthor ">Simone  Difilippantinio</span>, <span class="hlFld-ContribAuthor ">Robert W.  Robey</span>, <span class="hlFld-ContribAuthor ">Craig J.  Thomas</span>, <span class="hlFld-ContribAuthor ">Dan L.  Sackett</span>, <span class="hlFld-ContribAuthor ">Deborah K.  Morrison</span>, <span class="hlFld-ContribAuthor ">Paul A.  Randazzo</span>, <span class="hlFld-ContribAuthor ">Lisa M. Miller  Jenkins</span>, <span class="hlFld-ContribAuthor ">Marielle E.  Yohe</span>. </span><span class="cited-content_cbyCitation_article-title">Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 307-319. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0525" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0525%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DRigosertib%252BInduces%252BMitotic%252BArrest%252Band%252BApoptosis%252Bin%252BRAS-Mutated%252BRhabdomyosarcoma%252Band%252BNeuroblastoma%26aulast%3DKowalczyk%26aufirst%3DJoshua%2BT.%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D307%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thu-Huyen  Pham</span>, <span class="hlFld-ContribAuthor ">Hyo-Min  Park</span>, <span class="hlFld-ContribAuthor ">Jinju  Kim</span>, <span class="hlFld-ContribAuthor ">Jin Tae  Hong</span>, <span class="hlFld-ContribAuthor ">Do-Young  Yoon</span>. </span><span class="cited-content_cbyCitation_article-title">STAT3 and p53: Dual Target for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2020,</strong> <em>8 </em>
                                    (12)
                                     , 637. <a href="https://doi.org/10.3390/biomedicines8120637" title="DOI URL">https://doi.org/10.3390/biomedicines8120637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines8120637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines8120637%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DSTAT3%252Band%252Bp53%25253A%252BDual%252BTarget%252Bfor%252BCancer%252BTherapy%26aulast%3DPham%26aufirst%3DThu-Huyen%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D12%26spage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul A.  Wadsworth</span>, <span class="hlFld-ContribAuthor ">Aditya K.  Singh</span>, <span class="hlFld-ContribAuthor ">Nghi  Nguyen</span>, <span class="hlFld-ContribAuthor ">Nolan M.  Dvorak</span>, <span class="hlFld-ContribAuthor ">Cynthia M.  Tapia</span>, <span class="hlFld-ContribAuthor ">William K.  Russell</span>, <span class="hlFld-ContribAuthor ">Clifford  Stephan</span>, <span class="hlFld-ContribAuthor ">Fernanda  Laezza</span>. </span><span class="cited-content_cbyCitation_article-title">JAK2 regulates Nav1.6 channel function via FGF14Y158 phosphorylation. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</span><span> <strong>2020,</strong> <em>1867 </em>
                                    (10)
                                     , 118786. <a href="https://doi.org/10.1016/j.bbamcr.2020.118786" title="DOI URL">https://doi.org/10.1016/j.bbamcr.2020.118786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbamcr.2020.118786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbamcr.2020.118786%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Molecular%2520Cell%2520Research%26atitle%3DJAK2%252Bregulates%252BNav1.6%252Bchannel%252Bfunction%252Bvia%252BFGF14Y158%252Bphosphorylation%26aulast%3DWadsworth%26aufirst%3DPaul%2BA.%26date%3D2020%26volume%3D1867%26issue%3D10%26spage%3D118786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Cirotti</span>, <span class="hlFld-ContribAuthor ">Claudia  Contadini</span>, <span class="hlFld-ContribAuthor ">Daniela  Barilà</span>. </span><span class="cited-content_cbyCitation_article-title">SRC Kinase in Glioblastoma: News from an Old Acquaintance. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (6)
                                     , 1558. <a href="https://doi.org/10.3390/cancers12061558" title="DOI URL">https://doi.org/10.3390/cancers12061558</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12061558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12061558%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DSRC%252BKinase%252Bin%252BGlioblastoma%25253A%252BNews%252Bfrom%252Ban%252BOld%252BAcquaintance%26aulast%3DCirotti%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marija  Nešović</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Divac Rankov</span>, <span class="hlFld-ContribAuthor ">Ana  Podolski-Renić</span>, <span class="hlFld-ContribAuthor ">Igor  Nikolić</span>, <span class="hlFld-ContribAuthor ">Goran  Tasić</span>, <span class="hlFld-ContribAuthor ">Arianna  Mancini</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>, <span class="hlFld-ContribAuthor ">Milica  Pešić</span>, <span class="hlFld-ContribAuthor ">Jelena  Dinić</span>. </span><span class="cited-content_cbyCitation_article-title">Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (6)
                                     , 1570. <a href="https://doi.org/10.3390/cancers12061570" title="DOI URL">https://doi.org/10.3390/cancers12061570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12061570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12061570%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DSrc%252BInhibitors%252BPyrazolo%25255B3%25252C4-d%25255Dpyrimidines%25252C%252BSi306%252Band%252BPro-Si306%25252C%252BInhibit%252BFocal%252BAdhesion%252BKinase%252Band%252BSuppress%252BHuman%252BGlioblastoma%252BInvasion%252BIn%252BVitro%252Band%252BIn%252BVivo%26aulast%3DNe%25C5%25A1ovi%25C4%2587%26aufirst%3DMarija%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alina  Ghinet</span>, <span class="hlFld-ContribAuthor ">Xavier  Thuru</span>, <span class="hlFld-ContribAuthor ">Emilie  Floquet</span>, <span class="hlFld-ContribAuthor ">Joëlle  Dubois</span>, <span class="hlFld-ContribAuthor ">Amaury  Farce</span>, <span class="hlFld-ContribAuthor ">Benoît  Rigo</span>. </span><span class="cited-content_cbyCitation_article-title">Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>96 </em>, 103643. <a href="https://doi.org/10.1016/j.bioorg.2020.103643" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103643%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DEnhanced%252Bantitumor%252Bpotential%252Binduced%252Bby%252Bchloroacetate-loaded%252Bbenzophenones%252Bacting%252Bas%252Bfused%252Btubulin-pyruvate%252Bdehydrogenase%252Bkinase%252B1%252B%252528PDHK1%252529%252Bligands%26aulast%3DGhinet%26aufirst%3DAlina%26date%3D2020%26volume%3D96%26spage%3D103643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Klaske M  Schukken</span>, <span class="hlFld-ContribAuthor ">Yu-Chih  Lin</span>, <span class="hlFld-ContribAuthor ">Petra L  Bakker</span>, <span class="hlFld-ContribAuthor ">Michael  Schubert</span>, <span class="hlFld-ContribAuthor ">Stephanie F  Preuss</span>, <span class="hlFld-ContribAuthor ">Judith E  Simon</span>, <span class="hlFld-ContribAuthor ">Hilda  van den Bos</span>, <span class="hlFld-ContribAuthor ">Zuzana  Storchova</span>, <span class="hlFld-ContribAuthor ">Maria  Colomé-Tatché</span>, <span class="hlFld-ContribAuthor ">Holger  Bastians</span>, <span class="hlFld-ContribAuthor ">Diana CJ  Spierings</span>, <span class="hlFld-ContribAuthor ">Floris  Foijer</span>. </span><span class="cited-content_cbyCitation_article-title">Altering microtubule dynamics is synergistically toxic with spindle assembly checkpoint inhibition. </span><span class="cited-content_cbyCitation_journal-name">Life Science Alliance</span><span> <strong>2020,</strong> <em>3 </em>
                                    (2)
                                     , e201900499. <a href="https://doi.org/10.26508/lsa.201900499" title="DOI URL">https://doi.org/10.26508/lsa.201900499</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.26508/lsa.201900499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.26508%2Flsa.201900499%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Science%2520Alliance%26atitle%3DAltering%252Bmicrotubule%252Bdynamics%252Bis%252Bsynergistically%252Btoxic%252Bwith%252Bspindle%252Bassembly%252Bcheckpoint%252Binhibition%26aulast%3DSchukken%26aufirst%3DKlaske%2BM%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D2%26spage%3De201900499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Niu</span>, <span class="hlFld-ContribAuthor ">Jianhong  Yang</span>, <span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Yamei  Yu</span>, <span class="hlFld-ContribAuthor ">Yunhua  Zheng</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Qiang  Chen</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2019,</strong> <em>294 </em>
                                    (48)
                                     , 18099-18108. <a href="https://doi.org/10.1074/jbc.RA119.010732" title="DOI URL">https://doi.org/10.1074/jbc.RA119.010732</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.010732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.010732%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DReversible%252Bbinding%252Bof%252Bthe%252Banticancer%252Bdrug%252BKXO1%252B%252528tirbanibulin%252529%252Bto%252Bthe%252Bcolchicine-binding%252Bsite%252Bof%252B%2525CE%2525B2-tubulin%252Bexplains%252BKXO1%252527s%252Blow%252Bclinical%252Btoxicity%26aulast%3DNiu%26aufirst%3DLu%26date%3D2019%26volume%3D294%26issue%3D48%26spage%3D18099%26epage%3D18108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kashif  Haider</span>, <span class="hlFld-ContribAuthor ">Shaik  Rahaman</span>, <span class="hlFld-ContribAuthor ">M Shahar  Yar</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (8)
                                     , 623-641. <a href="https://doi.org/10.1080/13543776.2019.1648433" title="DOI URL">https://doi.org/10.1080/13543776.2019.1648433</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1648433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1648433%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DTubulin%252Binhibitors%252Bas%252Bnovel%252Banticancer%252Bagents%25253A%252Ban%252Boverview%252Bon%252Bpatents%252B%2525282013-2018%252529%26aulast%3DHaider%26aufirst%3DKashif%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D8%26spage%3D623%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Wei</span>, <span class="hlFld-ContribAuthor ">Ling  Ma</span>, <span class="hlFld-ContribAuthor ">Chenglong  Li</span>, <span class="hlFld-ContribAuthor ">Christopher R.  Pierson</span>, <span class="hlFld-ContribAuthor ">Jonathan L.  Finlay</span>, <span class="hlFld-ContribAuthor ">Jiayuh  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells. </span><span class="cited-content_cbyCitation_journal-name">Current Cancer Drug Targets</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 571-582. <a href="https://doi.org/10.2174/1568009618666181016165604" title="DOI URL">https://doi.org/10.2174/1568009618666181016165604</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568009618666181016165604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568009618666181016165604%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Cancer%2520Drug%2520Targets%26atitle%3DTargeting%252BUpstream%252BKinases%252Bof%252BSTAT3%252Bin%252BHuman%252BMedulloblastoma%252BCells%26aulast%3DWei%26aufirst%3DJia%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D571%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kinsie E  Arnst</span>, <span class="hlFld-ContribAuthor ">Souvik  Banerjee</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Shanshan  Deng</span>, <span class="hlFld-ContribAuthor ">Dong‐Jin  Hwang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Duane D  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (4)
                                     , 1398-1426. <a href="https://doi.org/10.1002/med.21568" title="DOI URL">https://doi.org/10.1002/med.21568</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21568%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DCurrent%252Badvances%252Bof%252Btubulin%252Binhibitors%252Bas%252Bdual%252Bacting%252Bsmall%252Bmolecules%252Bfor%252Bcancer%252Btherapy%26aulast%3DArnst%26aufirst%3DKinsie%2BE%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D4%26spage%3D1398%26epage%3D1426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael J.  Ciesielski</span>, <span class="hlFld-ContribAuthor ">Yahao  Bu</span>, <span class="hlFld-ContribAuthor ">Stephan A.  Munich</span>, <span class="hlFld-ContribAuthor ">Paola  Teegarden</span>, <span class="hlFld-ContribAuthor ">Michael P.  Smolinski</span>, <span class="hlFld-ContribAuthor ">James L.  Clements</span>, <span class="hlFld-ContribAuthor ">Johnson Y. N.  Lau</span>, <span class="hlFld-ContribAuthor ">David G.  Hangauer</span>, <span class="hlFld-ContribAuthor ">Robert A.  Fenstermaker</span>. </span><span class="cited-content_cbyCitation_article-title">KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuro-Oncology</span><span> <strong>2018,</strong> <em>140 </em>
                                    (3)
                                     , 519-527. <a href="https://doi.org/10.1007/s11060-018-2992-4" title="DOI URL">https://doi.org/10.1007/s11060-018-2992-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11060-018-2992-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11060-018-2992-4%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuro-Oncology%26atitle%3DKX2-361%25253A%252Ba%252Bnovel%252Borally%252Bbioavailable%252Bsmall%252Bmolecule%252Bdual%252BSrc%25252Ftubulin%252Binhibitor%252Bthat%252Bprovides%252Blong%252Bterm%252Bsurvival%252Bin%252Ba%252Bmurine%252Bmodel%252Bof%252Bglioblastoma%26aulast%3DCiesielski%26aufirst%3DMichael%2BJ.%26date%3D2018%26date%3D2018%26volume%3D140%26issue%3D3%26spage%3D519%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of dual MOA Src and tubulin polymerization inhibitors that are under clinical evaluation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Conceptual design process for <b>3</b> as a nonpeptide, non-ATP competitive, insulin receptor tyrosine kinase inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Domain crystal structure of the inactive form of c-Src kinase (SH1) with nonhydrolyzable ATP analogue, AMP–PNP (red) bound in the ATP site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SRC">2SRC</a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The structure is displayed as a Molcad surface, and the generated image was colored based on hydrophobic potential using Sybyl 6.9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Color coded MOLCAD substrate site surface of the active form of the insulin receptor tyrosine kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IR3">1IR3</a>)<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> with AMP–PNP bound (left side) and the visible region (GDYMNM, right side) of the peptide substrate KKKLPAT<u class="uu">GDYMNM</u>SPVGD shown as atom color-coded ball and stick structures. Brown and green surfaces are hydrophobic and blue surfaces are hydrophilic as generated using Sybyl 6.9. The substrate tyrosine is clearly seen adjacent to the ATP mimic terminal phosphate. Hydrogen bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Conceptual design for naphthalene and indole conformationally restricted Tyr scaffolds and analogues <b>4</b> and <b>5</b> based upon IRTK autoinhibited crystal structure. The three corresponding pharmacophore H-bonding groups are labeled 1 through 3 within the structures shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Docked indole Src inhibitor <b>5</b> in the Src peptide substrate site built upon a shared homology to that in IRTK. The Src structure is displayed as a Molcad surface, and the generated image was colored based on hydrophobic potential using Sybyl 6.9. H-bonds are indicated by yellow dotted lines, and some of the key interactions are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Conceptual genesis of clinical compound <b>1</b> from indole Src inhibitor <b>5</b>. Inhibition data for compounds <b>6</b> through <b>1</b> have been reported previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Docked clinical Src inhibitor <b>1</b> in the Src homology-built peptide substrate site. The Src structure is displayed as a Molcad surface, and the generated image was colored based on hydrophobic potential using Sybyl 6.9. H-Bonds are indicated by yellow dotted lines, and some of the key interactions are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Comparative inhibition of Src autophosphorylation (Src-poY416) vs growth inhibition for Src3T3 and HT29 cells. Compound <b>1</b> is compared to the ATP competitive Src inhibitor AZ28.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Cells were lysed, subjected to PAGE, and probed with phospho-Src family (poTyr416) antibody (Cell Signaling Technology no. 2101). Densitometry was used to quantify the results from the gels and the <i>Y</i> axis shows the fold change in the Src-Y416 densitometry signal from the control (no inhibitor). The <i>X</i> axis is scored with multiples of the individual compound’s GI<sub>50</sub>. The activity against Src autophosphorylation correlates with the growth inhibition for Src3T3 and HT29 cell lines, driven by active Src.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Design of photoaffinity analogue <b>10</b> from <b>1</b> and protein target(s) labeling in whole cells. Details of the labeling experiments are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. SDS-PAGE separation and in-gel fluorescent scanning visualization of protein targets labeled by photoaffinity analogue <b>10</b> in the presence or absence of a 200-fold excess of the parental drug <b>1</b>. Protein labeling that increased with higher concentrations of <b>10</b> and are lost in the presence of excess <b>1</b>, are indicated by the arrows. These proteins appear to be targets for the parent drug <b>1</b>. The left side of the figure indicates molecular weight markers in kD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Analysis of labeled target proteins with <b>10</b> in HT29 cells by 2D gel. One mg of HT29 protein lysates were incubated with 2 μM <b>10</b> in the presence or absence of a 200-fold excess of the parent drug <b>1</b> on ice for 1 h under UV irradiation at 365 nm, followed by click chemistry with a rhodamine-azide tag and 2D-gel electrophoresis. The gel spot indicated by the red circle was excised and subjected to in-gel trypsin digestion followed by LC-MS/MS (MALDI-TOF) analyses for protein identification. The protein IDs with high confidence score are listed in the accompanying table.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Competition of known tubulin-binding drugs with photoaffinity analogue <b>10</b> (200 nM). Purified porcine brain tubulin (2 μg) was incubated with photoaffinity analogue <b>10</b> on ice for 1 h under UV irradiation at 365 nm, followed by click chemistry with a TAMRA-azide tag, SDS-PAGE separation and in-gel fluorescence scanning. The indicated inhibitors were included during the incubation at 100- or 500-fold molar excess relative to <b>10</b>. The lack of competition by other known drugs indicates that <b>1</b> binds to a novel site on tubulin. The left side of the gel shows molecular weight markers in kD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Disruption of microtubule structures in PBMCs by <b>1</b>. Human PBMCs were treated with <b>1</b> at the indicated concentrations for 2 h, followed by indirect immunofluorescence staining with anti-α-tubulin antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/medium/jm-2018-00164t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Phase 1 metastatic ovarian cancer patient sequence of prior therapy before compound <b>1</b> (left side) and response of patient CA-125 ovarian cancer biomarker to compound <b>1</b> (right side).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00164/20180608/images/large/jm-2018-00164t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00164&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i15">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">The hunting of the Src</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1038/35073094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2F35073094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=11389470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=467-475&author=G.+S.+Martin&title=The+hunting+of+the+Src&doi=10.1038%2F35073094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The hunting of the Src</span></div><div class="casAuthors">Martin, G. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 120 refs.  The non-receptor tyrosine kinase Src is important for many aspects of cell physiol.  The viral src gene was the 1st retroviral oncogene to be identified, and its cellular counterpart was the 1st protooncogene to be discovered in the vertebrate genome.  Src has been important, not only as an object of study in itself, but also as an entry point into the mol. genetics of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqId3YlI11q77Vg90H21EOLACvtfcHk0lj16UC681MmAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D&md5=36cad805c8b312f84b692efc42b16094</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2F35073094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35073094%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DThe%2520hunting%2520of%2520the%2520Src%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D467%26epage%3D475%26doi%3D10.1038%2F35073094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">The road to Src</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7910</span>– <span class="NLM_lpage">7917</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2Fsj.onc.1208077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=7910-7917&author=G.+S.+Martin&title=The+road+to+Src&doi=10.1038%2Fsj.onc.1208077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208077%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DThe%2520road%2520to%2520Src%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D7910%26epage%3D7917%26doi%3D10.1038%2Fsj.onc.1208077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Src in cancer: Deregulation and consequences for cell behavior</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1602</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/S0304-419X(02)00040-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0304-419X%2802%2900040-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=12020799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=114-130&author=M.+C.+Frame&title=Src+in+cancer%3A+Deregulation+and+consequences+for+cell+behavior&doi=10.1016%2FS0304-419X%2802%2900040-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Src in cancer: deregulation and consequences for cell behavior</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-130</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Considerable evidence now implicates elevated expression and/or activity of Src in cancer development.  In cells, endogenous Src is switched from an inactive to an active state by a variety of mechanisms that simultaneously relieve constraints on the kinase and protein-interacting Src homol. (SH) domains.  As a result, Src is translocated to the cell periphery, often to sites of cell adhesion, where myristylation mediates attachment to the inner surface of the plasma membrane.  From these peripheral sites, Src's catalytic activity initiates intracellular signal transduction pathways that influence cell growth and adhesion strength, the latter contributing to control of cell migration.  De-regulation in cancer cells may therefore enhance tumor growth and/or stimulate migratory or invasive potential in cells that would normally be relatively non-motile.  Evidence now exists to suggest that Src may also influence the life or death decisions that cells make during many biol. processes.  Thus, Src modulation in cancer cells can alter cell responses that are often perturbed in cancer.  Consequently, there is optimism that drugs which inhibit Src's kinase activity, or the activity of its downstream effectors, might have profound effects on cancer cell behavior and be useful therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PUbbCfYCTrVg90H21EOLACvtfcHk0lhXk5wtH8XGAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D&md5=ac3f4d59c7979798349ea7f0db807d67</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900040-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900040-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DSrc%2520in%2520cancer%253A%2520Deregulation%2520and%2520consequences%2520for%2520cell%2520behavior%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2002%26volume%3D1602%26spage%3D114%26epage%3D130%26doi%3D10.1016%2FS0304-419X%2802%2900040-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Newest findings on the oldest oncogene; how activated src does it</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1242/jcs.01111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1242%2Fjcs.01111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=14996930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVyru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=989-998&author=M.+C.+Frame&title=Newest+findings+on+the+oldest+oncogene%3B+how+activated+src+does+it&doi=10.1242%2Fjcs.01111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Newest findings on the oldest oncogene; how activated src does it</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">989-998</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncogenic forms of the non-receptor tyrosine kinase Src alter cell structure, in particular the actin cytoskeleton and the adhesion networks that control cell migration, and also transmit signals that regulate proliferation and cell survival.  Recent work indicates that they do so by influencing the RhoA-ROCK pathway that controls contractile actin filament assembly, the STAT family of transcription factors needed for transformation, and the Cbl ubiquitin ligase that controls Src protein levels.  These studies also shed light on the role of focal adhesion kinase (FAK) downstream of v-Src and other signaling pathways in controlling migration, invasion and survival of transformed cells.  Src directly phosphorylates integrins and can also modulate R-Ras activity.  Moreover, it stimulates the E-cadherin regulator Hakai, interacts with and phosphorylates the novel podosome-linked adaptor protein Fish, and progressively phosphorylates the gap junction component connexion 43.  A recurring theme is the identification of novel and important Src substrates that mediate key biol. events assocd. with transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6rvTTcPN9XLVg90H21EOLACvtfcHk0lhXk5wtH8XGAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVyru7g%253D&md5=c50d2426c7d5e3672e9b3d7180b56576</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.01111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.01111%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DNewest%2520findings%2520on%2520the%2520oldest%2520oncogene%253B%2520how%2520activated%2520src%2520does%2520it%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2004%26volume%3D117%26spage%3D989%26epage%3D998%26doi%3D10.1242%2Fjcs.01111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Summy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galllick, G. E.</span></span> <span> </span><span class="NLM_article-title">Src family kinases in tumor progression and metastasis</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1023/A:1023772912750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1023%2FA%3A1023772912750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=12884910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslyiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=337-358&author=J.+M.+Summyauthor=G.+E.+Galllick&title=Src+family+kinases+in+tumor+progression+and+metastasis&doi=10.1023%2FA%3A1023772912750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases in tumor progression and metastasis</span></div><div class="casAuthors">Summy, Justin M.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-358</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  The Src family of non-receptor protein tyrosine kinases plays crit. roles in a variety of cellular signal transduction pathways, regulating such diverse processes as cell division, motility, adhesion, angiogenesis, and survival.  Constitutively activated variants of Src family kinases, including the viral oncoproteins v-Src and v-Yes, are capable of inducing malignant transformation of a variety of cell types.  Src family kinases, most notably although not exclusively c-Src, are frequently overexpressed and/or aberrantly activated in a variety of epithelial and non-epithelial cancers.  Activation is very common in colorectal and breast cancers, and somewhat less frequent in melanomas, ovarian cancer, gastric cancer, head and neck cancers, pancreatic cancer, lung cancer, brain cancers, and blood cancers.  Further, the extent of increased Src family activity often correlates with malignant potential and patient survival.  Activation of Src family kinases in human cancers may occur through a variety of mechanisms and is frequently a crit. event in tumor progression.  Exactly how Src family kinases contribute to individual tumors remains to be defined completely, however they appear to be important for multiple aspects of tumor progression, including proliferation, disruption of cell/cell contacts, migration, invasiveness, resistance to apoptosis, and angiogenesis.  This review details the evidence for Src family activation in human tumors, and emphasizes possible consequences to tumor progression.  Given the ability of Src and its family members to participate in so many aspects of tumor progression and metastasis, Src family kinases are attractive targets for future anti-cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkVr5TJ1KYLVg90H21EOLACvtfcHk0lhXk5wtH8XGAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslyiu74%253D&md5=9ae3b863e9e79978efbee6e92206cd2b</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023772912750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023772912750%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DGalllick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520family%2520kinases%2520in%2520tumor%2520progression%2520and%2520metastasis%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2003%26volume%3D22%26spage%3D337%26epage%3D358%26doi%3D10.1023%2FA%3A1023772912750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Summy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span> <span> </span><span class="NLM_article-title">Treatment for advanced tumors: Src reclaims center stage</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1401</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1078-0432.CCR-05-2692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=16533761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1398-1401&issue=5&author=J.+M.+Summyauthor=G.+E.+Gallick&title=Treatment+for+advanced+tumors%3A+Src+reclaims+center+stage&doi=10.1158%2F1078-0432.CCR-05-2692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment for advanced tumors: Src reclaims center stage</span></div><div class="casAuthors">Summy, Justin M.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1398-1401</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The recent advances in roles of Src in tumor progression and clin./translational advances are discussed.  Src activation in tumor cells indirectly regulates Src activity in endothelial cells.  Increased Src activity in the tumor cells increases VEGF expression, resulting in increased binding to VEGF expression, resulting in increased binding to VEGF receptors on endothelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2D4rtkj8O3LVg90H21EOLACvtfcHk0ligs3iXe3MM-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D&md5=96eb5f53cf01bd47bc52e250b81e5c71</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2692%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DTreatment%2520for%2520advanced%2520tumors%253A%2520Src%2520reclaims%2520center%2520stage%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26issue%3D5%26spage%3D1398%26epage%3D1401%26doi%3D10.1158%2F1078-0432.CCR-05-2692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yeatman, T. J.</span></span> <span> </span><span class="NLM_article-title">A renaissance for Src</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1038/nrc1366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2Fnrc1366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=15170449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=470-480&author=T.+J.+Yeatman&title=A+renaissance+for+Src&doi=10.1038%2Fnrc1366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">A renaissance for SRC</span></div><div class="casAuthors">Yeatman, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The c-SRC non-receptor tyrosine kinase is overexpressed and activated in a large no. of human malignancies and has been linked to the development of cancer and progression to distant metastases.  These observations have led to the recent targeting of c-SRC for the development of anticancer therapeutics, which show promise as a new avenue for cancer treatment.  Despite this, however, the precise functions of c-SRC in cancer remain unclear.  In addn. to increasing cell proliferation, a key role of c-SRC in cancer seems to be to promote invasion and motility, functions that might contribute to tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCGFL31NDP4LVg90H21EOLACvtfcHk0ligs3iXe3MM-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D&md5=e14e862826b2881721d0f6bb14356650</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1038%2Fnrc1366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1366%26sid%3Dliteratum%253Aachs%26aulast%3DYeatman%26aufirst%3DT.%2BJ.%26atitle%3DA%2520renaissance%2520for%2520Src%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D470%26epage%3D480%26doi%3D10.1038%2Fnrc1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span> <span> </span><span class="NLM_article-title">Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis</span>. <i>Cell Tissue Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>335</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1007/s00441-008-0682-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs00441-008-0682-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18815812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOru7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2009&pages=249-259&issue=1&author=M.+P.+Kimauthor=S.+I.+Parkauthor=S.+Kopetzauthor=G.+E.+Gallick&title=Src+family+kinases+as+mediators+of+endothelial+permeability%3A+effects+on+inflammation+and+metastasis&doi=10.1007%2Fs00441-008-0682-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis</span></div><div class="casAuthors">Kim, M. P.; Park, S. I.; Kopetz, S.; Gallick, G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell & Tissue Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">CTSRCS</span>;
        ISSN:<span class="NLM_cas:issn">0302-766X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Src family kinases (SFKs) are signaling enzymes that have long been recognized to regulate crit. cellular processes such as proliferation, survival, migration, and metastasis.  Recently, considerable work has elucidated mechanisms by which SFKs regulate normal and pathol. processes in vascular biol., including endothelial cell proliferation and permeability.  Further, when inappropriately activated, SFKs promote pathol. inflammatory processes and tumor metastasis, in part through their effects on the regulation of endothelial monolayer permeability.  In this review, we discuss the roles of aberrantly activated SFKs in mediating endothelial permeability in the context of inflammatory states and tumor cell metastasis.  We further summarize recent efforts to translate Src-specific inhibitors into therapy for systemic inflammatory conditions and numerous solid organ cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqg4M3dV7u7Vg90H21EOLACvtfcHk0ligs3iXe3MM-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOru7vO&md5=dd515c1f832199b7401753bd8ba082cb</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.1007%2Fs00441-008-0682-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00441-008-0682-9%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BP.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520family%2520kinases%2520as%2520mediators%2520of%2520endothelial%2520permeability%253A%2520effects%2520on%2520inflammation%2520and%2520metastasis%26jtitle%3DCell%2520Tissue%2520Res.%26date%3D2009%26volume%3D335%26issue%3D1%26spage%3D249%26epage%3D259%26doi%3D10.1007%2Fs00441-008-0682-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span> <span> </span><span class="NLM_article-title">Src continues aging: current and future clinical directions</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7232</span>– <span class="NLM_lpage">7236</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1078-0432.CCR-07-1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18094400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCktr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=7232-7236&issue=24&author=S.+Kopetzauthor=A.+N.+Shahauthor=G.+E.+Gallick&title=Src+continues+aging%3A+current+and+future+clinical+directions&doi=10.1158%2F1078-0432.CCR-07-1902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Src Continues Aging: Current and Future Clinical Directions</span></div><div class="casAuthors">Kopetz, Scott; Shah, Ami N.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7232-7236</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of members of the Src family of nonreceptor protein tyrosine kinases is common in solid tumor malignancies and may contribute to the development and/or progression of these tumors.  As a result, four Src inhibitors are now in more than 50 clin. trials for at least 14 different types of solid tumors.  In this review, we briefly discuss the preclin. rationale for Src inhibitors, the development strategies most likely to be successful in the clinic, and the rationale for Src inhibitors in combination with other agents as part of a more comprehensive therapeutic strategy.  As the use of Src family inhibitors in clin. trials on solid tumors is in its infancy, further studies on the roles of Src family kinases in tumor progression, chemoresistance, epidermal-to-mesenchymal transition, and other properties of tumor progression will be important in designing the most effective clin. trials using these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXLm8EfhR0A7Vg90H21EOLACvtfcHk0lhXLjhaBG4EvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCktr%252FO&md5=9035c1e855115b9616c6c9e4f3729222</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1902%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DA.%2BN.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520continues%2520aging%253A%2520current%2520and%2520future%2520clinical%2520directions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D24%26spage%3D7232%26epage%3D7236%26doi%3D10.1158%2F1078-0432.CCR-07-1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span> <span> </span><span class="NLM_article-title">Targeting Src family kinases in anti-cancer therapies: turning promise into triumph</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2011.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.tips.2011.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=22153719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=122-128&author=S.+Zhangauthor=D.+Yu&title=Targeting+Src+family+kinases+in+anti-cancer+therapies%3A+turning+promise+into+triumph&doi=10.1016%2Fj.tips.2011.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src family kinases in anti-cancer therapies: turning promise into triumph</span></div><div class="casAuthors">Zhang, Siyuan; Yu, Dihua</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Src is a non-receptor tyrosine kinase that is deregulated in many types of cancer.  Decades of research have revealed the crucial role of Src in many aspects of tumor development, including proliferation, survival, adhesion, migration, invasion and, most importantly, metastasis, in multiple tumor types.  Despite extensive preclin. evidence that warrants targeting Src as a promising therapeutic approach for cancer, Src inhibitor(s) showed only minimal therapeutic activity in various types of solid tumors when used as a single agent in recent early-phase clin. trials.  In this review, we highlight the most recent advances from preclin. studies and clin. trials that shed light on potential clin. use of Src inhibitor-contg. combinatorial regimens in overcoming resistance to current anticancer therapies and in preventing metastatic recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZvQcvwj_23bVg90H21EOLACvtfcHk0lhXLjhaBG4EvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOqtrk%253D&md5=22c9483e90ec6b390f42b74806d87d21</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DTargeting%2520Src%2520family%2520kinases%2520in%2520anti-cancer%2520therapies%253A%2520turning%2520promise%2520into%2520triumph%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.tips.2011.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bogoyevitch, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketterman, A. J.</span></span> <span> </span><span class="NLM_article-title">Peptide inhibitors of protein kinases—discovery, characterisation and use</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2005.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.bbapap.2005.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=16182621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlagsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=79-99&author=M.+A.+Bogoyevitchauthor=R.+K.+Barrauthor=A.+J.+Ketterman&title=Peptide+inhibitors+of+protein+kinases%E2%80%94discovery%2C+characterisation+and+use&doi=10.1016%2Fj.bbapap.2005.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide inhibitors of protein kinases-discovery, characterisation and use</span></div><div class="casAuthors">Bogoyevitch, Marie A.; Barr, Renae K.; Ketterman, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">79-99</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are now the second largest group of drug targets, and most protein kinase inhibitors in clin. development are directed towards the ATP-binding site.  However, these inhibitors must compete with high intracellular ATP concns. and they must discriminate between the ATP-binding sites of all protein kinases as well the other proteins that also utilize ATP.  It would therefore be beneficial to target sites on protein kinases other than the ATP-binding site.  This review describes the discovery, characterization and use of peptide inhibitors of protein kinases.  In many cases, the development of these peptides has resulted from an understanding of the specific protein-binding partners for a particular protein kinase.  In addn., novel peptide sequences have been discovered in library screening approaches and have provided new leads in the discovery and/or design of peptide inhibitors of protein kinases.  These approaches are therefore providing exciting new opportunities in the development of ATP non-competitive inhibitors of protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4P4RRYVXgzbVg90H21EOLACvtfcHk0lhXLjhaBG4EvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlagsL7P&md5=c148db5b6586ff09ef0c27c239d53971</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DBogoyevitch%26aufirst%3DM.%2BA.%26aulast%3DBarr%26aufirst%3DR.%2BK.%26aulast%3DKetterman%26aufirst%3DA.%2BJ.%26atitle%3DPeptide%2520inhibitors%2520of%2520protein%2520kinases%25E2%2580%2594discovery%252C%2520characterisation%2520and%2520use%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D79%26epage%3D99%26doi%3D10.1016%2Fj.bbapap.2005.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span> <span> </span><span class="NLM_article-title">Progress in the development of non-ATP-competitive protein kinase inhibitors for oncology</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-396492-2.00029-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FB978-0-12-396492-2.00029-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=459-474&author=C.+McInnes&title=Progress+in+the+development+of+non-ATP-competitive+protein+kinase+inhibitors+for+oncology&doi=10.1016%2FB978-0-12-396492-2.00029-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00029-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00029-1%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DC.%26atitle%3DProgress%2520in%2520the%2520development%2520of%2520non-ATP-competitive%2520protein%2520kinase%2520inhibitors%2520for%2520oncology%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D459%26epage%3D474%26doi%3D10.1016%2FB978-0-12-396492-2.00029-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1021/cb5008376</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5008376" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVGmtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=175-189&author=M.+E.+Breenauthor=M.+B.+Soellner&title=Small+molecule+substrate+phosphorylation+site+inhibitors+of+protein+kinases%3A+approaches+and+challenges&doi=10.1021%2Fcb5008376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Substrate Phosphorylation Site Inhibitors of Protein Kinases: Approaches and Challenges</span></div><div class="casAuthors">Breen, Meghan E.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-189</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein kinases are important mediators of cellular communication and attractive drug targets for many diseases.  Although success has been achieved with developing ATP-competitive kinase inhibitors, the disadvantages of ATP-competitive inhibitors have led to increased interest in targeting sites outside of the ATP binding pocket.  Kinase inhibitors with substrate-competitive, ATP-noncompetitive binding modes are promising due to the possibility of increased selectivity and better agreement between biochem. and in vitro potency.  However, the difficulty of identifying these types of inhibitors has resulted in significantly fewer small mol. substrate phosphorylation site inhibitors being reported compared to ATP-competitive inhibitors.  This review surveys reported substrate phosphorylation site inhibitors and methods that can be applied to the discovery of such inhibitors, including a discussion of the challenges inherent to these screening methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIZJGtYNoHhrVg90H21EOLACvtfcHk0likPbiUirFX-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVGmtr%252FN&md5=6a4eb9aae91c2241d7baa559ef839a0d</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fcb5008376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5008376%26sid%3Dliteratum%253Aachs%26aulast%3DBreen%26aufirst%3DM.%2BE.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DSmall%2520molecule%2520substrate%2520phosphorylation%2520site%2520inhibitors%2520of%2520protein%2520kinases%253A%2520approaches%2520and%2520challenges%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D175%26epage%3D189%26doi%3D10.1021%2Fcb5008376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachacz, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwarcinski, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7010</span>– <span class="NLM_lpage">7013</span>, <span class="refDoi"> DOI: 10.1002/anie.201311096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1002%2Fanie.201311096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=7010-7013&author=M.+B.+Breenauthor=M.+E.+Steffeyauthor=E.+J.+Lachaczauthor=F.+E.+Kwarcinskiauthor=C.+C.+Foxauthor=M.+B.+Soellner&title=Substrate+activity+screening+with+kinases%3A+discovery+of+small-molecule+substrate-competitive+c-Src+inhibitors&doi=10.1002%2Fanie.201311096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201311096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201311096%26sid%3Dliteratum%253Aachs%26aulast%3DBreen%26aufirst%3DM.%2BB.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DLachacz%26aufirst%3DE.%2BJ.%26aulast%3DKwarcinski%26aufirst%3DF.%2BE.%26aulast%3DFox%26aufirst%3DC.%2BC.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DSubstrate%2520activity%2520screening%2520with%2520kinases%253A%2520discovery%2520of%2520small-molecule%2520substrate-competitive%2520c-Src%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D7010%26epage%3D7013%26doi%3D10.1002%2Fanie.201311096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parang, K.</span></span> <span> </span><span class="NLM_article-title">Development of Src tyrosine kinase substrate binding site inhibitors</span>. <i>Curr. Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">613</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=605-613&author=G.+Yeauthor=R.+Tiwariauthor=K.+Parang&title=Development+of+Src+tyrosine+kinase+substrate+binding+site+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DG.%26aulast%3DTiwari%26aufirst%3DR.%26aulast%3DParang%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520Src%2520tyrosine%2520kinase%2520substrate%2520binding%2520site%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D605%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Compositions for Treating Cell Proliferation Disorders</span>. <span class="NLM_patent">US 7,300,931 B2</span>, Nov 27, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+G.+Hangauer&title=Compositions+for+Treating+Cell+Proliferation+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DCompositions%2520for%2520Treating%2520Cell%2520Proliferation%2520Disorders%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods of Treating Cell Proliferation Disorders</span>. U.S. Patent <span class="NLM_patent">US 8,003,641 B2</span>, Aug 23, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+G.+Hangauer&title=Compositions+and+Methods+of+Treating+Cell+Proliferation+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DCompositions%2520and%2520Methods%2520of%2520Treating%2520Cell%2520Proliferation%2520Disorders%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saperstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicario, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strout, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondeyka, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5694</span>– <span class="NLM_lpage">5701</span>, <span class="refDoi"> DOI: 10.1021/bi00439a053</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00439a053" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=5694-5701&author=R.+Sapersteinauthor=P.+P.+Vicarioauthor=V.+S.+Stroutauthor=E.+Bradyauthor=E.+E.+Slaterauthor=W.+J.+Greenleeauthor=D.+L.+Ondeykaauthor=A.+A.+Patchettauthor=D.+G.+Hangauer&title=Design+of+a+selective+insulin+receptor+tyrosine+kinase+inhibitor+and+its+effect+on+glucose+uptake+and+metabolism+in+intact+cells&doi=10.1021%2Fbi00439a053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fbi00439a053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00439a053%26sid%3Dliteratum%253Aachs%26aulast%3DSaperstein%26aufirst%3DR.%26aulast%3DVicario%26aufirst%3DP.%2BP.%26aulast%3DStrout%26aufirst%3DV.%2BS.%26aulast%3DBrady%26aufirst%3DE.%26aulast%3DSlater%26aufirst%3DE.%2BE.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DOndeyka%26aufirst%3DD.%2BL.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DDesign%2520of%2520a%2520selective%2520insulin%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520and%2520its%2520effect%2520on%2520glucose%2520uptake%2520and%2520metabolism%2520in%2520intact%2520cells%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D5694%26epage%3D5701%26doi%3D10.1021%2Fbi00439a053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Identification of efficient pentapeptide substrates for the tyrosine kinase pp60<sup>c-src</sup></span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4276</span>– <span class="NLM_lpage">4283</span>, <span class="refDoi"> DOI: 10.1021/jm00021a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00021a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=4276-4283&author=S.+A.+Nairauthor=M.+H.+Kimauthor=S.+D.+Warrenauthor=S.+Choiauthor=Z.+Songyangauthor=L.+C.+Cantleyauthor=D.+G.+Hangauer&title=Identification+of+efficient+pentapeptide+substrates+for+the+tyrosine+kinase+pp60c-src&doi=10.1021%2Fjm00021a017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm00021a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00021a017%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DWarren%26aufirst%3DS.%2BD.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DSongyang%26aufirst%3DZ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DIdentification%2520of%2520efficient%2520pentapeptide%2520substrates%2520for%2520the%2520tyrosine%2520kinase%2520pp60c-src%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D4276%26epage%3D4283%26doi%3D10.1021%2Fjm00021a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and activity of pentapeptide pp60<sup>c-src</sup> inhibitors containing L-phosphotyrosine mimics</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1998.tb00424.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fj.1399-3011.1998.tb00424.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=9560002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK1cXitFait7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1998&pages=271-281&author=J.+H.+Laiauthor=T.+H.+Marsiljeauthor=S.+Choiauthor=S.+A.+Nairauthor=D.+G.+Hangauer&title=The+design%2C+synthesis+and+activity+of+pentapeptide+pp60c-src+inhibitors+containing+L-phosphotyrosine+mimics&doi=10.1111%2Fj.1399-3011.1998.tb00424.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and activity of pentapeptide pp60c-src inhibitors containing L-phosphotyrosine mimics</span></div><div class="casAuthors">Lai, Jack H.; Marsilje, Thomas H.; Choi, Sun; Nair, Shrikumar A.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-281</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Efficient syntheses of 4-(R,S-hydroxyphosphonomethyl)-L-phenylalanine and 4-carboxy-L-phenylalanine within the context of the pentapeptide Ac-Ile-X-Gly-Glu-Phe-NH2 (wherein X = the unnatural amino acid) illustrate the use of a divergent synthetic strategy from an advanced common peptide intermediate to more readily access peptide-based tyrosine kinase inhibitors.  The key intermediate, Ac-Ile-Phe(4-formyl)-Gly-Glu(O-tBu)-Phe-NH2, was synthesized by a facile palladium-catalyzed carbonylation of Ac-Ile-Phe(4-iodo)-Gly-Glu(O-tBu)-Phe-NH2.  Oxidn. of Ac-Ile-Phe(4-formyl)-Gly-Glu(O-tBu)-Phe-NH2 with tetrabutylammonium permanganate or addn. of di-t-butylphosphite, both followed by trifluoroacetic acid deprotection, gave the target pentapeptide inhibitors wherein X = 4-carboxy-L-phenylalanine or 4-(R,S-hydroxyphosphonomethyl)-L-phenylalanine, resp.  These two peptides gave somewhat more potent inhibition of the tyrosine kinase pp60c-src than the corresponding pentapeptide wherein X = L-phenylalanine, demonstrating that appended functionalities at the 4-position are accepted and can enhance binding through added interactions within the catalytic region of the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPdRuBRDFzKbVg90H21EOLACvtfcHk0lgiku6LE_pM9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitFait7k%253D&md5=78e2d98f3df2c5c07282ecdfe3b8511f</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1998.tb00424.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1998.tb00424.x%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DS.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520activity%2520of%2520pentapeptide%2520pp60c-src%2520inhibitors%2520containing%2520L-phosphotyrosine%2520mimics%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D1998%26volume%3D51%26spage%3D271%26epage%3D281%26doi%3D10.1111%2Fj.1399-3011.1998.tb00424.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Tetrapeptide tyrosine kinase inhibitors: enantioselective synthesis of p-hydroxymethyl-L-phenylalanine, incorporation into a tetrapeptide, and subsequent elaboration into p-(hydroxy-phosphonomethyl) L-phenylalanine</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1994.tb00182.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fj.1399-3011.1994.tb00182.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=7896504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK2MXisFykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1994&pages=457-465&author=M.+H.+Kimauthor=J.+H.+Laiauthor=D.+G.+Hangauer&title=Tetrapeptide+tyrosine+kinase+inhibitors%3A+enantioselective+synthesis+of+p-hydroxymethyl-L-phenylalanine%2C+incorporation+into+a+tetrapeptide%2C+and+subsequent+elaboration+into+p-%28hydroxy-phosphonomethyl%29+L-phenylalanine&doi=10.1111%2Fj.1399-3011.1994.tb00182.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrapeptide tyrosine kinase inhibitors. Enantioselective synthesis of p-hydroxymethyl-L-phenylalanine, incorporation into a tetrapeptide, and subsequent elaboration into p-(R,S-hydroxyphosphonomethyl)-L-phenylalanine</span></div><div class="casAuthors">Kim, Moon H.; Lai, Jack H.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-65</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A convenient enantioselective synthesis of p-hydroxymethyl-L-phenylalanine (I) was developed which produces a 4/1 ratio of L/D enantiomers resulting from a chiral phase transfer-catalyzed alkylation.  I was coupled into the p561ck tyrosine kinase substrate Ac-Leu-Pro-Tyr-Ala-NHMe as a replacement for Tyr and can subsequently be elaborated into a variety of potential tyrosine kinase inhibitor designs of general structure Ac-Leu-Pro-AA-Ala-NHCH3, wherein AA is an unnatural amino acid.  The contaminating D enantiomer was readily removed after coupling to L-Ala-NHMe of this sequence.  The utility of the p-hydroxymethyl functionality in an efficient divergent synthetic strategy leading to various inhibitor designs is illustrated with the synthesis of Ac-Leu-Pro-AA-Ala-NHMe, wherein AA is p-(R,S-hydroxyphosphonomethyl)-L-phenylalanine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwmU9yR_dkurVg90H21EOLACvtfcHk0lgiku6LE_pM9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisFykt70%253D&md5=0e660e546c32b6602b7203d571b173d7</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1994.tb00182.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1994.tb00182.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BH.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DTetrapeptide%2520tyrosine%2520kinase%2520inhibitors%253A%2520enantioselective%2520synthesis%2520of%2520p-hydroxymethyl-L-phenylalanine%252C%2520incorporation%2520into%2520a%2520tetrapeptide%252C%2520and%2520subsequent%2520elaboration%2520into%2520p-%2528hydroxy-phosphonomethyl%2529%2520L-phenylalanine%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1994%26volume%3D44%26spage%3D457%26epage%3D465%26doi%3D10.1111%2Fj.1399-3011.1994.tb00182.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">638</span>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SRC">2SRC</a> <span class="refDoi"> DOI: 10.1016/S1097-2765(00)80356-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS1097-2765%2800%2980356-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10360179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=629-638&author=W.+Xuauthor=A.+Doshiauthor=M.+Leiauthor=M.+J.+Eckauthor=S.+C.+Harrison&title=Crystal+structures+of+c-Src+reveal+features+of+its+autoinhibitory+mechanism&doi=10.1016%2FS1097-2765%2800%2980356-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of c-Src reveal features of its autoinhibitory mechanism</span></div><div class="casAuthors">Xu, Wenqing; Doshi, Amish; Lei, Ming; Eck, Michael J.; Harrison, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-638</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Src family kinases are maintained in an assembled, inactive conformation by intramol. interactions of their SH2 and SH3 domains.  Full catalytic activity requires release of these restraints as well as phosphorylation of Tyr-416 in the activation loop.  In previous structures of inactive Src kinases, Tyr-416 and flanking residues are disordered.  We report here four addnl. c-Src structures in which this segment adopts an ordered but inhibitory conformation.  The ordered activation loop forms an α helix that stabilizes the inactive conformation of the kinase domain, blocks the peptide substrate-binding site, and prevents Tyr-416 phosphorylation.  Disassembly of the regulatory domains, induced by SH2 or SH3 ligands, or by dephosphorylation of Tyr-527, could lead to exposure and phosphorylation of Tyr-416.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsIh6d9RHa7Vg90H21EOLACvtfcHk0lgiku6LE_pM9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqu7o%253D&md5=926f6a6a4097ce667168b5b81d9a1092</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980356-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980356-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%26aulast%3DDoshi%26aufirst%3DA.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DHarrison%26aufirst%3DS.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520c-Src%2520reveal%2520features%2520of%2520its%2520autoinhibitory%2520mechanism%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D629%26epage%3D638%26doi%3D10.1016%2FS1097-2765%2800%2980356-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebetanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span> <span> </span><span class="NLM_article-title">The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1016/j.str.2005.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.str.2005.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=15939018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=861-871&author=S.+W.+Cowan-Jacobauthor=G.+Fendrichauthor=P.+W.+Manleyauthor=W.+Jahnkeauthor=D.+Fabbroauthor=J.+Liebetanzauthor=T.+Meyer&title=The+crystal+structure+of+a+c-Src+complex+in+an+active+conformation+suggests+possible+steps+in+c-Src+activation&doi=10.1016%2Fj.str.2005.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Fendrich, Gabriele; Manley, Paul W.; Jahnke, Wolfgang; Fabbro, Doriano; Liebetanz, Janis; Meyer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramol. interactions between the SH3, SH2, and kinase (SH1) domains.  We have detd. the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail.  This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe.  NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as obsd. for Abl, suggesting that c-Src may also be regulated by myristate binding.  In addn., the structure contains a des-Me analog of the antileukemia drug imatinib (STI571; Gleevec).  This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipzhBFIZrQ7Vg90H21EOLACvtfcHk0ljZ66Z8-gNdtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D&md5=f0de83e5bca45fe96795e5327e6d1369</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DThe%2520crystal%2520structure%2520of%2520a%2520c-Src%2520complex%2520in%2520an%2520active%2520conformation%2520suggests%2520possible%2520steps%2520in%2520c-Src%2520activation%26jtitle%3DStructure%26date%3D2005%26volume%3D13%26spage%3D861%26epage%3D871%26doi%3D10.1016%2Fj.str.2005.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenlechner, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kairies, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koll, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of active Src kinase domain complexes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2005.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.jmb.2005.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=16168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=222-231&author=C.+B.+Breitenlechnerauthor=N.+A.+Kairiesauthor=K.+Honoldauthor=S.+Scheiblichauthor=H.+Kollauthor=E.+Greiterauthor=S.+Kochauthor=W.+Schaferauthor=R.+Huberauthor=R.+A.+Engh&title=Crystal+structures+of+active+Src+kinase+domain+complexes&doi=10.1016%2Fj.jmb.2005.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Active Src Kinase Domain Complexes</span></div><div class="casAuthors">Breitenlechner, Christine B.; Kairies, Norman A.; Honold, Konrad; Scheiblich, Stefan; Koll, Hans; Greiter, Eva; Koch, Stefan; Schaefer, Wolfgang; Huber, Robert; Engh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">C-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs.  Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form.  Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms.  Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolns. ranging from 2.9 Å to 1.95 Å.  The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation.  The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340.  In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3P258chhrbVg90H21EOLACvtfcHk0lgL5rRyVdfUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF&md5=9bc8e1670457d34ac88e6b5b20efea21</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenlechner%26aufirst%3DC.%2BB.%26aulast%3DKairies%26aufirst%3DN.%2BA.%26aulast%3DHonold%26aufirst%3DK.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKoll%26aufirst%3DH.%26aulast%3DGreiter%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520active%2520Src%2520kinase%2520domain%2520complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D222%26epage%3D231%26doi%3D10.1016%2Fj.jmb.2005.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanafusa, H.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of cellular proteins in rous sarcoma virus-infected cells: analysis by use of anti-phosphotyrosine antibodies</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3035</span>– <span class="NLM_lpage">3042</span>, <span class="refDoi"> DOI: 10.1128/MCB.8.8.3035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1128%2FMCB.8.8.3035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=2463469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaL1cXltVygsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1988&pages=3035-3042&issue=8&author=M.+Hamaguchiauthor=C.+Grandoriauthor=H.+Hanafusa&title=Phosphorylation+of+cellular+proteins+in+rous+sarcoma+virus-infected+cells%3A+analysis+by+use+of+anti-phosphotyrosine+antibodies&doi=10.1128%2FMCB.8.8.3035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of cellular proteins in Rous sarcoma virus-infected cells:  analysis by use of anti-phosphotyrosine antibodies</span></div><div class="casAuthors">Hamaguchi, Michinari; Grandori, Carla; Hanafusa, Hidesaburo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3035-42</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The protein substrates for the tyrosine protein kinases in cells transformed by avian sarcoma viruses were analyzed by gel electrophoresis in combination with immunoblotting or immunopptn. by antibodies against phosphotyrosine.  More than 90% of phosphotyrosine-contg. cellular proteins can be immunopptd. by these antibodies.  The level of phosphotyrosine-contg. cellular proteins detectable by this method markedly increased upon transformation with Rous sarcoma virus-transformed cells.  Most of these phosphotyrosine-contg. proteins had not been identified by other methods, and their presence appeared to correlate with morphol. transformation in cells infected with various Rous sarcoma virus mutants and Y73, PRCII, and Fujinami sarcoma viruses.  However, considerably different patterns were obtained with cells infected with nontransforming Rous sarcoma virus mutants that encode nonmyristylated src kinases, indicating that most substrates that correlate with transformation can only be recognized by p60v-src assocd. with the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqMmr66XuaBLVg90H21EOLACvtfcHk0lgL5rRyVdfUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVygsbc%253D&md5=765c83949af11e5b5bb7de21525d0c9a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FMCB.8.8.3035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.8.8.3035%26sid%3Dliteratum%253Aachs%26aulast%3DHamaguchi%26aufirst%3DM.%26aulast%3DGrandori%26aufirst%3DC.%26aulast%3DHanafusa%26aufirst%3DH.%26atitle%3DPhosphorylation%2520of%2520cellular%2520proteins%2520in%2520rous%2520sarcoma%2520virus-infected%2520cells%253A%2520analysis%2520by%2520use%2520of%2520anti-phosphotyrosine%2520antibodies%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1988%26volume%3D8%26issue%3D8%26spage%3D3035%26epage%3D3042%26doi%3D10.1128%2FMCB.8.8.3035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S.
R.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5572</span>– <span class="NLM_lpage">5581</span>, <span class="refDoi"> DOI: 10.1093/emboj/16.18.5572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1093%2Femboj%2F16.18.5572" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5572-5581&issue=18&author=S.%0AR.+Hubbard&title=Crystal+structure+of+the+activated+insulin+receptor+tyrosine+kinase+in+complex+with+peptide+substrate+and+ATP+analog&doi=10.1093%2Femboj%2F16.18.5572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.18.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.18.5572%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520the%2520activated%2520insulin%2520receptor%2520tyrosine%2520kinase%2520in%2520complex%2520with%2520peptide%2520substrate%2520and%2520ATP%2520analog%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26issue%3D18%26spage%3D5572%26epage%3D5581%26doi%3D10.1093%2Femboj%2F16.18.5572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, W. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/372746a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1038%2F372746a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=7997262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=746-754&author=S.+R.+Hubbardauthor=L.+Weiauthor=W.+A.+Hendrickson&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+human+insulin+receptor&doi=10.1038%2F372746a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span></div><div class="casAuthors">Hubbard, Stevan R.; Wei, Lei; Ellis, Leland; Hendrickson, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">746-54</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The x-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been detd. by multiwavelength anomalous diffraction phasing and refined to 2.1 Å resoln.  The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1162, is bound in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp222kk0byoTrVg90H21EOLACvtfcHk0lgL5rRyVdfUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D&md5=ad60bacc76a642b2957c55ff82274cab</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1038%2F372746a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372746a0%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520human%2520insulin%2520receptor%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D746%26epage%3D754%26doi%3D10.1038%2F372746a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 1: hydroxynaphthalene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00039-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0960-894X%2800%2900039-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=477-481&author=T.+H.+Marsiljeauthor=K.+L.+Milkiewiczauthor=D.+G.+Hangauer&title=The+design%2C+synthesis+and+activity+of+non-ATP+competitive+inhibitors+of+pp60c-src+tyrosine+kinase.+Part+1%3A+hydroxynaphthalene+derivatives&doi=10.1016%2FS0960-894X%2800%2900039-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900039-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900039-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520activity%2520of%2520non-ATP%2520competitive%2520inhibitors%2520of%2520pp60c-src%2520tyrosine%2520kinase.%2520Part%25201%253A%2520hydroxynaphthalene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D477%26epage%3D481%26doi%3D10.1016%2FS0960-894X%2800%2900039-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, R. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 2: hydroxyindole derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00040-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0960-894X%2800%2900040-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=483-486&author=K.+L.+Milkiewiczauthor=T.+H.+Marsiljeauthor=R.+P.+Woodworthauthor=N.+Bifulcoauthor=M.+J.+Hangauerauthor=D.+G.+Hangauer&title=The+design%2C+synthesis+and+activity+of+non-ATP+competitive+inhibitors+of+pp60c-src+tyrosine+kinase.+Part+2%3A+hydroxyindole+derivatives&doi=10.1016%2FS0960-894X%2800%2900040-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900040-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900040-8%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DWoodworth%26aufirst%3DR.%2BP.%26aulast%3DBifulco%26aufirst%3DN.%26aulast%3DHangauer%26aufirst%3DM.%2BJ.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520activity%2520of%2520non-ATP%2520competitive%2520inhibitors%2520of%2520pp60c-src%2520tyrosine%2520kinase.%2520Part%25202%253A%2520hydroxyindole%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D483%26epage%3D486%26doi%3D10.1016%2FS0960-894X%2800%2900040-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span>Southern Research Institute, Birmingham, AL. Unpublished
results..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Southern+Research+Institute%2C+Birmingham%2C+AL.+Unpublished%0Aresults.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span>; <span class="NLM_string-name">El-Araby, M. E.</span>; <span class="NLM_string-name">Milkiewicz, K. L.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase and Phosphatase Inhibitors and Methods for Designing Them</span>. U.S. Patents <span class="NLM_patent">US 7,772,216 B2</span>, Aug 10, <span class="NLM_year">2010</span>, and <span class="NLM_patent">US 7,005,445, B2</span>, Feb 28, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+G.+Hangauer&author=M.+E.+El-Araby&author=K.+L.+Milkiewicz&title=Protein+Kinase+and+Phosphatase+Inhibitors+and+Methods+for+Designing+Them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DProtein%2520Kinase%2520and%2520Phosphatase%2520Inhibitors%2520and%2520Methods%2520for%2520Designing%2520Them%26date%3D2010%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Compositions and Methods of Treating Cell Proliferation Disorders</span>. <span class="NLM_patent">US 8,980,890 B2</span>, Mar 17, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+G.+Hangauer&title=Compositions+and+Methods+of+Treating+Cell+Proliferation+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DCompositions%2520and%2520Methods%2520of%2520Treating%2520Cell%2520Proliferation%2520Disorders%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span>; <span class="NLM_string-name">Bu, Y.</span>; <span class="NLM_string-name">Smithgall, T.</span>; <span class="NLM_string-name">Hangauer, D. G.</span>; <span class="NLM_string-name">Gelman, I. H.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gao%2C+L.%3B+Bu%2C+Y.%3B+Smithgall%2C+T.%3B+Hangauer%2C+D.+G.%3B+Gelman%2C+I.+H.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moy, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stochaj, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosyak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, D. H. H.</span></span> <span> </span><span class="NLM_article-title">Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1021/jm901525b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901525b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1238-1249&author=F.+J.+Moyauthor=A.+Leeauthor=L.+K.+Gavrinauthor=Z.+B.+Xuauthor=A.+Sieversauthor=E.+Kierasauthor=W.+Stochajauthor=L.+Mosyakauthor=J.+McKewauthor=D.+H.+H.+Tsao&title=Novel+synthesis+and+structural+characterization+of+a+high-affinity+paramagnetic+kinase+probe+for+the+identification+of+non-ATP+site+binders+by+nuclear+magnetic+resonance&doi=10.1021%2Fjm901525b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901525b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901525b%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DXu%26aufirst%3DZ.%2BB.%26aulast%3DSievers%26aufirst%3DA.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DStochaj%26aufirst%3DW.%26aulast%3DMosyak%26aufirst%3DL.%26aulast%3DMcKew%26aufirst%3DJ.%26aulast%3DTsao%26aufirst%3DD.%2BH.%2BH.%26atitle%3DNovel%2520synthesis%2520and%2520structural%2520characterization%2520of%2520a%2520high-affinity%2520paramagnetic%2520kinase%2520probe%2520for%2520the%2520identification%2520of%2520non-ATP%2520site%2520binders%2520by%2520nuclear%2520magnetic%2520resonance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1238%26epage%3D1249%26doi%3D10.1021%2Fjm901525b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plé, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert-van
der Brempt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1021/jm030317k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030317k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=871-887&author=P.+A.+Pl%C3%A9author=T.+P.+Greenauthor=L.+F.+Hennequinauthor=J.+Curwenauthor=M.+Fennellauthor=J.+Allenauthor=C.+Lambert-van%0Ader+Bremptauthor=G.+Costello&title=Discovery+of+a+new+class+of+anilinoquinazoline+inhibitors+with+high+affinity+and+specificity+for+the+tyrosine+kinase+domain+of+c-Src&doi=10.1021%2Fjm030317k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm030317k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030317k%26sid%3Dliteratum%253Aachs%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%2BA.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520new%2520class%2520of%2520anilinoquinazoline%2520inhibitors%2520with%2520high%2520affinity%2520and%2520specificity%2520for%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520c-Src%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D871%26epage%3D887%26doi%3D10.1021%2Fjm030317k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span>; <span class="NLM_string-name">Bu, Y.</span>; <span class="NLM_string-name">Munich, S. A.</span>; <span class="NLM_string-name">Smolinski, M. P.</span>; <span class="NLM_string-name">Clements, J. L.</span>; <span class="NLM_string-name">Lau, J. Y. N.</span>; <span class="NLM_string-name">Hangauer, D. G.</span>; <span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">KX2-361: A novel small molecule inhibitor of Src signaling and tubulin polymerization that prolongs survival in mice with GL261 cerebral gliomas</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ciesielski%2C+M.+J.%3B+Bu%2C+Y.%3B+Munich%2C+S.+A.%3B+Smolinski%2C+M.+P.%3B+Clements%2C+J.+L.%3B+Lau%2C+J.+Y.+N.%3B+Hangauer%2C+D.+G.%3B+Fenstermaker%2C+R.+A.+KX2-361%3A+A+novel+small+molecule+inhibitor+of+Src+signaling+and+tubulin+polymerization+that+prolongs+survival+in+mice+with+GL261+cerebral+gliomas.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26atitle%3DKX2-361%253A%2520A%2520novel%2520small%2520molecule%2520inhibitor%2520of%2520Src%2520signaling%2520and%2520tubulin%2520polymerization%2520that%2520prolongs%2520survival%2520in%2520mice%2520with%2520GL261%2520cerebral%2520gliomas" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span>; <span class="NLM_string-name">Munich, S. A.</span>; <span class="NLM_string-name">Hangauer, D. G.</span>; <span class="NLM_string-name">Dyster, L. M.</span>; <span class="NLM_string-name">Clements, J. L.</span>; <span class="NLM_string-name">Barnett, A.</span>; <span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">KX02 a novel therapeutic for glioma</span>. In  <i>AACR 101st Annual Meeting, Washington, DC, April 17–21</i>, <span class="NLM_year">2010</span>; poster abstract no.  <span class="NLM_fpage">5598</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=5598&author=M.+J.+Ciesielski&author=S.+A.+Munich&author=D.+G.+Hangauer&author=L.+M.+Dyster&author=J.+L.+Clements&author=A.+Barnett&author=R.+A.+Fenstermaker&title=KX02+a+novel+therapeutic+for+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26atitle%3DKX02%2520a%2520novel%2520therapeutic%2520for%2520glioma%26jtitle%3DAACR%2520101st%2520Annual%2520Meeting%252C%2520Washington%252C%2520DC%252C%2520April%252017%25E2%2580%259321%26date%3D2010%26spage%3D5598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fex, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span> <span> </span><span class="NLM_article-title">2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of <i>N</i>-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent <i>pan</i>-Src kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6819</span>– <span class="NLM_lpage">6832</span>, <span class="refDoi"> DOI: 10.1021/jm060727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=F.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-Aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure-activity+relationship+studies+toward+the+discovery+of+N-%282-Chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor&doi=10.1021%2Fjm060727j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure-Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor</span></div><div class="casAuthors">Das, Jagabandhu; Chen, Ping; Norris, Derek; Padmanabha, Ramesh; Lin, James; Moquin, Robert V.; Shen, Zhongqi; Cook, Lynda S.; Doweyko, Arthur M.; Pitt, Sidney; Pang, Suhong; Shen, Ding Ren; Fang, Qiong; de Fex, Henry F.; McIntyre, Kim W.; Shuster, David J.; Gillooly, Kathleen M.; Behnia, Kamelia; Schieven, Gary L.; Wityak, John; Barrish, Joel C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6819-6832</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Aminothiazole was discovered as a novel Src family kinase inhibitor template through screening of our internal compd. collection.  Optimization through successive structure-activity relationship iterations identified analogs I [R = 4-(2-hydroxyethyl)piperazino, Q] (Dasatinib, BMS-354825) and I [R = Me]as pan-Src inhibitors with nanomolar to subnanomolar potencies in biochem. and cellular assays.  Mol. modeling was used to construct a putative binding model for Lck inhibition by this class of compds.  The framework of key hydrogen-bond interactions proposed by this model was in agreement with the subsequent, published crystal structure of I [R = Q] bound to structurally similar Abl kinase.  The oral efficacy of this class of inhibitors was demonstrated with I [R = Me] in inhibiting the proinflammatory cytokine IL-2 ex vivo in mice (ED50 ∼ 5 mg/kg) and in reducing TNF levels in an acute murine model of inflammation (90% inhibition in LPS-induced TNFα prodn. when dosed orally at 60 mg/kg, 2 h prior to LPS administration).  The oral efficacy of I [R = Me] was further demonstrated in a chronic model of adjuvant arthritis in rats with established disease when administered orally at 0.3 and 3 mg/kg twice daily.  I [R = Q] is currently in clin. trials for the treatment of chronic myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrbDd3Qks9cLVg90H21EOLACvtfcHk0liVlCv4Ep5hxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI&md5=9eed66048de7ab90b8a8015385d6f581</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DF.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-Aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure-activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-Chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832%26doi%3D10.1021%2Fjm060727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity labeling in target- and binding-site identification</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.4155%2Ffmc.14.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=25686004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=159-183&issue=2&author=E.+Smithauthor=I.+Collins&title=Photoaffinity+labeling+in+target-+and+binding-site+identification&doi=10.4155%2Ffmc.14.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labeling in target- and binding-site identification</span></div><div class="casAuthors">Smith, Ewan; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-183</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Photoaffinity labeling (PAL) using a chem. probe to covalently bind its target in response to activation by light has become a frequently used tool in drug discovery for identifying new drug targets and mol. interactions, and for probing the location and structure of binding sites.  Methods to identify the specific target proteins of hit mols. from phenotypic screens are highly valuable in early drug discovery.  In this review, we summarize the principles of PAL including probe design and exptl. techniques for in vitro and live cell investigations.  We emphasize the need to optimize and validate probes and highlight examples of the successful application of PAL across multiple disease areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpIXjEh35goLVg90H21EOLACvtfcHk0liVlCv4Ep5hxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D&md5=ca00880405324587a542f19f8bd10d6c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.152%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DPhotoaffinity%2520labeling%2520in%2520target-%2520and%2520binding-site%2520identification%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26issue%3D2%26spage%3D159%26epage%3D183%26doi%3D10.4155%2Ffmc.14.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazim, L.</span>; <span class="NLM_string-name">Choi, K.-S.</span></span> <span class="NLM_publisher-name">Roswell Park Cancer Institute</span>: <span class="NLM_publisher-loc">Buffalo, NY</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kazim%2C+L.%3B+Choi%2C+K.-S.+Roswell+Park+Cancer+Institute%3A+Buffalo%2C+NY.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DKazim%26aufirst%3DL.%26pub%3DRoswell%2520Park%2520Cancer%2520Institute" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span> <span class="NLM_publisher-name">University at Buffalo</span>: <span class="NLM_publisher-loc">Buffalo, NY</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Qu%2C+J.+University+at+Buffalo%3A+Buffalo%2C+NY.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DJ.%26pub%3DUniversity%2520at%2520Buffalo" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span> <span> </span><span class="NLM_article-title">An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2012.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2Fj.jprot.2012.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=22982362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Klsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=187-201&author=C.+Tuauthor=J.+Liauthor=Y.+Buauthor=D.+Hangauerauthor=J.+Qu&title=An+ion-current-based%2C+comprehensive+and+reproducible+proteomic+strategy+for+comparative+characterization+of+the+cellular+responses+to+novel+anti-cancer+agents+in+a+prostate+cell+model&doi=10.1016%2Fj.jprot.2012.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model</span></div><div class="casAuthors">Tu, Chengjian; Li, Jun; Bu, Yahao; Hangauer, David; Qu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187-201</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Proteome-level investigation of the mol. targets in anticancer action of promising pharmaceutical candidates is highly desirable but remains challenging due to the insufficient proteome coverage, limited capacity for biol. replicates, and largely unregulated false pos. biomarker discovery of current methods.  This study described a practical platform strategy to address these challenges, using comparison of drug response proteomic signatures by two promising anti-cancer agents (KX01/KX02) as the model system for method development/optimization.  Drug-treated samples were efficiently extd. followed by pptn./on-pellet-digestion procedure that provides high, reproducible peptide recovery.  High-resoln. sepns. were performed on a 75-cm-long, heated nano-LC column with a 7-h gradient, with a highly reproducible nano-LC/nanospray configuration.  An LTQ Orbitrap hybrid mass spectrometer with a charge overfilling approach to enhance sensitivity was used for detection.  Anal. procedures were optimized and well-controlled to achieve high run-to-run reproducibility that permits numerous replicates in one set, and an ion-current-based approach was utilized for quantification.  The false positives of biomarker discovery arising from tech. variability was controlled based on FBDR measurement by comparing biomarker nos. in each drug-treated group vs. "sham samples", which were analyzed in an order randomly interleaved with the anal. drug-treated samples.  More than 1500 unique protein groups were quantified under stringent criteria, and of which about 30% displayed differential expression with FBDR of 0.3-2.1% across groups.  Comparison of drug-response proteomic signatures and the subsequent immunoassay revealed that the action mechanisms of KX01/KX02 are similar but significantly different from vinblastine, which correlates well with clin. and pre-clin. observations.  Furthermore, the results strongly supported the hypothesis that KX01/KX02 are dual-action agents (through inhibition of tubulin and Src).  Moreover, informative insights into the drug-actions on cell cycle, growth/proliferation, and apoptosis were obtained.  This platform technol. provides extensive evaluation of drug candidates and facilitates in-depth mechanism studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF7cSS9rdVKbVg90H21EOLACvtfcHk0li12VREzZ9yzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Klsr3O&md5=cd3761a487119886c37ed72387e9927a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2012.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2012.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DQu%26aufirst%3DJ.%26atitle%3DAn%2520ion-current-based%252C%2520comprehensive%2520and%2520reproducible%2520proteomic%2520strategy%2520for%2520comparative%2520characterization%2520of%2520the%2520cellular%2520responses%2520to%2520novel%2520anti-cancer%2520agents%2520in%2520a%2520prostate%2520cell%2520model%26jtitle%3DJ.%2520Proteomics%26date%3D2012%26volume%3D77%26spage%3D187%26epage%3D201%26doi%3D10.1016%2Fj.jprot.2012.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1535-7163.MCT-12-0146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=22784709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1936-1947&issue=9&author=M.+Anbalaganauthor=A.+Aliauthor=R.+K.+Jonesauthor=C.+G.+Marsdenauthor=M.+Shengauthor=L.+Carrierauthor=Y.+Buauthor=D.+Hangauerauthor=B.+G.+Rowan&title=Peptidomimetic+Src%2Fpretubulin+inhibitor+KX-01+alone+and+in+combination+with+paclitaxel+suppresses+growth%2C+metastasis+in+human+ER%2FPR%2FHER2-negative+tumor+xenografts&doi=10.1158%2F1535-7163.MCT-12-0146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts</span></div><div class="casAuthors">Anbalagan, Muralidharan; Ali, Alaa; Jones, Ryan K.; Marsden, Carolyn G.; Sheng, Mei; Carrier, Latonya; Bu, Yahao; Hangauer, David; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1936-1947</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Src kinase is elevated in breast tumors that are ER/PR neg. and do not overexpress HER2, but clin. trials with Src inhibitors have shown little activity.  The present study evaluated preclin. efficacy of a novel peptidomimetic compd., KX-01 (KX2-391), that exhibits dual action as an Src and pretubulin inhibitor.  KX-01 was evaluated as a single-agent and in combination with paclitaxel in MDA-MB-231, MDA-MB-157, and MDA-MB-468 human ER/PR/HER2-neg. breast cancer cells.  Treatments were evaluated by growth/apoptosis, isobologram anal., migration/invasion assays, tumor xenograft vol., metastasis, and measurement of Src, focal adhesion kinase (FAK), microtubules, Ki67, and microvessel d.  KX-01 inhibited cell growth in vitro and in combination with paclitaxel resulted in synergistic growth inhibition.  KX-01 resulted in a dose-dependent inhibition of MDA-MB-231 and MDA-MB-157 tumor xenografts (1 and 5 mg/kg, twice daily).  KX-01 inhibited activity of Src and downstream mediator FAK in tumors that was coincident with reduced proliferation and angiogenesis and increased apoptosis.  KX01 also resulted in microtubule disruption in tumors.  Combination of KX-01 with paclitaxel resulted in significant regression of MDA-MB-231 tumors and reduced metastasis to mouse lung and liver.  KX-01 is a potently active Src/pretubulin inhibitor that inhibits breast tumor growth and metastasis.  As ER/PR/HER2-neg. patients are candidates for paclitaxel therapy, combination with KX-01 may potentiate antitumor efficacy in management of this aggressive breast cancer subtype.  Mol Cancer Ther; 11(9); 1936-47. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPQgufjmNZ7Vg90H21EOLACvtfcHk0li12VREzZ9yzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI&md5=dd688323209801ec45284d3dc86ead48</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0146%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DR.%2BK.%26aulast%3DMarsden%26aufirst%3DC.%2BG.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DPeptidomimetic%2520Src%252Fpretubulin%2520inhibitor%2520KX-01%2520alone%2520and%2520in%2520combination%2520with%2520paclitaxel%2520suppresses%2520growth%252C%2520metastasis%2520in%2520human%2520ER%252FPR%252FHER2-negative%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D9%26spage%3D1936%26epage%3D1947%26doi%3D10.1158%2F1535-7163.MCT-12-0146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor effect of KX-01 through inhibiting Src family kinases and mitosis</span>. <i>Cancer Research and Treatment</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.4143/crt.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.4143%2Fcrt.2016.168" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=643-655&issue=3&author=S.+Kimauthor=A.+Minauthor=K.-H.+Leeauthor=Y.+Yangauthor=T.-Y.+Kimauthor=J.+M.+Limauthor=S.+J.+Parkauthor=H.-J.+Namauthor=J.+E.+Kimauthor=S.-H.+Songauthor=S.-W.+Hanauthor=D.-O.+Ohauthor=J.+H.+Kimauthor=T.-Y.+Kimauthor=D.+Hangauerauthor=J.+Y-N.+Lauauthor=K.+Imauthor=D.+S.+Leeauthor=Y.-J.+Bangauthor=S.-A.+Im&title=Anti-tumor+effect+of+KX-01+through+inhibiting+Src+family+kinases+and+mitosis&doi=10.4143%2Fcrt.2016.168"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DLim%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DNam%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DJ.%2BE.%26aulast%3DSong%26aufirst%3DS.-H.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DOh%26aufirst%3DD.-O.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DJ.%2BY-N.%26aulast%3DIm%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BS.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DIm%26aufirst%3DS.-A.%26atitle%3DAnti-tumor%2520effect%2520of%2520KX-01%2520through%2520inhibiting%2520Src%2520family%2520kinases%2520and%2520mitosis%26jtitle%3DCancer%2520Research%2520and%2520Treatment%26date%3D2017%26volume%3D49%26issue%3D3%26spage%3D643%26epage%3D655%26doi%3D10.4143%2Fcrt.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glodowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1007/s10549-011-1513-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs10549-011-1513-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=21509526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=391-409&issue=2&author=M.+Anbalaganauthor=L.+Carrierauthor=S.+Glodowskiauthor=D.+Hangauerauthor=B.+Shanauthor=B.+G.+Rowan&title=KX-01%2C+a+novel+Src+kinase+inhibitor+directed+toward+the+peptide+substrate+site%2C+synergizes+with+tamoxifen+in+estrogen+receptor+%CE%B1+positive+breast+cancer&doi=10.1007%2Fs10549-011-1513-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span></div><div class="casAuthors">Anbalagan, Muralidharan; Carrier, Latonya; Glodowski, Seth; Hangauer, David; Shan, Bin; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-409</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX-01 is the first clin. Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase.  The present study was designed to evaluate the effects of KX-01 as a single agent and in combination with tamoxifen (TAM) on cell growth and apoptosis of ERα pos. breast cancer in vitro and in vivo.  Flow cytometry demonstrated that KX-01 induced cell cycle arrest in G2/M phase.  Immunofluorescent staining for mitotic phase markers and TUNEL staining indicated that cells had arrested in the mitotic phase and mitotic arrested cells were undergoing apoptosis.  KX-01 induced nuclear accumulation of cyclin B1, and activation of CDK1, MPM2, and Cdc25C that is required for progression past the G2/M checkpoint.  Apoptosis resulted from activation of caspases 6, 7, 8, and 9.  Combinational index anal. revealed that combinations of KX-01 with TAM resulted in synergistic growth inhibition of breast cancer cell lines.  KX-01 combined with TAM resulted in decreased ERα phosphorylation at Src-regulated phosphorylation sites serines 118 and 167 that were assocd. with reduced ERα transcriptional activity.  Orally administered KX-01 resulted in a dose dependent growth inhibition of MCF-7 tumor xenografts, and in combination with TAM exhibited synergistic growth inhibition.  Immunohistochem. anal. revealed that combinational treatment reduced angiogenesis, and ERα signaling in tumors compared to either drug alone that may underlie the synergistic tumor growth inhibition.  Combinations of KX-01 with endocrine therapy present a promising new strategy for clin. management of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjBSgfh5qJbVg90H21EOLACvtfcHk0lg5PaXh9qHZSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D&md5=e55cc94c076cfd5f38a715c4b55b15dd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1513-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1513-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DGlodowski%26aufirst%3DS.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DKX-01%252C%2520a%2520novel%2520Src%2520kinase%2520inhibitor%2520directed%2520toward%2520the%2520peptide%2520substrate%2520site%252C%2520synergizes%2520with%2520tamoxifen%2520in%2520estrogen%2520receptor%2520%25CE%25B1%2520positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26issue%3D2%26spage%3D391%26epage%3D409%26doi%3D10.1007%2Fs10549-011-1513-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecot, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottsford-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumovitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeting Src and tubulin in mucinous ovarian carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6532</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1078-0432.CCR-13-1305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=24100628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6532-6543&issue=23&author=T.+Liuauthor=H.+Huauthor=H.+J.+Daltonauthor=H.+J.+Choiauthor=J.+Huangauthor=Y.+Kangauthor=S.+Pradeepauthor=T.+Miyakeauthor=J.+H.+Songauthor=Y.+Wenauthor=C.+Luauthor=C.+V.+Pecotauthor=J.+Bottsford-Millerauthor=B.+Zandauthor=N.+B.+Jenningsauthor=C.+Ivanauthor=G.+E.+Gallickauthor=K.+A.+Baggerlyauthor=D.+G.+Hangauerauthor=R.+L.+Colemanauthor=M.+Frumovitzauthor=A.+K.+Sood&title=Targeting+Src+and+tubulin+in+mucinous+ovarian+carcinoma&doi=10.1158%2F1078-0432.CCR-13-1305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src and Tubulin in Mucinous Ovarian Carcinoma</span></div><div class="casAuthors">Liu, Tao; Hu, Wei; Dalton, Heather J.; Choi, Hyun Jin; Huang, Jie; Kang, Yu; Pradeep, Sunila; Miyake, Takahito; Song, Jian H.; Wen, Yunfei; Lu, Chunhua; Pecot, Chad V.; Bottsford-Miller, Justin; Zand, Behrouz; Jennings, Nicholas B.; Ivan, Cristina; Gallick, Gary E.; Baggerly, Keith A.; Hangauer, David G.; Coleman, Robert L.; Frumovitz, Michael; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6532-6543</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian carcinoma.  Exptl. Design: The in vitro and in vivo effects and mol. mechanisms of KX-01, which inhibits Src pathway and tubulin polymn., were examd. in mucinous ovarian cancer models.  Results: In vitro studies using RMUG-S and RMUG-L cell lines showed that KX-01 inhibited cell proliferation, induced apoptosis, arrested the cell cycle at the G2-M phase, and enhanced the cytotoxicity of oxaliplatin in the KX-01-sensitive cell line, RMUG-S.  In vivo studies showed that KX-01 significantly decreased tumor burden in RMUG-S and RMUG-L mouse models relative to untreated controls, and the effects were greater when KX-01 was combined with oxaliplatin.  KX-01 alone and in combination with oxaliplatin significantly inhibited tumor growth by reducing cell proliferation and inducing apoptosis in vivo.  PTEN knock-in expts. in RMUG-L cells showed improved response to KX-01.  Reverse phase protein array anal. showed that in addn. to blocking downstream mols. of Src family kinases, KX-01 also activated acute stress-inducing mols.  Conclusion: Our results showed that targeting both the Src pathway and tubulin with KX-01 significantly inhibited tumor growth in preclin. mucinous ovarian cancer models, suggesting that this may be a promising therapeutic approach for patients with mucinous ovarian carcinoma.  Clin Cancer Res; 19(23); 6532-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-wBwf5SGhLVg90H21EOLACvtfcHk0lg5PaXh9qHZSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM&md5=cea052b1774b6850f996f05a5d02d10b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1305%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DPradeep%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DJ.%2BH.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPecot%26aufirst%3DC.%2BV.%26aulast%3DBottsford-Miller%26aufirst%3DJ.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DFrumovitz%26aufirst%3DM.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DTargeting%2520Src%2520and%2520tubulin%2520in%2520mucinous%2520ovarian%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D23%26spage%3D6532%26epage%3D6543%26doi%3D10.1158%2F1078-0432.CCR-13-1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matossian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins-Burow, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">Dual Src kinase/pretubulin inhibitor KX-01, sensitizes ERα-negative breast cancers to tamoxifen through ERα reexpression</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-16-0297-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1158%2F1541-7786.MCR-16-0297-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=28751463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGisrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1491-502&issue=11&author=M.+Anbalaganauthor=M.+Shengauthor=B.+Fleischerauthor=Y.+Zhangauthor=Y.+Gaoauthor=V.+Hoangauthor=M.+Matossianauthor=H.+E.+Burksauthor=M.+E.+Burowauthor=B.+M.+Collins-Burowauthor=D.+Hangauerauthor=B.+G.+Rowan&title=Dual+Src+kinase%2Fpretubulin+inhibitor+KX-01%2C+sensitizes+ER%CE%B1-negative+breast+cancers+to+tamoxifen+through+ER%CE%B1+reexpression&doi=10.1158%2F1541-7786.MCR-16-0297-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression</span></div><div class="casAuthors">Anbalagan, Muralidharan; Sheng, Mei; Fleischer, Brian; Zhang, Yifang; Gao, Yuanjun; Hoang, Van; Matossian, Margarite; Burks, Hope E.; Burow, Matthew E.; Collins-Burow, Bridgette M.; Hangauer, David; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1491-1502</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Unlike breast cancer that is pos. for estrogen receptor-α (ERα), there are no targeted therapies for triple-neg. breast cancer (TNBC).  ERα is silenced in TNBC through epigenetic changes including DNA methylation and histone acetylation.  Restoring ERα expression in TNBC may sensitize patients to endocrine therapy.  Expression of c-Src and ERα are inversely correlated in breast cancer suggesting that c-Src inhibition may lead to reexpression of ERα in TNBC.  KX-01 is a peptide substrate-targeted Src/pretubulin inhibitor in clin. trials for solid tumors.  KX-01 (1 mg/kg body wt.-twice daily) inhibited growth of tamoxifen-resistant MDA-MB-231 and MDA-MB-157 TNBC xenografts in nude mice that was correlated with Src kinase inhibition.  KX-01 also increased ERα mRNA and protein, as well as increased the ERα targets progesterone receptor (PR), pS2 (TFF1), cyclin D1 (CCND1), and c-myc (MYC) in MDA-MB-231 and MDA-MB-468, but not MDA-MB-157 xenografts.  MDA-MB-231 and MDA-MB-468 tumors exhibited redn. in mesenchymal markers (vimentin, β-catenin) and increase in epithelial marker (E-cadherin) suggesting mesenchymal-to-epithelial transition (MET).  KX-01 sensitized MDA-MB-231 and MDA-MB-468 tumors to tamoxifen growth inhibition and tamoxifen repression of the ERα targets pS2, cyclin D1, and c-myc.  Chromatin immunopptn. (ChIP) of the ERα promoter in KX-01-treated tumors demonstrated enrichment of active transcription marks (acetyl-H3, acetyl-H3Lys9), dissocn. of HDAC1, and recruitment of RNA polymerase II.  Methylation-specific PCR and bisulfite sequencing demonstrated no alteration in ERα promoter methylation by KX-01.  These data demonstrate that in addn. to Src kinase inhibition, peptidomimetic KX-01 restores ERα expression in TNBC through changes in histone acetylation that sensitize tumors to tamoxifen.  Implications: Src kinase/pretubulin inhibitor KX-01 restores functional ERα expression in ERα- breast tumors, a novel treatment strategy to treat triple-neg. breast cancer.  Mol Cancer Res; 15(11); 1491-502. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTO0z5LBghubVg90H21EOLACvtfcHk0ljzk_o_Y4inOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGisrfO&md5=d7704aa0b28922ff3067dd3c00021504</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-16-0297-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-16-0297-T%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DFleischer%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DHoang%26aufirst%3DV.%26aulast%3DMatossian%26aufirst%3DM.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DBurow%26aufirst%3DM.%2BE.%26aulast%3DCollins-Burow%26aufirst%3DB.%2BM.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DDual%2520Src%2520kinase%252Fpretubulin%2520inhibitor%2520KX-01%252C%2520sensitizes%2520ER%25CE%25B1-negative%2520breast%2520cancers%2520to%2520tamoxifen%2520through%2520ER%25CE%25B1%2520reexpression%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2017%26volume%3D15%26issue%3D11%26spage%3D1491%26epage%3D502%26doi%3D10.1158%2F1541-7786.MCR-16-0297-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. S.</span></span> <span> </span><span class="NLM_article-title">Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1465</span>– <span class="NLM_lpage">1474</span>, <span class="refDoi"> DOI: 10.1007/s10620-008-0519-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs10620-008-0519-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18979199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmslOktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=1465-1474&issue=7&author=G.+M.+Lauauthor=G.+M.+Lauauthor=G.-L.+Yuauthor=I.+H.+Gelmanauthor=A.+Gutowskiauthor=D.+Hangauerauthor=W.+S.+Fang&title=Expression+of+Src+and+FAK+in+hepatocellular+carcinoma+and+the+effect+of+Src+inhibitors+on+hepatocellular+carcinoma+in+vitro&doi=10.1007%2Fs10620-008-0519-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro</span></div><div class="casAuthors">Lau, Grace M.; Lau, Gillian M.; Yu, Guo-Liang; Gelman, Irwin H.; Gutowski, Alan; Hangauer, David; Fang, Jane W. S.</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1465-1474</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The expressions of c-Src and focal adhesion kinase (FAK) were studied in 65 Chinese patients with hepatocellular carcinoma (HCC) by immunohistochem. using rabbit monoclonal antibodies.  Expressions of total Src, an active form of Src, and FAK were found in 44/65 (67.7%), 36/45 (55.4%), and 33/56 (58.9%) HCC cases, resp.  There was a good correlation between the expression of total Src, active form of Src, and FAK in these HCC cases (P < 0.001).  Expression of Src was not correlated to any clin. parameters, cancer cell phenotypic markers, and pathol. features apart from a pos. correlation with alpha-fetoprotein (P < 0.01).  The expression of FAK was correlated with earlier onset and the expression of Ki-67 but not proliferating cell nuclear antigen (PCNA) in these HCC cases.  Four liver-cancer-derived cell lines (three derived from HCC and one from hepatoblastoma) were then tested with inhibitors against Src.  A small mol., KX2-391, designed to target the substrate binding pocket of Src, was found to have more broad-spectrum activity and better potency than Dasatinib, an ATP-competitive inhibitor in vitro.  The authors' data indicates that Src and FAK expression are both elevated and active in Chinese patients with HCC and that Src may play a key role in supporting HCC progression.  Src antagonism with specific inhibitors may be an attractive treatment paradigm for patients with HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTP7JpKNhgbVg90H21EOLACvtfcHk0ljzk_o_Y4inOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmslOktrw%253D&md5=124da89ed8688b1e4124da5fd6cb7c3c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs10620-008-0519-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-008-0519-0%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DG.%2BM.%26aulast%3DLau%26aufirst%3DG.%2BM.%26aulast%3DYu%26aufirst%3DG.-L.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DGutowski%26aufirst%3DA.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DW.%2BS.%26atitle%3DExpression%2520of%2520Src%2520and%2520FAK%2520in%2520hepatocellular%2520carcinoma%2520and%2520the%2520effect%2520of%2520Src%2520inhibitors%2520on%2520hepatocellular%2520carcinoma%2520in%2520vitro%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2009%26volume%3D54%26issue%3D7%26spage%3D1465%26epage%3D1474%26doi%3D10.1007%2Fs10620-008-0519-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naing, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dy, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of KX2–391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">973</span>, <span class="refDoi"> DOI: 10.1007/s10637-013-9929-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs10637-013-9929-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=967-973&issue=4&author=A.+Naingauthor=R.+Cohenauthor=G.+K.+Dyauthor=D.+S.+Hongauthor=L.+Dysterauthor=D.+G.+Hangauerauthor=R.+Kwanauthor=G.+Fetterlyauthor=R.+Kurzrockauthor=A.+A.+Adjei&title=A+phase+I+trial+of+KX2%E2%80%93391%2C+a+novel+non-ATP+competitive+substrate-pocket-+directed+SRC+inhibitor%2C+in+patients+with+advanced+malignancies&doi=10.1007%2Fs10637-013-9929-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-9929-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-9929-8%26sid%3Dliteratum%253Aachs%26aulast%3DNaing%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DDyster%26aufirst%3DL.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DFetterly%26aufirst%3DG.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520KX2%25E2%2580%2593391%252C%2520a%2520novel%2520non-ATP%2520competitive%2520substrate-pocket-%2520directed%2520SRC%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26issue%3D4%26spage%3D967%26epage%3D973%26doi%3D10.1007%2Fs10637-013-9929-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, M-F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyster, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M. A.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of KX2–391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2079-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1007%2Fs00280-013-2079-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=23314737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2013&pages=883-892&issue=4&author=E.+S.+Antonarakisauthor=E.+I.+Heathauthor=E.+M.+Posadasauthor=E.+Y.+Yuauthor=M.+R.+Harrisonauthor=J.+Y.+Bruceauthor=S.+Y.+Choauthor=G.+E.+Wildingauthor=G.+J.+Fetterlyauthor=D.+G.+Hangauerauthor=M-F.+R.+Kwanauthor=L.+M.+Dysterauthor=M.+A.+Carducci&title=A+phase+2+study+of+KX2%E2%80%93391%2C+an+oral+inhibitor+of+Src+kinase+and+tubulin+polymerization%2C+in+men+with+bone-metastatic+castration-resistant+prostate+cancer&doi=10.1007%2Fs00280-013-2079-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Antonarakis, Emmanuel S.; Heath, Elisabeth I.; Posadas, Edwin M.; Yu, Evan Y.; Harrison, Michael R.; Bruce, Justine Y.; Cho, Steve Y.; Wilding, Gregory E.; Fetterly, Gerald J.; Hangauer, David G.; Kwan, Min-Fun R.; Dyster, Lyn M.; Carducci, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymn.  In phase 1 trials, prostate-specific antigen (PSA) declines were seen in patients with advanced prostate cancer.  We conducted a single-arm phase 2 study evaluating KX2-391 in men with chemotherapy-naive bone-metastatic castration-resistant prostate cancer (CRPC).  We treated 31 patients with oral KX2-391 (40 mg twice-daily) until disease progression or unacceptable toxicity.  The primary endpoint was 24-wk progression-free survival (PFS); a 50 % success rate was pre-defined as clin. significant.  Secondary endpoints included PSA progression-free survival (PPFS) and PSA response rates.  Exploratory outcomes included pharmacokinetic studies, circulating tumor cell (CTC) enumeration, and anal. of markers of bone resorption [urinary N-telopeptide (uNTx); C-telopeptide (CTx)] and formation [bone alk. phosphatase (BAP); osteocalcin].  The trial closed early after accrual of 31 patients, due to a pre-specified futility rule.  PFS at 24 wk was 8 %, and median PFS was 18.6 wk.  The PSA response rate (≥30 % decline) was 10 %, and median PPFS was 5.0 wk.  Addnl., 18 % of men with unfavorable (≥5) CTCs at baseline converted to favorable (<5) CTCs with treatment.  The proportion of men with declines in bone turnover markers was 32 % for uNTx, 21 % for CTx, 10 % for BAP, and 25 % for osteocalcin.  In pharmacokinetic studies, median C max was 61 (range 16-129) ng/mL, and median AUC was 156 (35-348) ng h/mL.  Common toxicities included hepatic derangements, myelosuppression, fatigue, nausea, and constipation.  KX2-391 dosed at 40 mg twice-daily lacks antitumor activity in men with CRPC, but has modest effects on bone turnover markers.  Because a C max of ≥142 ng/mL is required for tubulin polymn. inhibition (defined from preclin. studies), higher once-daily dosing will be used in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok7d6u2qkQ_7Vg90H21EOLACvtfcHk0lj-dQ6QM7TTAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2nu7o%253D&md5=117681a5f5cb6d09865c707673ec3e27</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2079-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2079-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DYu%26aufirst%3DE.%2BY.%26aulast%3DHarrison%26aufirst%3DM.%2BR.%26aulast%3DBruce%26aufirst%3DJ.%2BY.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DWilding%26aufirst%3DG.%2BE.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DKwan%26aufirst%3DM-F.%2BR.%26aulast%3DDyster%26aufirst%3DL.%2BM.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26atitle%3DA%2520phase%25202%2520study%2520of%2520KX2%25E2%2580%2593391%252C%2520an%2520oral%2520inhibitor%2520of%2520Src%2520kinase%2520and%2520tubulin%2520polymerization%252C%2520in%2520men%2520with%2520bone-metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D71%26issue%3D4%26spage%3D883%26epage%3D892%26doi%3D10.1007%2Fs00280-013-2079-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasner, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. E.</span></span> <span> </span><span class="NLM_article-title">A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2–391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">7043</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.7043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1200%2FJCO.2017.35.15_suppl.7043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=7043&author=M.+T.+Kasnerauthor=E.+K.+Ritchieauthor=D.+Cutlerauthor=G.+J.+Fetterlyauthor=D.+Kramerauthor=D.+Hangauerauthor=J.+E.+Thompson&title=A+phase+1b+dose+escalation+study+to+evaluate+safety%2C+tolerability+and+pharmacokinetics+of+oral+monotherapy+with+KX2%E2%80%93391+in+elderly+subjects+with+acute+myeloid+leukemia+who+are+refractory+to+or+have+declined+standard+induction+therapy&doi=10.1200%2FJCO.2017.35.15_suppl.7043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.7043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.7043%26sid%3Dliteratum%253Aachs%26aulast%3DKasner%26aufirst%3DM.%2BT.%26aulast%3DRitchie%26aufirst%3DE.%2BK.%26aulast%3DCutler%26aufirst%3DD.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DKramer%26aufirst%3DD.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DJ.%2BE.%26atitle%3DA%2520phase%25201b%2520dose%2520escalation%2520study%2520to%2520evaluate%2520safety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520oral%2520monotherapy%2520with%2520KX2%25E2%2580%2593391%2520in%2520elderly%2520subjects%2520with%2520acute%2520myeloid%2520leukemia%2520who%2520are%2520refractory%2520to%2520or%2520have%2520declined%2520standard%2520induction%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D7043%26doi%3D10.1200%2FJCO.2017.35.15_suppl.7043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ainger, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, R. A.</span></span> <span> </span><span class="NLM_article-title">Src and SCC: getting to the FAKs</span>. <i>Experimental dermatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1111/exd.12725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fexd.12725" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=487-488&issue=7&author=S.+A.+Aingerauthor=R.+A.+Sturm&title=Src+and+SCC%3A+getting+to+the+FAKs&doi=10.1111%2Fexd.12725"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1111%2Fexd.12725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.12725%26sid%3Dliteratum%253Aachs%26aulast%3DAinger%26aufirst%3DS.%2BA.%26aulast%3DSturm%26aufirst%3DR.%2BA.%26atitle%3DSrc%2520and%2520SCC%253A%2520getting%2520to%2520the%2520FAKs%26jtitle%3DExperimental%2520dermatology%26date%3D2015%26volume%3D24%26issue%3D7%26spage%3D487%26epage%3D488%26doi%3D10.1111%2Fexd.12725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.-S.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and Src expression in premalignant and malignant skin lesions</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1111/exd.12676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fexd.12676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=25711159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=361-364&author=C.+W.+Choiauthor=Y.+H.+Kimauthor=J.+H.+Sohnauthor=H.+Leeauthor=W.-S.+Kim&title=Focal+adhesion+kinase+and+Src+expression+in+premalignant+and+malignant+skin+lesions&doi=10.1111%2Fexd.12676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and Src expression in premalignant and malignant skin lesions</span></div><div class="casAuthors">Choi, Chong Won; Kim, Yoon Hwan; Sohn, Jin Hee; Lee, Hyunjoo; Kim, Won-Serk</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-364</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">1600-0625</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) and Src are non-receptor tyrosine kinases.  FAK and Src play a crit. role in inducing malignant transformation in tumor cells.  We performed immunohistochem. staining for total and phosphorylated forms of FAK and Src, to evaluate the role of FAK and Src in the development of premalignant and malignant skin lesions.  A total of 59 facial skin samples (30 actinic keratoses, 10 Bowen's diseases, 13 squamous cell carcinomas and six perilesional skins) were immunohistochem. stained for Ki-67, total (t) and phosphorylated (p) form of FAK and Src.  Cells pos. for t-Src, p-Src-y530, t-FAK and pFAK-s722 were detected in premalignant intra-epithelial lesions (PELs) and squamous cell carcinomas (SCCs), but not in the perilesional skin.  There was a tendency towards high correlation between Ki-67 and t-FAK or pFAK-s722, suggestive of the active role of FAK in cell proliferation.  However, our findings of higher t-Src and p-Src-y530 pos. cells in PELs, as compared to SCCs (with higher Ki-67 level), are suggestive of the other role of Src in tumor formation and progression, which requires further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxSZeLjvao8bVg90H21EOLACvtfcHk0lj-dQ6QM7TTAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGksr0%253D&md5=8c81b87591dbdf4495851f76ed9b66d3</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1111%2Fexd.12676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.12676%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSohn%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.-S.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520Src%2520expression%2520in%2520premalignant%2520and%2520malignant%2520skin%2520lesions%26jtitle%3DExp.%2520Dermatol.%26date%3D2015%26volume%3D24%26spage%3D361%26epage%3D364%26doi%3D10.1111%2Fexd.12676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Montagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallichet-Blanc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sng, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottaz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degueurce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruchet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antsiferova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Saati, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">tan, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahli, W.</span></span> <span> </span><span class="NLM_article-title">Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1002/emmm.201302666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1002%2Femmm.201302666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=24203162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=80-98&author=A.+Montagnerauthor=M.+B.+Delgadoauthor=C.+Tallichet-Blancauthor=J.+S.+K.+Chanauthor=M.+K.+Sngauthor=H.+Mottazauthor=G.+Degueurceauthor=Y.+Lippiauthor=C.+Moretauthor=M.+Baruchetauthor=M.+Antsiferovaauthor=S.+Wernerauthor=D.+Hohlauthor=T.+Al+Saatiauthor=P.+J.+Farmerauthor=N.+S.+tanauthor=L.+Michalikauthor=W.+Wahli&title=Src+is+activated+by+the+nuclear+receptor+peroxisome+proliferator-activated+receptor+%CE%B2%2F%CE%B4+in+ultraviolet+radiation-induced+skin+cancer&doi=10.1002%2Femmm.201302666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37cR"><div class="casContent"><span class="casTitleNuber">37c</span><div class="casTitle"><span class="NLM_cas:atitle">Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer</span></div><div class="casAuthors">Montagner, Alexandra; Delgado, Maria B.; Tallichet-Blanc, Corinne; Chan, Jeremy S. K.; Sng, Ming K.; Mottaz, Helene; Degueurce, Gwendoline; Lippi, Yannick; Moret, Catherine; Baruchet, Michael; Antsiferova, Maria; Werner, Sabine; Hohl, Daniel; Al Saati, Talal; Farmer, Pierre J.; Tan, Nguan S.; Michalik, Liliane; Wahli, Walter</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-98</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Although non-melanoma skin cancer (NMSC) is the most common human cancer and its incidence continues to rise worldwide, the mechanisms underlying its development remain incompletely understood.  Here, we unveil a cascade of events involving peroxisome proliferator-activated receptor (PPAR) β/δ and the oncogene Src, which promotes the development of UV-induced skin cancer in mice.  UV-induced PPARβ/δ activity, which directly stimulated Src expression, increased Src kinase activity and enhanced the EGFR/Erk1/2 signalling pathway, resulting in increased epithelial-to-mesenchymal transition (EMT) marker expression.  Consistent with these observations, PPARβ/δ-null mice developed fewer and smaller skin tumors, and a PPARβ/δ antagonist prevented UV-dependent Src stimulation.  Furthermore, the expression of PPARβ/δ pos. correlated with the expression of SRC and EMT markers in human skin squamous cell carcinoma (SCC), and critically, linear models applied to several human epithelial cancers revealed an interaction between PPARβ/δ and SRC and TGFβ1 transcriptional levels.  Taken together, these observations motivate the future evaluation of PPARβ/δ modulators to attenuate the development of several epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKDhlgcaReIrVg90H21EOLACvtfcHk0lhINiisdfwmAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKhuw%253D%253D&md5=daebc7b735f53c0dad38e00b09139d9f</span></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=10.1002%2Femmm.201302666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201302666%26sid%3Dliteratum%253Aachs%26aulast%3DMontagner%26aufirst%3DA.%26aulast%3DDelgado%26aufirst%3DM.%2BB.%26aulast%3DTallichet-Blanc%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%2BS.%2BK.%26aulast%3DSng%26aufirst%3DM.%2BK.%26aulast%3DMottaz%26aufirst%3DH.%26aulast%3DDegueurce%26aufirst%3DG.%26aulast%3DLippi%26aufirst%3DY.%26aulast%3DMoret%26aufirst%3DC.%26aulast%3DBaruchet%26aufirst%3DM.%26aulast%3DAntsiferova%26aufirst%3DM.%26aulast%3DWerner%26aufirst%3DS.%26aulast%3DHohl%26aufirst%3DD.%26aulast%3DAl%2BSaati%26aufirst%3DT.%26aulast%3DFarmer%26aufirst%3DP.%2BJ.%26aulast%3Dtan%26aufirst%3DN.%2BS.%26aulast%3DMichalik%26aufirst%3DL.%26aulast%3DWahli%26aufirst%3DW.%26atitle%3DSrc%2520is%2520activated%2520by%2520the%2520nuclear%2520receptor%2520peroxisome%2520proliferator-activated%2520receptor%2520%25CE%25B2%252F%25CE%25B4%2520in%2520ultraviolet%2520radiation-induced%2520skin%2520cancer%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D80%26epage%3D98%26doi%3D10.1002%2Femmm.201302666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Serrels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldeschi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackintosh, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansom, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span> <span> </span><span class="NLM_article-title">A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgn278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1093%2Fcarcin%2Fbgn278" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=249-257&issue=2&author=B.+Serrelsauthor=A.+Serrelsauthor=S.+M.+Masonauthor=C.+Baldeschiauthor=G.+H.+Ashtonauthor=M.+Canelauthor=L.+J.+Mackintoshauthor=B.+Doyleauthor=T.+P.+Greenauthor=M.+C.+Frameauthor=O.+J.+Sansomauthor=V.+G.+Brunton&title=A+novel+Src+kinase+inhibitor+reduces+tumour+formation+in+a+skin+carcinogenesis+model&doi=10.1093%2Fcarcin%2Fbgn278"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37d&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgn278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgn278%26sid%3Dliteratum%253Aachs%26aulast%3DSerrels%26aufirst%3DB.%26aulast%3DSerrels%26aufirst%3DA.%26aulast%3DMason%26aufirst%3DS.%2BM.%26aulast%3DBaldeschi%26aufirst%3DC.%26aulast%3DAshton%26aufirst%3DG.%2BH.%26aulast%3DCanel%26aufirst%3DM.%26aulast%3DMackintosh%26aufirst%3DL.%2BJ.%26aulast%3DDoyle%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DSansom%26aufirst%3DO.%2BJ.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26atitle%3DA%2520novel%2520Src%2520kinase%2520inhibitor%2520reduces%2520tumour%2520formation%2520in%2520a%2520skin%2520carcinogenesis%2520model%26jtitle%3DCarcinogenesis%26date%3D2009%26volume%3D30%26issue%3D2%26spage%3D249%26epage%3D257%26doi%3D10.1093%2Fcarcin%2Fbgn278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picarles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsaesser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolopp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winiski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meingassner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Brugerolle de Fraissinette, A.</span></span> <span> </span><span class="NLM_article-title">LAV694, a new antiproliferative agent showing improved skin tolerability vs. clinical standards for the treatment of actinic keratosis</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1895</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(03)00369-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1016%2FS0006-2952%2803%2900369-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2003&pages=1885-1895&author=J.+Medinaauthor=V.+Picarlesauthor=B.+Greinerauthor=C.+Elsaesserauthor=M.+Koloppauthor=A.+Mahlauthor=D.+Romanauthor=B.+Vogelauthor=P.+Nussbaumerauthor=A.+Winiskiauthor=J.+Meingassnerauthor=A.+de+Brugerolle+de+Fraissinette&title=LAV694%2C+a+new+antiproliferative+agent+showing+improved+skin+tolerability+vs.+clinical+standards+for+the+treatment+of+actinic+keratosis&doi=10.1016%2FS0006-2952%2803%2900369-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2803%2900369-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252803%252900369-1%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DPicarles%26aufirst%3DV.%26aulast%3DGreiner%26aufirst%3DB.%26aulast%3DElsaesser%26aufirst%3DC.%26aulast%3DKolopp%26aufirst%3DM.%26aulast%3DMahl%26aufirst%3DA.%26aulast%3DRoman%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DB.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DWiniski%26aufirst%3DA.%26aulast%3DMeingassner%26aufirst%3DJ.%26aulast%3Dde%2BBrugerolle%2Bde%2BFraissinette%26aufirst%3DA.%26atitle%3DLAV694%252C%2520a%2520new%2520antiproliferative%2520agent%2520showing%2520improved%2520skin%2520tolerability%2520vs.%2520clinical%2520standards%2520for%2520the%2520treatment%2520of%2520actinic%2520keratosis%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2003%26volume%3D66%26spage%3D1885%26epage%3D1895%26doi%3D10.1016%2FS0006-2952%2803%2900369-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulent Tastan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbil, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumlu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gur, A. R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratosis</span>. <i>J. Dermatol. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1080/09546630152696314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1080%2F09546630152696314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=12241628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtV2ksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=199-203&author=A.+Akarauthor=H.+Bulent+Tastanauthor=H.+Erbilauthor=E.+Arcaauthor=Z.+Kurumluauthor=A.+R.+Gur&title=Efficacy+and+safety+assessment+of+0.5%25+and+1%25+colchicine+cream+in+the+treatment+of+actinic+keratosis&doi=10.1080%2F09546630152696314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses</span></div><div class="casAuthors">Akar, Ahmet; Tastan, H. Bulent; Erbil, Hakan; Arca, Ercan; Kurumlu, Zafer; Gur, Ali Riza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Treatment</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">199-203</span>CODEN:
                <span class="NLM_cas:coden">JDTREY</span>;
        ISSN:<span class="NLM_cas:issn">0954-6634</span>.
    
            (<span class="NLM_cas:orgname">Martin Dunitz Ltd.</span>)
        </div><div class="casAbstract">Background: Topical colchicine has been reported to be an effective treatment for actinic keratoses, but the optimal concn. has not been fully defined.  Objective: The aim of this study was to further support the beneficial effect of topical colchicine therapy for actinic keratoses, and to compare the efficacy and safety of two different concns. of colchicine cream, 0.5% and 1%.  Methods: Sixteen patients with actinic keratoses were enrolled in this comparative randomized study.  Eight patients applied 1% colchicine cream, twice daily on their lesions while the other eight were treated with a 0.5% colchicine cream for 10 days.  Some patients were applied a second course of 10 days' therapy.  Patients were examd. before treatment and at 10 days, and followed up at 1, 2 and 6 mo of treatment.  Visible and palpable actinic keratoses lesions in each group were counted.  Safety and efficacy were also assessed by clin. examn. at each study visit.  Routine lab. tests were performed before and after treatment.  Results: Actinic keratoses lesions showed significant clin. improvement following treatment with 0.5% and 1% colchicine cream.  Complete healing of actinic keratoses were obsd. in six of the eight patients in the 1% colchicine group, and in seven of the eight patients in the 0.5% colchicine group.  The redn. rate in no. of actinic keratoses at the end of treatment in the 1% colchicine group was 73.9% (48/65) (p < 0.001), and the redn. rate in the 0.5% colchicine group was 77.7% (52/67) in total (p < 0.001).  The redn. in no. of actinic keratoses (mean ± SD) at the end of treatment was similar in the 1% colchicine group (0.7 ± 1.3), and the 0.5% colchicine group (mean 0.6 ± 1.7) (p > 0.05).  Systemic side effects were not seen in either concn.  Conclusions: Topical colchicine is an effective and safe alternative agent.  Cream contg. 0.5% of colchicine is equally effective as 1% colchicine cream in the treatment of actinic keratoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFXR59Mt0s47Vg90H21EOLACvtfcHk0lhgzG5_6N6T_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtV2ksrw%253D&md5=45d73e565ae1bbc4b5a6e607828416f5</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1080%2F09546630152696314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09546630152696314%26sid%3Dliteratum%253Aachs%26aulast%3DAkar%26aufirst%3DA.%26aulast%3DBulent%2BTastan%26aufirst%3DH.%26aulast%3DErbil%26aufirst%3DH.%26aulast%3DArca%26aufirst%3DE.%26aulast%3DKurumlu%26aufirst%3DZ.%26aulast%3DGur%26aufirst%3DA.%2BR.%26atitle%3DEfficacy%2520and%2520safety%2520assessment%2520of%25200.5%2525%2520and%25201%2525%2520colchicine%2520cream%2520in%2520the%2520treatment%2520of%2520actinic%2520keratosis%26jtitle%3DJ.%2520Dermatol.%2520Treat.%26date%3D2001%26volume%3D12%26spage%3D199%26epage%3D203%26doi%3D10.1080%2F09546630152696314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korgavkar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M. A.</span></span> <span> </span><span class="NLM_article-title">Current perspective on actinic keratosis: a review</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1111/bjd.14852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fbjd.14852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=27500794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A280%3ADC%252BC2s3osVentA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=350-358&author=J.+A.+Siegelauthor=K.+Korgavkarauthor=M.+A.+Weinstock&title=Current+perspective+on+actinic+keratosis%3A+a+review&doi=10.1111%2Fbjd.14852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspective on actinic keratosis: a review</span></div><div class="casAuthors">Siegel J A; Korgavkar K; Weinstock M A; Siegel J A; Korgavkar K; Weinstock M A</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-358</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Actinic keratoses (AKs) are common, with prevalence in the U.S.A. estimated at almost 40 million in 2004 and annual costs of > $1 billion (U.S.D.).  However, there is no universally accepted definition of AK and thus it is difficult to identify reliably.  AKs are lesions of epidermal keratinocytic dysplasia that result from chronic sun exposure and have the ability to progress to invasive squamous cell carcinoma (SCC), but clinicians disagree about whether AKs are premalignant lesions, superficial SCCin situ or epiphenomena of chronically sun-damaged skin.  Yearly AK to SCC progression rates of 0·6% were reported in an elderly population with multiple prior keratinocyte carcinomas (KCs); and rates of spontaneous AK regression have been reported to be > 50%, but regressed lesions often reappear.  As AKs have both cosmetic consequences and potential for malignant transformation, there are multiple reasons for treatment.  There is no current agreement on the most efficacious treatment, but 5-fluorouracil has been shown to both prevent and treat AKs, and imiquimod and photodynamic therapy may have the best cosmetic outcomes.  AKs may be treated to improve appearance and relieve symptoms, but the keratinocytic dysplasia that gives rise to malignancy, and sometimes appears as an AK, may be what actually threatens patient health.  Thus, treatments should aim to decrease the risk of KC or facilitate KC diagnosis by reducing the potential for misidentification created when a KC appears in a field of AKs.  Improved agreement among clinicians on AK definition may improve management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSwkYWOJcD75NiNltV31zlfW6udTcc2eaFqY8kwQ7PJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3osVentA%253D%253D&md5=e0016ac6105073f8ccb59c8bb9e53d58</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14852%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DJ.%2BA.%26aulast%3DKorgavkar%26aufirst%3DK.%26aulast%3DWeinstock%26aufirst%3DM.%2BA.%26atitle%3DCurrent%2520perspective%2520on%2520actinic%2520keratosis%253A%2520a%2520review%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2017%26volume%3D177%26spage%3D350%26epage%3D358%26doi%3D10.1111%2Fbjd.14852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="note"><p class="first last">Compound <b>1</b> clinical trials for actinic keratosis listed on ClinicalTrials.gov:</p></div><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span>Phase 1: NCT02337205. A phase
1, single-center, safety, tolerability, and pharmacokinetic study
of KX2-391 ointment in subjects with actinic keratosis..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+1%3A+NCT02337205.+A+phase%0A1%2C+single-center%2C+safety%2C+tolerability%2C+and+pharmacokinetic+study%0Aof+KX2-391+ointment+in+subjects+with+actinic+keratosis.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span>Phase
2: NCT02838628. A phase 2a, open-label, multicenter, activity, and
safety study of KX2-391 ointment in subjects with actinic keratosis
on the face or scalp..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase%0A2%3A+NCT02838628.+A+phase+2a%2C+open-label%2C+multicenter%2C+activity%2C+and%0Asafety+study+of+KX2-391+ointment+in+subjects+with+actinic+keratosis%0Aon+the+face+or+scalp.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40c"><span><span class="NLM_label">(c) </span>Phase 3: NCT03285477. A phase 3, double-blind,
vehicle-controlled, randomized, parallel group, multicenter, efficacy,
and safety study of KX2–391 ointment 1% in adult subjects with
actinic keratosis on the face or scalp..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+3%3A+NCT03285477.+A+phase+3%2C+double-blind%2C%0Avehicle-controlled%2C+randomized%2C+parallel+group%2C+multicenter%2C+efficacy%2C%0Aand+safety+study+of+KX2%E2%80%93391+ointment+1%25+in+adult+subjects+with%0Aactinic+keratosis+on+the+face+or+scalp.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40d"><span><span class="NLM_label">(d) </span>Phase 3: NCT03285490. A phase
3, double-blind, vehicle-controlled, randomized, parallel group, multicenter,
efficacy and safety study of KX2-391 ointment 1% in adult subjects
with actinic keratosis on the face or scalp..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+3%3A+NCT03285490.+A+phase%0A3%2C+double-blind%2C+vehicle-controlled%2C+randomized%2C+parallel+group%2C+multicenter%2C%0Aefficacy+and+safety+study+of+KX2-391+ointment+1%25+in+adult+subjects%0Awith+actinic+keratosis+on+the+face+or+scalp.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span>; <span class="NLM_string-name">Jarratt, M.</span>; <span class="NLM_string-name">Kempers, S.</span>; <span class="NLM_string-name">Forman, S.</span>; <span class="NLM_string-name">Cutler, D.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Kwan, R.</span></span> <span> </span><span class="NLM_article-title">Phase II study of KX2-391 ointment 1%, a novel field treatment based on Src/tubulin polymerization inhibition, for actinic keratosis</span>. In  <i>American Academy of Dermatology Meeting in Feb. 17</i>, <span class="NLM_year">2018</span>. Oral presentation and online ePoster ID  <span class="NLM_fpage">6134</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=6134&author=J.+Fang&author=M.+Jarratt&author=S.+Kempers&author=S.+Forman&author=D.+Cutler&author=H.+Wang&author=R.+Kwan&title=Phase+II+study+of+KX2-391+ointment+1%25%2C+a+novel+field+treatment+based+on+Src%2Ftubulin+polymerization+inhibition%2C+for+actinic+keratosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520study%2520of%2520KX2-391%2520ointment%25201%2525%252C%2520a%2520novel%2520field%2520treatment%2520based%2520on%2520Src%252Ftubulin%2520polymerization%2520inhibition%252C%2520for%2520actinic%2520keratosis%26jtitle%3DAmerican%2520Academy%2520of%2520Dermatology%2520Meeting%2520in%2520Feb.%252017%26date%3D2018%26spage%3D6134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayli, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenitsas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seykora, J. T.</span></span> <span> </span><span class="NLM_article-title">Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders</span>. <i>J. Cutaneous Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0560.2007.00807.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=10.1111%2Fj.1600-0560.2007.00807.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=18251740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FpsVektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=273-277&issue=3&author=E.+E.+Ayliauthor=W.+Liauthor=T.+T.+Brownauthor=A.+Witkiewiczauthor=R.+Elenitsasauthor=J.+T.+Seykora&title=Activation+of+Src-family+tyrosine+kinases+in+hyperproliferative+epidermal+disorders&doi=10.1111%2Fj.1600-0560.2007.00807.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders</span></div><div class="casAuthors">Ayli Elias E; Li Weijie; Brown Tamu T; Witkiewicz Agnieszka; Elenitsas Rosalie; Seykora John T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cutaneous pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Src-family tyrosine kinases (SFKs) are important regulators of keratinocyte growth and differentiation.  In a broad range of cell types, persistent activation of SFKs correlates with increased cell proliferation.  In this study, we determined if SFK activity is increased in cutaneous neoplasia and psoriasis, common hyperproliferative epidermal disorders.  METHODS:  Formalin-fixed tissue sections of unremarkable epidermis, psoriasis, actinic keratoses (AKs), squamous cell carcinoma in situ (SCIS) and squamous cell carcinoma (SCC) were subjected to immunohistochemical staining for activated SFKs.  RESULTS:  All psoriasis specimens displayed significantly greater staining for activated SFKs than sections of unremarkable skin.  In the psoriasis biopsies, the degree of epidermal hyperplasia was proportional to the level of activated SFK staining.  All AKs, SCISs and SCCs exhibited more prominent staining than sections of unremarkable epidermis.  No discernable difference in activated SFK staining was seen between AKs, SCIS and SCC specimens.  CONCLUSIONS:  This study shows increased staining of activated SFKs in human biopsy specimens of psoriasis and cutaneous neoplasia.  These data provide direct evidence for increased activation of SFKs in the pathogenesis of hyperproliferative epidermal disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1SM7m24OtqLqxQ2mb9Pu8fW6udTcc2eZAhcP7klkoxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FpsVektw%253D%253D&md5=4410af9243e307f3f3f3dd8833a92855</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0560.2007.00807.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0560.2007.00807.x%26sid%3Dliteratum%253Aachs%26aulast%3DAyli%26aufirst%3DE.%2BE.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DBrown%26aufirst%3DT.%2BT.%26aulast%3DWitkiewicz%26aufirst%3DA.%26aulast%3DElenitsas%26aufirst%3DR.%26aulast%3DSeykora%26aufirst%3DJ.%2BT.%26atitle%3DActivation%2520of%2520Src-family%2520tyrosine%2520kinases%2520in%2520hyperproliferative%2520epidermal%2520disorders%26jtitle%3DJ.%2520Cutaneous%2520Pathol.%26date%3D2008%26volume%3D35%26issue%3D3%26spage%3D273%26epage%3D277%26doi%3D10.1111%2Fj.1600-0560.2007.00807.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="note"><p class="first last">Taiwan clinical trial KX01-PS-01-TW in collaboration with Athenex Inc. partner PharmaEssentia Corp.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="note"><p class="first last">ClinicalTrials.gov, NCT02326441, A phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of KX2-361 in subjects with advanced malignancies that are refractory to conventional therapies.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SRC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2SRC','PDB','2SRC'); return false;">PDB: 2SRC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IR3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IR3','PDB','1IR3'); return false;">PDB: 1IR3</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i12"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00164">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_13084"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00164">10.1021/acs.jmedchem.8b00164</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemical and structural formulas, and the synthesis of compounds <b>1</b>, <b>2</b>, <b>7</b>, <b>8</b>, <b>9</b>, and <b>10</b>, p<i>K</i><sub>a</sub> determinations of compounds <b>1</b> and <b>2</b>, homology modeling, in vitro biological testing, pharmacokinetic studies, and in vivo tumor drug distribution (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_002.csv">CSV</a>)</p></li><li><p class="inline">SrcH1 + compound <b>1</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_003.pdb">PDB</a>)</p></li><li><p class="inline">SrcH1 + indole <b>5</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_001.pdf">jm8b00164_si_001.pdf (613.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_002.csv">jm8b00164_si_002.csv (2.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_003.pdb">jm8b00164_si_003.pdb (442.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00164/suppl_file/jm8b00164_si_004.pdb">jm8b00164_si_004.pdb (440.35 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-11%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00164%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00164" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ad0b55dbb123e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
